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Abstract 
Background: Benzodiazepines are commonly prescribed for the reduction or 
management of anxiety and agitation. However, it is becoming increasingly apparent 
that for some individuals, benzodiazepine use is associated with increased agitation, 
and at times, aggressive or violent behaviour. The nature of aggressive behaviour, 
and the potential medico-legal outcomes associated with such behaviour, means that 
understanding of this response is warranted. Despite a number of studies being 
conducted on the association between benzodiazepine use and aggression, the 
response remains poorly understood. This thesis aims to enhance our understanding 
of this response, specifically by critically reviewing the currently available literature 
base and by conducting two original cross-sectional studies. 
Methods: The literature exploring benzodiazepine-related aggression was explored 
through a systematic review which was conducted in line with PRISMA guidelines. 
A cross-sectional study of 204 community benzodiazepine users, aged 18-51, applied 
the Reinforcement Sensitivity Theory to test the predictive nature of motivational 
tendencies in understanding aggression. Multiple hierarchical regression analyses 
were conducted on this data. A second, smaller cross-sectional study of 82 
community-based violent and non-violent offenders, aged 21-56, examined group 
differences in relation to benzodiazepine use patterns and intrapersonal 
characteristics. This data were analysed using independent samples t-tests and non-
parametric tests (i.e., when assumptions were violated). 
Results: The systematic review identified that although a number of studies have 
been conducted in this area, varying methodologies and the over-arching low quality 
of studies which have been conducted prompts more questions than clear 
conclusions. The research does however suggest that benzodiazepine-related 
  12 
 
aggressive responses may be linked most closely with alprazolam and diazepam use. 
The community-based cross-sectional study suggested that benzodiazepine-related 
aggression was more likely to be experienced by those who used alprazolam and 
exhibited persistent approach tendencies, or motivational drive. The offender cross-
sectional study demonstrated that violent offenders were significantly more likely to 
present with benzodiazepine dependence, alprazolam use at higher doses, depression 
and personality diagnoses, sensation seeking, and a history of violent behaviour than 
non-violent offenders. 
Conclusions: Taken together, the systematic review and two studies showed 
alprazolam use to pose a greater risk of subsequent aggression than diazepam use, 
and demonstrated that intrapersonal factors can further our understanding of 
benzodiazepine-related aggression. Specifically, the two empirical studies 
highlighted the role of impulse control and maladaptive coping strategies to manage 
negative affect in this response. Key implications include recommended changes to 
benzodiazepine prescribing practices and policy, especially in forensic contexts; the 
impact of such research on future medico-legal decision making; how these 
outcomes can inform selection of appropriate treatment targets within addiction and 
forensic mental health sectors; and future development of the literature base. 
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Chapter One: Overview of Benzodiazepine Misuse  
1.1 Introduction  
Recent estimates suggest that between 1-20% of benzodiazepine users 
experience some form of anger or aggressive response following consumption 
(Lader, 2011), rather than the expected sedating and calming effects. Concern about 
this response not only arises because it is paradoxical to the desired indications of 
benzodiazepines, but because it has the potential for significant health, personal and 
legal costs. Unfortunately, however, minimal research has explored the underlying 
mechanisms for why this response occurs. Instead, the majority of related literature 
merely assess whether or not an association exists between benzodiazepine use and 
aggressive behaviour. It is argued throughout this thesis that without an 
understanding of how benzodiazepine-related aggression occurs, or the factors 
associated with this response, little change can be affected to reduce the likelihood of 
related harms, or to improve the safety of benzodiazepine consumption. 
Benzodiazepines are frequently being noted by users as influencing their 
criminal and/or violent behaviour. For example, more than a quarter of Australian 
benzodiazepine-using police detainees (27.1%) attribute their current offence to 
benzodiazepine use, most commonly due to the psychopharmacological effect (74%; 
Payne & Gaffney, 2012); benzodiazepine use has been frequently blamed for 
unspecified crime (14%), unprovoked aggressive behaviour (20%) and fights (13%) 
by injecting drug users (Smith, Miller, O’Keefe, & Fry, 2007); and incarcerated 
young male violent offenders most frequently blame diazepam (in combination with 
alcohol) as a facilitator of violent crime (Forsyth, Khan & McKinlay, 2011). 
Although these data rest on self-reported (and potentially biased) attributions, they 
provide an insight into the potentially dangerous effects that benzodiazepines may 
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have in influencing aggressive behaviour, despite prior findings that benzodiazepines 
are mostly associated with acquisitive or property crime (e.g., Bradford & Payne, 
2012; Darke & Ross, 1994; Darke et al., 2010; Horyniak, Reddel, Quinn, & Dietze, 
2012; Payne & Gaffney, 2012). Of note, crimes against the person are the second 
most commonly reported criminal behaviour in Australia, behind public order 
offences (Australian Bureau of Statistics [ABS], 2013), and assault offences alone 
are estimated to cost the nation $3.03b annually (Smith, Jorna, Sweeney, & Fuller, 
2014). The potential legal and financial ramifications of this response (in addition to 
the medical and social costs) highlight the need to further understand 
benzodiazepine-related aggression.  
Further knowledge and understanding about benzodiazepine-related 
aggression is important in a number of ways. First, as a problematic substance-
related outcome, there will be implications for substance use treatment and relapse 
prevention strategies. Second, risks of violent behaviour could be identified and 
become violent offender rehabilitation treatment targets. Third, medical prescription 
and regulation of benzodiazepines in the greater community, addiction medicine, and 
in justice health (where a higher rate of violent tendencies may naturally be 
observed) are likely to be impacted. Finally, it is likely that such knowledge will 
inform future medico-legal decisions regarding an offender’s culpability, and their 
punishment and rehabilitation needs.  
1.1.1 Thesis overview  
The current thesis aims to enhance understanding of the relationship between 
benzodiazepine use and subsequent interpersonal aggression and violence. As will be 
argued in the following chapters, this seemingly paradoxical response is of particular 
concern given the frequency of benzodiazepine prescription coupled with the 
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increasing misuse of benzodiazepines across healthy, clinical, and forensic 
populations. Within this overarching aim, the following research has three specific 
directives:  
1. To systematically review the benzodiazepine-aggression literature base to 
specifically identify benzodiazepine type and dose, and individual 
characteristics associated with benzodiazepine-related aggression.  
2. To enhance the theoretical rigour of benzodiazepine-aggression literature.  
3. To identify characteristics associated with benzodiazepine-related violence in 
a benzodiazepine-using, community-based criminal justice sample.  
In order to achieve these aims, the thesis is structured as follows. Chapter 1 
provides an introduction to benzodiazepine use and misuse, and argues the 
importance of research exploring problematic, or contra-indicative, outcomes 
associated with benzodiazepine use. Chapter 2 follows with an introduction to 
interpersonal aggression, and its links with benzodiazepine use, and argues that 
intrapersonal factors are an important consideration when investigating aggressive 
behaviour. This chapter also introduces a well-validated theory of motivational 
tendencies, the Reinforcement Sensitivity Theory, which is used to enhance the 
theoretical rigour of the literature base (i.e., Aim 2). An argument is presented 
regarding how this theory specifically adds to our understanding of benzodiazepine-
related aggression. Chapter 3 presents a systematic review of the currently available 
literature exploring the association between benzodiazepine use and subsequent 
aggression or violence, providing a critical overview of what is currently understood 
about this response, and identifying key gaps in the literature base, some of which 
are then targeted by two original studies (i.e., Aim 1). Chapter 4 presents an original, 
cross-sectional study of community members which assesses the relative importance 
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of motivational tendencies (as defined by the Reinforcement Sensitivity Theory), 
compared to benzodiazepine-related factors (i.e., type, dose), in predicting 
aggression. Chapter 5 presents a second, smaller cross-sectional study which 
examines the differences between violent and non-violent offenders’ benzodiazepine 
use patterns and intrapersonal characteristics (i.e., Aim 3). Chapter 6 combines the 
findings of Chapters 3-5 with a discussion of how the thesis furthers our 
understanding of benzodiazepine-related aggression. Implications relating to 
benzodiazepine prescribing practices and policy, especially in forensic contexts, 
medico-legal decision making, and selection of appropriate treatment targets within 
addiction and forensic mental health sectors are discussed. Opportunities for further 
developing the literature base regarding benzodiazepine-related aggression are also 
considered. 
In order to understand the nature and depth of these implications, however, it 
is important to first understand the nature of benzodiazepine (mis)use. The following 
sections provide an overview of benzodiazepine use and misuse, including a 
discussion of why benzodiazepines are so frequently misused, common side effects, 
and the occurrence of behavioural disinhibition following benzodiazepines, which 
includes aggressive behaviour. It is then argued that although informative and 
necessary, neurological understandings of benzodiazepine-related aggression are 
currently insufficient and impractical platforms on which to base intervention, policy 
or management strategies, warranting closer investigation of other contributory and 
explanatory factors in this response.  
1.2 Medical Indications for Benzodiazepine Prescriptions  
Benzodiazepines are commonly prescribed to treat symptoms of stress, 
anxiety, and sleep disorders (Bisaga, 2008), as well as to assist in the management of 
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symptoms associated with alcohol (Ashton, 2002) and heroin dependence (Fry, 
Smith, Bruno, O’Keefe, & Miller, 2007). Benzodiazepines are also used for 
anaesthesia, epilepsy (Drugs and Crime Prevention Committee [DCPC], 2007), and 
acute psychosis with hyperexcitability and aggressiveness (Ashton, 2002). Despite 
their wide range of indications, which informs the doses at which they are prescribed, 
benzodiazepines are generally used for their anxiolytic and sedative properties. 
Benzodiazepines can be short- (e.g., oxazepam, temazepam, alprazolam) or long-
acting (e.g., diazepam), and bind primarily to the GABAA receptor (Paton, 2002), 
potentiating the inhibitory action of gamma-aminobutyric acid (GABA; Lader, 
2011). This suppresses the central nervous system (CNS), slowing down the 
messages received and sent from the brain (DCPC, 2007).  
Benzodiazepines are widely prescribed. For example, during 2005, 
benzodiazepines were among the most commonly prescribed pharmaceuticals in 
Victoria (DCPC, 2007) and across Australia (Nicholas, 2010). Between 2002 and 
2007 there was a national increase (from 23.76 to 24.11 defined daily dose/1000 
population/day) in the prescription of anxiolytics, sedatives, and hypnotics 
(Hollingworth & Siskind, 2010). Although it appears that the total amount of 
benzodiazepines dispensed has since decreased, the quantity of benzodiazepines 
prescribed per script has increased (Islam, Conigrave, Day, Nguyen, & Haber, 2014). 
Notably, rates of diazepam prescriptions have remained stable, and alprazolam 
prescriptions have increased eight-fold between 1992 and 2011 (Islam et al., 2014).  
A separate examination of prescription data indicated that in 2011, diazepam was the 
most commonly dispensed anxiolytic, and temazepam was the most commonly 
dispensed sedative (Stephenson, Karanges, & McGregor, 2013). Although less 
readily available, international data also indicate a high rate of benzodiazepine 
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prescription and dispensing. For example, Norwegian rates of benzodiazepine 
dispensing are increasing (Bjørner, Tvete, Aursnes, & Skomedal, 2013), 
benzodiazepine prescriptions are written at a rate of 37.6 per 100 persons across 
America (Paulozzi, Mack, & Hockenberry, 2014), and dispensing of diazepam and 
lorazepam significantly increased in England between 2011 and 2012 (The Health 
and Social Care Information Centre [HSCIC], 2013).  
Poor adherence to prescribing guidelines and protocols partially explains the 
high rate of benzodiazepine prescriptions. For example, an examination of 
Tasmanian nursing home residents’ medication (n = 2345) identified that 
benzodiazepines were among the most frequently inappropriately prescribed 
medications (Stafford, Alswayan, & Tenni, 2011). Prescribing guidelines suggest 
that benzodiazepines should only be used for short-term treatment, and that careful 
dose titration is necessary when coming off benzodiazepines, due to their 
dependence potential (e.g., Jones, Nielsen, Bruno, Frei, & Lubman, 2011; Nicholas, 
Lee, & Roche, 2011). Alprazolam is widely considered to have the most abuse and 
harm potential of the benzodiazepines, due to its short-acting effects, and has 
therefore been recently up-scheduled in Australia to a controlled substance (Schedule 
8).The only other benzodiazepine to fall under Schedule 8 restrictions is 
flunitrazepam. Australia’s rescheduling of alprazolam is despite unchanged 
classification of alprazolam as a drug of moderate risk of harm or dependence (i.e., 
Class C) in other countries (United Kingdom: Misuse of Drugs Act 1971 UK; New 
Zealand: Misuse of Drugs Act 1975 NZ). Such rescheduling attempts to reduce the 
accessibility of alprazolam, and therein reduce the associated harmful sequelae. 
However, as discussed by Islam and colleagues (2014), such rescheduling often leads 
to compensatory increased (mis)use of a substitute benzodiazepine, and a broader 
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policy regarding the prescribing and regulation of benzodiazepines as a psychotropic 
drug class is required.  
1.3 Prevalence of Non-Medical Use of Benzodiazepines 
The following sections outline the widespread misuse of benzodiazepines in 
Australia and internationally. Importantly, the Australian rates below were recorded 
prior to the recent rescheduling of alprazolam, and therefore it is as yet unclear how 
benzodiazepine use patterns have been impacted. 
1.3.1 Defining non-medical use. 
The terms ‘misuse’ and ‘non-medically prescribed use’ are used 
interchangeably within this thesis to refer to benzodiazepine use which is not within 
the explicit boundaries of a prescription from an appropriately qualified prescriber 
(except where otherwise stated). This may include using a higher dose than detailed 
on the prescription, extending use past the period (or the reason) for which 
benzodiazepines were indicated, or using non-prescribed (i.e., black market) 
benzodiazepines.  
1.3.2 Australian data. 
1.3.2.1 General community. The Australian Institute of Health and Welfare’s 
(AIHW) National Drug Strategy Household Survey (NDSHS) is conducted on a 
regular basis to explore the nature of substance use by Australian individuals aged 14 
years and over. They define non-medical use of a substance as use to enhance or 
induce a drug experience, enhance performance, or for cosmetic reasons (AIHW, 
2011). Unfortunately, this survey does not explicitly report on benzodiazepine use, 
but instead describes pharmaceutical medication misuse, which includes pain killers, 
tranquillisers, steroids, methadone and buprenorphine, and other medical opiates. 
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Therefore, both the specificity and the scope of the findings is greatly reduced, and 
the following rates are commented on with caution.  
The rate of pharmaceutical misuse in the general community has been 
steadily and significantly increasing over the past decade. In 2010, 7.4% of the 
general Australian population reported ever having misused pharmaceutical 
medications, with 4.2% reporting such use in the 12 months prior to the survey 
(AIHW, 2011). By 2013, 4.7% reported misusing pharmaceuticals in the past 12 
months, representing a 1% increase since 2007 (AIHW, 2014). Use of tranquilisers 
specifically displayed a non-significant increasing trend, though they were the 
second most frequently misused pharmaceutical drug following pain-
killers/analgesics, with 1.6% of people aged 14 years or older reporting their misuse 
(AIHW, 2014). Inspection of age and gender indicates that tranquilisers were 
predominantly misused by females aged 20-29 years, and males aged 30-39 years 
(AIHW, 2014). Compared to the 2010 data (AIHW, 2011), a new cohort of older 
males appear to be reporting tranquiliser misuse, potentially warranting targeted 
attention in community prevention strategies. Recent estimates however, indicate that 
benzodiazepine misuse occurs at a considerably greater rate in both clinical and 
forensic populations. 
1.3.2.2 Clinical samples. National figures demonstrate high use of 
benzodiazepines in illicit drug-using populations, as 83% of Australian people who 
inject drugs (PWID) have used benzodiazepines (Stafford & Burns, 2012). Within 
Victoria alone, the majority of PWID interviewed between 2008 and 2010 for the 
Illicit Drug Reporting System (IDRS) reported recent benzodiazepine use (74%), 
with 6% injecting benzodiazepines (Horyniak et al., 2012). Moreover, interviews 
with drug treatment clients have demonstrated that only 14% are using 
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benzodiazepines as prescribed, and that whilst only 7% present solely for 
benzodiazepine-related treatment, an additional 37% report benzodiazepine use to 
also cause concern (Nielsen et al., 2008). More recent national figures suggest that 
benzodiazepines are commonly used in the context of other substance use, as 85% of 
those who seek treatment primarily for benzodiazepine use report additional drugs of 
concern (mostly alcohol and cannabis; AIHW, 2013a). It is noted, however, that the 
number of people presenting for treatment for benzodiazepine misuse has reduced, 
with only 2% of national drug and alcohol treatment episodes targeting 
benzodiazepines as the principal drug of concern, and a further 7% of episodes 
targeting benzodiazepines as an additional drug of concern (AIHW, 2013a). 
Historical data suggests that females were more likely to report difficulties with 
benzodiazepines (DCPC, 2007), however recent figures are suggesting males are 
now reporting slightly higher rates of benzodiazepine-related problems than females 
(AIHW, 2013a). Alprazolam and diazepam appear to be the favoured 
benzodiazepines in clinical drug-using populations (Nielsen et al., 2008; Stafford & 
Burns, 2012).   
1.3.2.3 Forensic samples. The Drug Use Monitoring in Australia (DUMA) 
program, an initiative of the Australian Institute of Criminology, reviews the 
substance use and crime patterns of police detainees on a quarterly basis. Compared 
to 2007, when 15% of police detainees reported having used illegal (i.e., non-
prescribed) benzodiazepines in the previous 12 months (Loxley, 2007), recent figures 
indicate that 25% of adult police detainees now report non-medical benzodiazepine 
use (Ng & Macgregor, 2012). This rate is also higher than that pertaining to 
tranquiliser or sleeping pills misuse reported by new prison entrants (16%; AIHW, 
2013b). Importantly, benzodiazepines are the most commonly used type of 
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pharmaceutical among police detainees, often used in combination with other drugs 
(McGregor, Gately & Fleming, 2011; Ng & Macgregor, 2012).  Specifically, 
alprazolam and diazepam are preferred (McGregor et al., 2011; Sweeney & Payne, 
2012).  
The recent inclusion of urinalysis into the DUMA program provides 
corroboration of self-reported substance use. Consistent with self-reported rates, 
nearly one in five (23%) detainees tested positive for benzodiazepines between 2009 
and 2010 (Sweeney & Payne, 2012). During this period, benzodiazepines were the 
second most commonly detected drug (following cannabis), and were most 
commonly detected among females (36%), detainees aged 31-35 years old (32%), 
and property offenders (31%; Sweeney & Payne, 2012). Of note, 20% of violent 
detainees tested positive for benzodiazepines (Sweeney & Payne, 2012), highlighting 
the importance of elucidating the link between benzodiazepine use and violent 
behaviour.  
1.3.3 International data.  
Similar to Australia, benzodiazepines are among the most commonly misused 
pharmaceuticals in New Zealand (Sheridan, Jones, & Aspden, 2012), England 
(Home Office Statistics, 2012; HSCIC, 2011), America (Substance Abuse and 
Mental Health Services Administration [SAMHSA], 2011), and Thailand (Kerr et al., 
2010; Puangkot, Laohasiriwong, Saenqsuwan, & Chiawiriyabunya, 2011). 
Furthermore, illicit benzodiazepines are being seized at increasing rates in European 
countries, and benzodiazepine trafficking and abuse across the Middle East is also 
rising (International Narcotics Control Board, 2014). Given such international use of 
benzodiazepines, enhanced understanding of benzodiazepine-related aggression is 
likely to have wide-reaching implications. 
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1.4 Motivations to Misuse Benzodiazepines 
Despite their widespread misuse, few studies have assessed why people use 
benzodiazepines for non-medical reasons. There is some indication that 
benzodiazepines are used as relief from negative emotions and life experiences, 
predominantly by individuals with low levels of novelty seeking (Adams et al., 
2003). However, studies of clinical and forensic populations suggest that 
benzodiazepine use may be more complex, as findings indicate that benzodiazepines 
are used for multiple reasons. Non-medical use of benzodiazepines has been 
primarily attributed to the reduction of anxiety and stress by American street-based 
illicit drug users, methadone maintenance patients, and residential drug treatment 
clients (Rigg & Ibañez, 2010), and Australian adult police detainees (n = 986; 
McGregor et al., 2011) and injecting drug users (n = 102; Best, Wilson, Reed, & 
Harney, 2012). Subsidiary reasons for non-medical use of benzodiazepines include 
pain relief, drug substitution, to get high (Rigg & Ibañez, 2010; Nielsen et al., 2013), 
and managing alcohol and drug withdrawal (Best et al., 2012; McGregor et al., 2011; 
Nielsen et al., 2008; Nielsen et al., 2013). At other times, benzodiazepines are used 
merely due to availability and curiosity (McGregor et al., 2011), and specifically to 
improve the effects of heroin (Best et al., 2012). As such, opioid users may be more 
likely to use benzodiazepines for recreational reasons (i.e., enhance their opioid 
intoxication; Jones, Mogali, & Comer, 2012), although one French study of opiate-
dependent individuals (n = 92) suggested that benzodiazepines were most commonly 
used for a combination of self-therapeutic and hedonistic motivations over time 
(Fatséas, Lavie, Denis, & Auriacombe, 2009). This deviation may reflect cultural 
differences, or be an effect of self-report data where recall bias may have impacted 
the various outcomes. The literature, however, does paint a concerning picture of 
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benzodiazepines which are inappropriately prescribed and then used to excess for 
both self-medication and to enhance other substance use. As discussed by Bennett, 
Holloway, Brookman, Parry, and Gorden (2014), users may apply ‘techniques of 
neutralization’ to justify their misuse of prescription medication. Introduced as a 
method to explain away delinquent criminal behaviour (Sykes & Matza, 1957), 
techniques of neutralization enable the individual to dismiss any social or legal 
constraints on their behaviour (Bennett et al., 2014). Initially, these included denial 
of responsibility, denial of injury, denial of victim, condemnation of condemners, 
and appeals to higher loyalties (Sykes & Matza, 1957). Application of the concept to 
cannabis use has resulted in substance use specific ‘risk denial techniques’ (e.g., 
scapegoating, comparing risk, emphasising personal control; Peretti-Watel, 2003; 
Sandberg, 2012). Indeed, to justify prescription medication misuse, university 
students most commonly referenced biological need (i.e., desperate for medication), 
legitimacy (i.e., person had superior knowledge or experience of the drug), or denial 
of choice (i.e., GP unavailability, cost of prescription; Bennett et al., 2014). 
Unfortunately, however, although sedatives and tranquilisers were misused by this 
sample, the results are not medication type specific. Regarding benzodiazepines 
specifically, some Australian drug users perceive them to be an “entitlement” as they 
are legally available (Nielsen et al., 2008). This sentiment is likely to impact the 
effectiveness of public health promotion and awareness strategies regarding 
benzodiazepine-related aggression.  
1.4.1 Benzodiazepine sources. 
Not only are benzodiazepines inappropriately prescribed and misused, but so 
too are they acquired from a number of sources. Consequently, there is concern about 
a large hidden population of pharmaceutical misusers who may be unable to be 
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accessed through regular health care streams. Analysis of drug trends in Melbourne, 
Hobart, and Darwin demonstrate that benzodiazepines are often diverted through the 
black market, commonly through forged prescriptions or doctor shopping (Fry et al., 
2007). Indeed, although reflecting a reduction since the 2011-2012 period, 
benzodiazepines were the most commonly detected pharmaceuticals on the 
Australian border during 2012-2013 (Australian Crime Commission [ACC], 2014). It 
appears, however, that substance users are using a combination of legitimate 
prescriptions and illegitimate methods (i.e., street dealers, theft, from friends, as a 
gift) to source benzodiazepines (Best et al., 2013; Havens, Walker, & Leukefeld, 
2010; Nielsen et al., 2013). Poor adherence to prescribing protocols appears to be 
inadvertently supporting benzodiazepine diversion onto the black market. For 
example, Ibañez, Levi-Minzi, Rigg, and Mooss (2013) recently identified that 
diversion of benzodiazepines from healthcare providers is resulting in the provision 
of more benzodiazepine pills (on average) than street dealers. Their survey of various 
drug users (n = 1207) indicated that although patients were accessing healthcare 
providers at a lesser frequency than non-healthcare sources, they were receiving 
greater quantities of benzodiazepines per visit. In addition, healthcare providers were 
more likely to be accessed by higher income participants (Ibañez et al., 2013), again 
highlighting the likelihood of a hidden population of benzodiazepine users who are 
unlikely to be accessed through health care streams. Combined, the findings 
demonstrated that benzodiazepines are easily accessible, and such ease appears to be 
resulting in increasing incidence of benzodiazepine-related harms. 
1.5 Benzodiazepine-related Harms 
Benzodiazepines are being increasingly linked with medical emergencies and 
harm. Worryingly, between 2000 and 2009, benzodiazepine-related cases made up 
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the highest proportion of pharmaceutical drug-related ambulance attendances in 
Melbourne, and there was a significant increase in the proportion of benzodiazepine-
related cases requiring transport to hospital (Lloyd & McElwee, 2011). These rates 
continue to rise across Victoria, with benzodiazepines becoming the second most 
common drug category overall (after alcohol) involved in attendances (Lloyd, 
Matthews, & Gao, 2014). Worse, coronial data from 2011 indicates that half (50.3%) 
of Victorian drug-related deaths involve benzodiazepines; a figure second only to 
opioid analgesics (51.4%; Coroners Court of Victoria, 2013). Benzodiazepines are 
similarly reported at high, and increasing, rates in hospitalisation and/or mortality 
data in America (SAMHSA, 2012), England and Wales (Office for National 
Statistics, 2014), and Scotland (Zador et al., 2007). International findings 
demonstrate benzodiazepine use is common in non-fatally injured emergency room 
patients (e.g., Rockett, Putnam, Jia, & Smith, 2006), especially those with violent 
injuries (e.g., Kurzthaler et al., 2005) and overdose (Hamad, Al-Ghadban, Carvounis, 
Soliman, & Coritsidis, 2000). Injection of benzodiazepines can also lead to a number 
of intravenous-related health complications (Breen, Degenhardt, Roxburgh, Bruno, 
& Jenkinson, 2004). In addition, benzodiazepines increase the risk of being involved 
in a traffic accident by 60-80%, with a 40% increase in responsibility (Dassanayake, 
Michie, Carter, & Jones, 2011). Indeed, benzodiazepines are the second most 
prevalent form of drug found in the blood of Victorian drivers injured in motor 
vehicle collisions, following cannabis (Ch’ng et al., 2007). Of note, benzodiazepine-
related harm data appears to suggest that females may be more likely than males to 
require ambulance or medical attention following benzodiazepine use (Longo, 
Hunter, Lokan, White, & White, 2000; Lloyd & McElwee, 2011; Lloyd et al., 2014). 
This gender inequality reflects a population experiencing drug-related harm which is 
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not reflected in the illicit drug research. Consideration of specific benzodiazepines 
has suggested that alprazolam may be the most toxic benzodiazepine (Isbister, 
O’Regan, Sibbritt, & Whyte, 2004). Indeed, since 2005, and the rise of alprazolam 
prescribing, alprazolam has been increasingly associated with heroin-related deaths 
in Victoria (Rintoul, Dobbin, Nielsen, Degenhardt, & Drummer, 2010). However, 
recent coronial data from Australia and England indicate diazepam to be the most 
commonly identified benzodiazepine in drug-related deaths (Coroners Court of 
Victoria, 2013; Office for National Statistics, 2014). Through reviewing such 
national and international data on benzodiazepine-related harms, a number of 
improvements to benzodiazepine prescribing protocols have been suggested.  
Where benzodiazepines are prescribed, Dobbin (2014) suggests that 
benzodiazepine-related harms can be reduced via thorough assessments of patient 
needs and drug risk, as well as a comprehensive management plan involving 
pharmaceutical medication not subject to abuse and non-medicinal approaches. 
Lader (2014) further argues that a combined pharmaceutical and psychological 
strategy is most appropriate, and that benzodiazepine prescription should only follow 
the exhaustion of alternative options. Such recommendations are made not only in 
response to the concerning harms identified above, but also the more common side 
effects associated with benzodiazepine use.  
1.5.1 Medical effects of benzodiazepine use.  
Benzodiazepines can produce multiple short- and long-term side effects. 
Other than the intended anxiolytic and sedative effects, short term effects can include 
drowsiness, vertigo, motor incoordination, mild impairments in memory and 
concentration, and emotional depression (Longo & Johnson, 2000). Aggravation or 
production of depressive symptoms may be due to serotonin and norepinephrine 
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inhibition, whilst blunted pleasure and pain may be due to the inhibition of the 
emotional centers in the brain (Ashton, 2002). At very high doses the depressing 
effects of benzodiazepines can induce unconsciousness, coma, and even death when 
used in combination with other drugs (DCPC, 2007). Furthermore, benzodiazepines 
can induce neurological changes leading to tolerance, withdrawal, and dependence 
(DCPC, 2007). Withdrawal symptoms can include anxiety, insomnia, autonomic 
hyperactivity, and seizures (Longo & Johnson, 2000).    
Continued use of benzodiazepines can result in effects such as avolition, 
memory loss, personality change, anxiety, irritability, sleep problems, somatic 
problems, and increased aggressiveness (DCPC, 2007). Moreover, benzodiazepine-
induced impaired concentration and attention can negatively affect memory, 
especially episodic memory, which may influence uncharacteristic behaviours 
(Ashton, 2002). As such, benzodiazepine use has been frequently associated with 
increased paradoxical behaviour. 
 1.5.2 Paradoxical effects of benzodiazepines.  
Benzodiazepines have been associated with paradoxical effects, such as 
excitement, irritability, aggression, hostility, and impulsivity (Longo & Johnson, 
2000). Such disinhibition, or the loss of restraint over behaviour, is often socially 
inappropriate, unpredictable, and uncharacteristic of the individual (Bond, 1998). 
Whilst only in a minority of cases (Paton, 2002), disinhibitory reactions (e.g., 
aggression, hyperactivity, inappropriate sexual behaviour) have been observed 
during benzodiazepine use and withdrawal (Bond, 1998), and may lead to 
involvement with the criminal justice system (Redman, 1994). This so called ‘Rambo 
effect’ can occur at both therapeutic and higher doses (DCPC, 2007), and has been 
suggested to be more common following intravenous administration (Ashton, 2002). 
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Two main physiological mechanisms have been hypothesised to explain such 
disinhibition. In some cases, benzodiazepines can stimulate the CNS, leading to 
increased talkativeness, mania, anxiety, restlessness, sleep disturbances, acute rage, 
and extreme aggression (DCPC, 2007). This can also include nightmares, 
hallucinations, exacerbated seizures, and hyperactive behaviour (Ashton, 2002). 
Individuals report feeling invisible and invincible, and are sometimes unaware of 
committing a crime (Fry et al., 2007). Conversely, the Rambo effect may result from 
CNS depression which reduces inhibitions, leading to impaired judgement (DCPC, 
2007) and the suppression of external social cues which would normally guide 
behaviour (Longo & Johnson, 2000). By decreasing the restraining influence of the 
cortex, such depression can provoke increased excitement, psychosis, anxiety, 
hostility, rage, and alcohol use (Paton, 2002). It is unclear what influences these two 
seemingly opposite effects.  
Additional neurological theories specifically attempting to account for 
aggressive behaviour post-benzodiazepine consumption include discussion of genetic 
factors, GABA-related inhibition of neurotransmission, and disruption of the 
endogenous anxiety/threat-detection system (for reviews, see Essman, 1978; Hoaken 
& Stewart, 2003; Paton, 2002; van der Bijl & Roelofse, 1991). The majority of 
related research has been conducted on animals, and therefore has limited 
generalizability to humans. These studies have noted, however, that certain subunits 
on the GABAA receptors (γ, α) may be implicated in aggression mediation (e.g., Lee 
& Gammie, 2010; Miczek, Fish, & DeBold, 2003), with one study suggesting low 
doses of the receptor agonists (i.e., midazolam, triazolam) can significantly increase 
aggression duration and frequency (i.e., biting; Gourley, DeBold, Yin, Cook, & 
Mizek, 2005). Combining benzodiazepines with alcohol has also been demonstrated 
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to enhance aggressive responding in rodents (de Almeida, Saft, Rosa, & Miczek, 
2010; Miczek, Weerts, & DeBold, 1993), and some evidence suggests a history of 
(Ferrari, Parmigiani, Rodgers, & Palanza, 1997), or predisposition towards (Weerts, 
Miller, Hood, & Miczek, 2010), aggressive behaviour enhances benzodiazepine-
related aggression. As informative as such findings are, however, the majority of 
such research provide little options in the way of realistic screening or intervention 
targets for benzodiazepine-related aggression in humans, or have yet to be replicated 
in human research (i.e., role of pre-existing aggressive tendencies). Dose seems 
equally unable to assist our understanding, as both high (Paton, 2002) and low doses 
(Hoaken & Stewart, 2003) of benzodiazepines have been implicated in subsequent 
aggressive responding.  It is therefore important to extend beyond neurological 
reasoning to explore more easily measurable, and potentially changeable, factors, 
such as situational and intrapersonal elements which are associated with this 
response, and base such research on examination of human participants. It is 
precisely these factors that have been argued to be more important in understanding 
the benzodiazepine-aggression relationship (Hoaken & Stewart, 2003; Lion, 
Azcarate, & Koepke, 1975), but which have failed to attract much investigation.  
1.6 Summary 
Benzodiazepines are frequently prescribed and misused, often in an attempt 
to secure a physiological high and/or reduce negative affective experiences. 
However, benzodiazepines have increasingly become associated with medical and 
psychosocial harm on a global level, with ambulance and morbidity data reflecting a 
rise in benzodiazepine use in their patients. Of note, approximately one fifth of users 
experience increased aggressive behaviour following benzodiazepine use, and such 
incidents are as yet poorly understood. Animal data suggests that those who 
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experience an aggressive response may be physiologically vulnerable; however the 
applicability of such findings to human screening and prescribing policies is limited. 
This thesis aims to improve our understanding of benzodiazepine-related aggression 
by exploring the role of contributory factors (such as personality or intrapersonal 
characteristics), in an effort to provide risk indicators more amenable to rapid 
screening (for prescribers) and intervention. The following chapter begins by 
defining the concept of aggression in general in an attempt to provide a broader 
context, before presenting an argument that intrapersonal factors are a highly 
relevant and important concept to explore in order to more fully understand 
benzodiazepine-related aggression. A well-validated theory of personality and 
motivational tendencies which will be used to explore the role of such factors in 
benzodiazepine-related aggression is then introduced. The chapter concludes with a 
more in-depth discussion of the aims of the thesis and how three unique studies (a 
systematic review and two cross-sectional studies) were developed to attend to these 
aims.   
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Chapter Two: Aggression, Intrapersonal factors and Rationale for Thesis 
2.1 Understanding Aggression 
Like all behaviour, aggression cannot be explained through recourse to one 
explanatory factor. Instead, it is multiply-determined, influenced by a complex 
interplay of internal (i.e., beliefs, neurobiology, personality, intoxication) and 
external (i.e., environment, opportunity, frustration) factors. The general aggression 
model (GAM; Anderson & Bushman, 2002), for example, proposes that situational 
(e.g., aggression cues, drugs, frustration, incentives, pain) and person inputs (e.g., 
traits, beliefs, values, attitudes, goals) inform behavioural outcomes (i.e., an 
aggressive episode) through the internal states that they create. Such internal states 
may include cognitions such as hostile thoughts or aggressive scripts, feelings such 
as anger or hostility, and heightened physiological arousal (Anderson & Bushman, 
2002). Factors which have been empirically linked with aggressive behaviour include 
certain neurotransmitters and brain structures (i.e., serotonin, GABA, frontal lobe, 
limbic system), mental health diagnoses and distress, sociological factors (i.e., peer 
pressure, social information processing), personality predispositions (i.e., 
impulsivity, hostility, antisociality, anger), and criminal history (for reviews, see 
Anderson & Bokor, 2012; Chereji, Pintea, & David, 2012; Schenk & Fremouw, 
2012). Notably, associations between illicit drugs and violent crime have been well 
established in the literature (Friedman, 1998), with particular reference to alcohol 
(e.g., Lennings, Copeland, & Howard, 2003), methamphetamines (e.g., McKetin et 
al., 2014), and anabolic steroids (e.g., Klötz, Petersson, Isaacson, & Thiblin, 2007; 
Lundolm, Kall, Wallin, & Thiblin, 2010). Surprisingly, however, examinations of 
benzodiazepine-related aggression or violence have rarely included exploration of 
potential contributory factors such as those listed above (i.e., mental health, 
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sociological factors, intrapersonal differences). By improving our understanding of 
benzodiazepine-related aggression, we can hope to affect change in reducing the 
frequency of this response, reducing health care costs (financial and personal), and 
reducing forensic spending for judiciary, incarceration, and rehabilitation phases. 
2.1.1 A note on definitions. 
There is contention within the literature regarding the definitions of 
‘aggression’ and ‘violence’. This includes various definitions of aggression as 
involving anger, verbal, psychological, indirect (or social), and physical aspects (e.g., 
Björkqvist, 1994; Buss & Perry, 1992); instrumental or reactive motives (Buss, 
1961); and highly specific types of violence (i.e., intimate partner violence; e.g., 
Straus & Mickey, 2012; Grych & Swan, 2012). Violence has been described as a 
more severe type of aggression (DeWall, Anderson & Bushman, 2011), and is 
therefore more frequently used in forensic contexts than research arenas (which 
favour the term ‘aggression’), although the two terms have and can be used 
interchangeably (e.g., Anderson & Bokor, 2012).  
The current thesis adopts the definition of ‘aggression’ proposed by Baron 
and Richardson (1994), which is commonly referenced in aggression and violence 
literature (e.g., Anderson & Bokor, 2012; Hoaken & Stewart, 2003). However, as 
physical aggression is the topic of interest, some modifications to the definition have 
been made, in order to exclude instances and discussion of verbal or psychological 
aggression, as it is considered that they reflect very different types of aggression, and 
likely include different psychological barriers and different consequences. For the 
purposes of this thesis, aggression is therefore defined as physical force directed 
towards a person motivated to avoid such force (i.e., psychological or verbal 
aggression/violence was excluded). The current thesis also uses ‘violence’ to refer to 
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more severe or officially documented acts of aggression (i.e., resulting in 
conviction). To not include ‘violence’ within our definition would exclude the 
forensic studies which explored ‘violent behaviour’ or ‘violent crime’, and to 
exclude studies exploring ‘aggression’ would exclude a wealth of data from clinical 
and healthy populations (including the experimental data), involving a somewhat 
lower severity of violent behaviour.  
2.1.2 Importance of intrapersonal factors. 
Personality traits and motivational tendencies provide indicators of a person’s 
characteristic manner of interacting with the world. They are pervasive and endure 
across time and situations, and can inform the likelihood of engagement in certain 
behaviours. Research in the addiction field has demonstrated the applicability of an 
individual’s personality traits to problematic substance use, related problems, and 
treatment (e.g., Staiger Kambouropoulos, & Dawe, 2007). Similar findings have also 
been demonstrated in the aggression and violence literature (e.g., Hosie, Gilbert, 
Simpson, & Daffern, 2014; Jones, Miller, & Lynam, 2011; Miller, Lynam, & 
Leukefeld, 2003). Not surprisingly, such intrinsic person characteristics have been 
argued to be highly influential in the benzodiazepine-violence relationship (Hoaken 
& Stewart, 2002; Lion et al., 1975). Interestingly, however, little research has been 
conducted into these potential explanatory factors.  
Investigation of the benzodiazepine-aggression relationship has tended to 
focus on establishing and replicating associative findings. As will be discussed in 
greater depth in Chapter 3, cross-sectional and laboratory studies have found positive 
findings between certain benzodiazepines, such as diazepam and alprazolam, and 
self-reported aggression or behavioural proxies of aggressive behaviour. However, 
only cursory investigation of contributory or explanatory factors has occurred. 
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Notably, only a handful of cross-sectional and experimental studies have assessed the 
potential role of intrapersonal characteristics, including psychiatric vulnerability or 
personality traits, when examining benzodiazepine-related aggression. For example, 
Dåderman and colleagues explored the case histories of Swedish male forensic 
populations (via file review and semi-structured interviews) to identify whether there 
was a link between flunitrazepam use, personality and violent offending. Although in 
one study they found no personality differences between flunitrazepam users and 
non-users (Dåderman & Edman, 2001), they suggested that certain personality traits 
(i.e., boredom susceptibility, verbal aggression, Dåderman & Lidberg, 1999; anxiety, 
low self-esteem, Dåderman, Fredriksson, Kristiansson, Nilsson, & Lidberg, 2002; 
psychopathy characteristics, Dåderman, Edman, Meurling, Levander, & 
Kristiansson, 2012) may influence an aggressive response to flunitrazepam. 
However, their conclusions relied on targeted examination of flunitrazepam-using 
violent offenders (Dåderman & Lidberg, 1999; Dåderman et al., 2002) or violent 
offenders without non-violent control groups (Dåderman & Edman, 2001; Dåderman 
et al., 2012), failed to statistically account for poly-substance use, have limited 
generality, and cannot suggest temporal causality between flunitrazepam use and 
violent offending. However, the use of more stringent, controlled designs has 
provided little further explanation of the role of intrapersonal factors in this response. 
To date, only two experimental studies have explicitly examined the role of 
personality in benzodiazepine-related aggression (Ben-Porath & Taylor, 2002; 
Wilkinson, 1985), though an additional early study did identify interesting 
personality-related results post-hoc (Cherek, Steinberg, Kelly, Robinson, & Spiga, 
1990). Wilkinson (1985), using double-blind and placebo-controlled methods, and a 
competitive reaction time task, identified that diazepam-related aggression may be 
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mediated by trait anxiety. In her study, undergraduates who were less cautious of 
their environment (i.e., low trait-anxious) displayed the greatest enhancement in 
responding indicative of aggression following diazepam consumption, compared to 
high trait-anxious undergraduates. In a similarly designed study, Ben-Porath and 
Taylor (2002) suggested that diazepam-related aggression may be related to hostility, 
as undergraduates who exhibited higher scores on a standardised hostility measure 
displayed greater increases in aggression following diazepam use than those with 
lower hostility scores. This group difference, however, failed to reach significance. 
Cherek and colleagues (1990) also highlighted the role of hostility, as increased 
aggressive responding following diazepam use was only observed in participants 
with high hostility scores. However, the sample on which this conclusion is based 
was very small (n = 9), making overall conclusions regarding the role of hostility in 
this response tentative at best. Unfortunately, additional laboratory studies which 
reported to measure personality characteristics failed to analyse or discuss whether 
individual differences affected aggressive responding (Bond, Curran, Bruce, 
O’Sullivan, & Shine, 1995; Bond & Lader, 1988; Bond & Silveira, 1993; Pietras et 
al., 2005).  
Research into benzodiazepine-related aggression has rarely explored the role 
of contributory factors, such as intrapersonal characteristics. As noted above, the 
handful of studies which have included such analysis examined various 
characteristics, often with minimal (if any) theoretical reasoning as to the relevance 
or importance of the characteristic(s) selected. The current thesis aims to build on 
this research, by taking a theory-driven approach to understanding the personality 
and motivational factors associated with benzodiazepine-related aggression. Such an 
approach can provide treatment and risk management outcomes which are based 
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upon a strong theoretical basis, are testable, and can inform the development of 
further research. As will be demonstrated in Chapter 4, a large community-based 
study will use a well-validated theory of approach and avoidance motivation, the 
Reinforcement Sensitivity Theory (RST), to measure the role of motivational 
tendencies in benzodiazepine-related aggression. The main assumptions of this 
theory are presented below, with commentary on how this theory may be valuable in 
furthering our understanding of benzodiazepine-related aggression.  
2.1.2.1 Gray’s (revised) Reinforcement Sensitivity Theory. The RST is a 
neuropsychological theory of emotion, motivation, learning processes, and 
personality (Corr, 2009). The theory has undergone substantial revisions since its 
original conceptualisation (Gray, 1982), and the current thesis applies the Gray and 
McNaughton (2003) revision (rRST). The theory postulates that individual 
sensitivities to punishment and reward lead to motivations to engage in approach or 
avoidance behaviour. An individual’s tendency to engage in approach or avoidance 
behaviour provides an indication of their underlying personality (i.e., trait 
impulsivity or anxiety, respectively; Corr, 2009). This theory was purposefully 
selected due to its strong validation across research of problematic substance use and 
related outcomes (e.g., Booth & Hasking, 2009; Dissabandara, Loxton, Dias, 
Daglish, & Stadlin, 2012; Loxton et al., 2008), its biological underpinnings which 
specifically account for the impact of benzodiazepines on the functioning of certain 
motivational tendencies (see discussion below; Gray & McNaughton, 2003), and its 
conceptually sound nature. In addition, the current application of the rRST not only 
enhances our understanding of benzodiazepine-related aggression and theoretical 
rigour of related research, but it also expandes the rRST literature to include 
benzodiazepine use, providing precedence for future comparative studies. The theory 
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proposes three separate but interacting motivational systems which make up 
personality (Corr, 2004), and influence approach, avoidant, and cautious behaviour 
(Corr, 2008).  
Approach tendencies. The behavioural approach system (BAS) mediates 
reactions to appetitive stimuli (Corr, 2004), and is thought to be primarily modulated 
by dopamine (Pickering & Corr, 2008). Approach motivation promotes anticipatory 
pleasure, and is associated with the personality traits of optimism, hope, reward 
orientation, and impulsivity (Corr & Perkins, 2006). However, it has been suggested 
that impulsivity does not explain the full range of processes involved in this system, 
such as restraint and planning (Corr, 2009), and that extraversion (Pickering & Corr, 
2008) or reward learning (Berkman, Lieberman, & Gable, 2009) may mediate 
activation of the system instead. This contention is reflected in the two main 
measures of the BAS, where Torrubia, Ávila, Moltó, and Caseras (2001) 
conceptualise the system as primarily involving sensitivity to reward cues in their 
Sensitivity to Punishment Sensitivity to Reward Questionnaire (SPSRQ), whilst 
Carver and White’s (1994) BIS/BAS scales include three components which seem to 
involve the processes mentioned above – drive (i.e., goal pursuit, functional 
impulsivity), fun seeking (i.e., dysfunctional impulsivity, minimal thought to 
consequences), and reward responsiveness (i.e., positive energy and affect in 
response to reward cues; Tull, Gratz, Latzman, Kimbre, & Lejuez, 2010). Clinically, 
approach motivation has been associated with addictive behaviours, high-risk 
impulsive behaviours, and some aspects of mania (Corr & Perkins, 2006). It has been 
suggested that impulsivity, more than reward responsiveness, underlies the approach 
motivation and substance use relationship (Corr, 2008). Of note, and as will be 
discussed in Chapter 4, approach motivations have been consistently associated with 
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aggressive behaviour, most notably the BAS characteristic Drive. Reflecting a 
tendency to be persistent in the pursuit of desired goals, Drive has been positively 
associated with anger (Smits & Kuppens, 2005), the tendency to not suppress anger 
or its expression (Cooper, Gomez, & Buck, 2008), and aggressive behaviour 
(Harmon-Jones, 2003; Seibert, Miller, Pryor, Reidy, & Zeichner, 2010), and appears 
to operate along similar neural structures and pathways as does aggressive behaviour 
(Beaver, Lawrence, Passamonti, & Calder, 2008). Due to its strong association with 
aggressive tendencies, particular attention is paid to whether Drive can contribute to 
our understanding of benzodiazepine-related aggression.  
Aversive (inhibitory) tendencies. The fight-flight-freeze system (FFFS) 
mediates reactions to both conditioned and unconditioned aversive stimuli, and 
produces escape or avoidance behaviours (Corr, 2004). This system is associated 
with the emotion of fear (Corr, 2004), and fearful and avoidant personality traits 
(Corr & Perkins, 2006). When threat is distal, this system produces flight or freezing, 
whilst in the face of proximal danger, it produces a fight reaction (Jackson, 2009). 
Empirical research has demonstrated that individuals highly sensitive to fear are 
more likely to engage in threat magnification, perceiving threats as especially close 
and intense (Perkins, Cooper, Abdelall, Smilie, & Corr, 2010). Clinically, a strong 
fear system is associated with phobia and panic (Corr & Perkins, 2006). 
The behavioural inhibition system (BIS) aims to resolve goal conflict which 
generates anxiety (Corr, 2004). Thought to be distributed over a number of neural 
structures (Pickering & Corr, 2008), this system assesses risk and works to increase 
risk aversion (Corr, 2008). Conflicts are usually approach-avoidance, but can also be 
approach-approach, or avoidance-avoidance (Corr & Perkins, 2006). Simultaneous 
and similar activation of the above two systems stimulates this conflict resolution 
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system (Pickering & Corr, 2008). The system increases arousal (Tull et al., 2010), 
initiates risk assessment, scans memory (Corr, 2004), and increases the negative 
valence of stimuli in order to resolve the goal conflict (Corr & Perkins, 2006). 
Subjectively, the process presents as rumination and worry, with a sense of possible 
danger or loss (Corr, 2004), and is predominantly associated with trait anxiety (Corr, 
2002). Clinically, inadequate goal resolution presents as generalised anxiety and 
obsessive-compulsive disorder (Corr & Perkins, 2006). An important distinction 
between the BIS and FFFS is that in situations of threat which do not need to be 
faced, fear mediates avoidant behaviour (Perkins, Kemp, & Corr, 2007), yet when 
threatening stimuli must be faced,  the BIS is activated, producing anxiety-mediated 
risk assessment, cautious approach behaviour, or withheld entrance (Perkins et al., 
2007). Anxiolytics (i.e., benzodiazepines) have been demonstrated to selectively 
impact the BIS, and reduce the salience of threats of punishment, failure, or the 
uncertainties of novel situations, reducing inhibited behaviour and promoting a more 
care-free attitude (Gray & McNaughton, 2003).  
Collectively, the approach and avoidance motivations driven mediated by the 
BIS and FFFS in response to aversive stimuli are referred to as punishment 
sensitivity. Individuals who display strong punishment sensitivity only are argued to 
be least likely to engage in aggressive behaviour following benzodiazepine 
consumption. Although benzodiazepines may induce a change from threat-reactive 
behaviour to neutral, pre-threat behaviour, it is suggested that in most individuals this 
does not extend to violent behaviour. These individuals are not sensitive to reward 
cues or impulsive by nature, and therefore would be less likely to act with minimal 
thought to consequences, such as responding aggressively to slights or frustration. It 
is acknowledged that some trait-fearful individuals may engage in aggressive 
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behaviour when they perceive a threat to be especially close or intense (Jackson, 
2009), though this behaviour presents only in a minority of cases. However, as 
outlined below, if a punishment sensitive individual also exhibits strong approach 
motivation, benzodiazepine-related aggression is argued to be increasingly likely.   
System interactions and frustrative non-reward. Initially, the RST conceived 
reward and punishment sensitivity as separate motivational systems 
(Kambouropoulos & Staiger, 2004). However, inconsistent findings in the literature 
regarding individual responses to reward and punishment prompted a different 
conceptualisation (Corr, 2004). The Joint Systems Hypothesis (JSH) proposes that 
under certain conditions, reward and punishment can exert interdependent effects, as 
the related sensitivities are both facilitative and antagonistic (Corr, 2004). This 
hypothesis describes the ability of aversive stimuli to facilitate fear and anxiety 
whilst antagonising approach motivation, and of appetitive stimuli to facilitate 
approach behaviour whilst inhibiting avoidance (Corr, 2004). Specifically, 
individuals with high levels of impulsivity (or approach motivation) and low levels 
of trait anxiety will demonstrate the strongest reactions to appetitive stimuli, and vice 
versa for aversive stimuli (Kambouropoulos & Staiger, 2004). 
However, the systems do not always interact in such an antagonistic fashion. 
Whilst it has been suggested that a personality characterised by both high trait 
anxiety and high impulsivity is unlikely (Pickering & Corr, 2008), individuals with 
such a trait pattern have been found to demonstrate the greatest level of behavioural 
inhibition (Kambouropoulos & Staiger, 2004),  neuroticism (Perkins et al., 2007), 
and quick response times during goal pursuit (Berkman et al., 2009). Moreover, such 
an interaction between appetitive and aversive motivations is evident in frustrative 
non-reward (FN), experienced when the expected reward is higher than the actual 
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reward (Corr, 2002). FN is a signal of non-reward (i.e., punishment) which 
implicates aversive motivation, and also reflects a sensitivity to reward cues and 
expectancies, implicating appetitive motivation; an individual with high appetitive 
motivation (i.e., BAS) would be the first to detect non-reward and experience FN 
(Corr, 2002). This suggests that FN may be caused by reward sensitivity and 
mediated by punishment sensitivity, and therefore levels of FN should be greatest in 
individuals with both high approach and avoidance motivation (Corr, 2002). It is 
these individuals who we would expect to be most likely to experience aggressive 
responses in the face of frustration or goal blocking.  
Such interactive effects have yet to be explored in relation to substance-
related aggression, much less benzodiazepine-related aggression. The complexity of 
the antagonistic and facilitative interactions between human motivational systems 
demonstrates why it is essential to more deeply explore the intrapersonal 
characteristics of those who experience benzodiazepine-related aggressive behaviour, 
in order to provide more educated treatment and pharmaceutical management 
options. The original study presented in Chapter 4 was specifically designed in order 
to elucidate such deeper understanding of this response. 
2.2 Summary and Thesis Rationale 
A number of serious medical and forensic outcomes are associated with 
benzodiazepine use. Most notably, benzodiazepine-related disinhibition is a cause for 
concern, due to its association with motor vehicle accidents, risk taking, aggressive 
incidents, and subsequent memory deficits, which can have implications in both 
medical and forensic arenas. In particular, benzodiazepine-related aggression is 
poorly understood, despite the high rate of benzodiazepine misuse in criminal justice 
samples (including violent offenders), in countries where violent crime remains 
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among the most commonly recorded types of crime. The potential legal, medical and 
social ramifications of violent behaviour, and the increasing diversion of 
benzodiazepines onto the black market and subsequent increases in misuse, indicates 
a need to further understand the relationship between benzodiazepine use and 
violence. The complexity likely involved in this response has impacted the literature 
base, as there are a number of explanatory gaps and flaws in what we understand 
about benzodiazepine-related aggressive behaviour. One core gap in the literature is 
the identification of clear, consistent risk indicators for this response.  
It has been suggested that a drug can alter the occurrence of aggressive 
behaviour in an individual, depending on the individual’s underlying personality 
(Paton, 2002). This premise is supported by laboratory findings demonstrating 
individuals with certain underlying characteristics (i.e., hostility, low trait anxiety) to 
be more likely to experience significant increases in aggressive behaviour following 
benzodiazepine consumption (e.g., Cherek et al., 1990; Wilkinson, 1985). However, 
despite such early theorizing (Lion et al., 1975), surprisingly little empirical literature 
has been conducted into contributory factors such as personality or motivational 
states. Without clear understanding of such contributory mechanisms, efforts cannot 
be made to curtail benzodiazepine-related violence and its harmful medical and legal 
sequelae. Furthermore, prescribing policy cannot be informed about potential risks 
and contraindications for the prescription of benzodiazepines. This thesis will 
therefore investigate the premise that intrapersonal factors (i.e., personality, 
motivational factors, mental health) provide strong indicators of whether aggressive 
behaviour is experienced post benzodiazepine consumption. Examining such 
individual differences provides clear, easily identifiable risk factors to be considered 
when prescribing benzodiazepines. 
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2.2.1 Thesis aims, hypotheses and chapters. 
The overall aim of the following research is to further understand the 
relationship between benzodiazepine use and subsequent interpersonal aggression 
and violence. This seemingly paradoxical response is of concern given the reasons 
that benzodiazepines are generally prescribed, the context in which they are 
prescribed, and the increasing misuse of benzodiazepines in healthy, clinical, and 
forensic populations. Within this overarching aim, the following research has three 
specific directives:  
1. To systematically review the benzodiazepine-aggression literature base to 
specifically identify benzodiazepine type and dose, and individual 
characteristics associated with benzodiazepine-related aggression.  
2. To enhance the theoretical rigour of benzodiazepine-aggression literature.  
3. To identify characteristics associated with benzodiazepine-related violence in 
a benzodiazepine-using, community-based criminal justice sample.  
Attending to Aim 1, Chapter 3 presents a systematic review of the currently 
available literature exploring benzodiazepine-related aggression. Particular attention 
is paid to the role of different benzodiazepine types and dose, as well as participant 
characteristics, in understanding this response. As will be discussed, the current 
literature base, whilst informative, is flawed and often inconsistent, and highlights 
the need for further systematic research of the various types of benzodiazepines and 
greater statistical and measurement control.  
Attending to Aim 2, Chapter 4 presents an original, cross-sectional study of 
community members which tests a well-validated theory of motivational tendencies 
against benzodiazepine-related aggression, and assesses the relative importance of 
such tendencies, compared to benzodiazepine-related factors (i.e., type, dose), in 
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predicting general aggression (i.e., including anger, verbal aggression) and physical 
aggression specifically. Participants are community members over the age of 18 
years, who report having used benzodiazepines at some point during the past year. 
Through the use of hierarchical multiple regression, the study tests the hypotheses 
that: 
1. Motivational factors will significantly predict engagement in benzodiazepine-
related aggressive behaviour over and above benzodiazepine type or use; 
2. BAS-Drive will significantly predict general aggression and physical 
aggression; and 
3. BAS-Drive will moderate the relationship between BIS and aggressive 
outcomes. Specifically, it is predicted that the relationship between BIS and 
aggressive behaviour will be stronger for individuals with high levels of 
BAS-Drive. 
Attending to the final aim, Chapter 5 presents a second, smaller cross-
sectional study which examines the differences between violent and non-violent 
offenders’ benzodiazepine use patterns and intrapersonal characteristics (i.e., mental 
health, personality). Participants are community-based offenders who committed a 
crime in the six months prior to data collection, and who report using 
benzodiazepines on a regular (at least monthly) basis. The study predicts that: 
1. Individuals engaged in violent crime will report greater benzodiazepine use, 
and higher doses, than non-violent offenders; and 
2. Violent offenders will display a more complex psychiatric and social history 
than non-violent offenders. 
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The findings of Chapters 3-5 will be combined in Chapter 6 in a discussion of 
how the thesis furthers our understanding of benzodiazepine-related aggression. 
Based on the combined research, the chapter will discuss the implications for 
benzodiazepine prescribing practices and policy, provide commentary on the recent 
rescheduling of alprazolam to a controlled substance (Schedule 8), discuss access to 
benzodiazepines in forensic contexts, and indicate treatment targets both within the 
addiction and forensic mental health sectors. It is hoped that this research will also 
inform legal decision making about the potential culpability of an offender, and the 
use of (in)appropriate legal defences. 
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Chapter Three: Benzodiazepine Use and Aggressive Behaviour: A Systematic 
Review 
Please note, this chapter presents an expanded version of a systematic review 
published in the Australian and New Zealand Journal of Psychiatry (2014), due to 
copyright reasons. A link to the original article has been appended for your 
consideration (Appendix A).  
3.1 Rationale  
Benzodiazepines are one of the most commonly prescribed pharmaceuticals 
in developed countries (AIHW, 2011; Home Office Statistics, 2012; HSCIC, 2011; 
Stephenson, Karanges, & McGregor, 2013; SAMHSA, 2011). They are commonly 
prescribed for the management of anxiety, sleep disorders, agitation and alcohol 
withdrawal (Ashton, 2002). Although the most common effects of benzodiazepines 
include sedation and reduced anxiety, there have been reports of some users 
experiencing behavioural disinhibition following consumption, which includes 
aggressive behaviour (Bond, 1998; Fry, Smith, Bruno, O’Keefe, & Miller, 2007; 
Paton, 2002). In fact, it is estimated that anywhere between 1-20% of benzodiazepine 
users experience some form of increased anger or express aggression (Lader, 2011).  
Furthermore, a number of clinical case studies report that individuals experience 
aggressive responding following administration of a range of benzodiazepines 
including diazepam (Gardos, 1980; Lion, Azcarate, & Koepke, 1975; Zisook and 
DeVaul, 1977), clorazepate (Karch, 1979), alprazolam (Rosenbaum, Woods, Groves, 
& Klerman, 1984), clonazepam (Binder, 1987; Kalachnik, Hanzel, Sevenich, & 
Harder, 2003), and flunitrazepam (Dåderman, Stridlund, Wiklund, Fredriksen, & 
Lidberg, 2003). Such incidents occurred at both high and low doses (approximate 
diazepam equivalent doses (DZM) ranging between 5-240mg), and by individuals 
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with (Kalachnik et al., 2003; Lion et al., 1975) and without (Karch, 1979) histories of 
aggressive behaviour. Despite this accumulating clinical evidence, there has been no 
systematic review of the existing literature to inform policy or practice.  
A complicating factor is the variable definitions of aggression used within the 
literature. For the purposes of this report, aggressive behaviour is defined as physical 
behaviour directed toward another person with the goal of harming or injuring that 
person, who is motivated to avoid such behaviour (Baron & Richardson, 1994). The 
term ‘violence’ is often used interchangeably with ‘aggression’, although commonly 
reflects more serious harm (Anderson & Bushman, 2002) and forensic contexts 
(Anderson & Bokor, 2012). Our deliberate and sole focus on physical aggression 
directed toward another person is due to the potential severe medical and legal 
consequences of such responses (i.e., hospitalisation and mortality; legal 
responsibility, sentencing, and rehabilitation considerations).  
Of note, this issue has significant implications for judicial decision-making 
pertaining to violent offending behaviour. For example, a study of 102 injecting drug 
users (with a range of criminal histories) reported that benzodiazepine use was 
associated with unprovoked aggressive behaviour (20%), fights (13%) and crime 
(14%; Smith, Miller, O’Keefe, & Fry, 2007). Furthermore, self-reported substance 
use in adult police detainees (n = 1884) indicated that 27% of users attributed their 
current offence to benzodiazepine use (Payne & Gaffney, 2012).  Although limited 
by the use of retrospective self-attributions of behaviour and the lack of control for 
concurrent substance use, these findings do highlight that disentangling these issues 
via a systematic and critical analysis of the literature is timely.  
In terms of how benzodiazepines increase aggressive responding, Lion and 
colleagues (1975) suggest an interaction between drug use, personality, and 
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environmental factors, with more recent research highlighting that personality may 
be as, or more, important than pharmacological factors (Ben-Porath & Taylor, 2002; 
Hoaken & Stewart, 2003; Paton, 2002; Wilkinson, 1985). The latter premise is 
highlighted by research implicating both high (Paton, 2002) and low doses (Hoaken 
& Stewart, 2003) of benzodiazepines in subsequent aggressive responding. The 
circumstances under which aggressive behaviour is likely to result following 
benzodiazepine consumption are poorly understood and the literature lacks a 
systematic review of the empirical research investigating the relationship between 
benzodiazepine consumption and subsequent aggressive or violent behaviour. This 
relationship needs to be understood when considering prescribing protocols, and the 
potential clinical and legal implications of aggressive responses.  This chapter 
therefore reports on a systematic review addressing the question: Does 
benzodiazepine consumption increase aggressive behaviour in adult humans? 
3.2 Methods 
A systematic review was designed and reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
(Liberati et al., 2009; Moher, Liberati, Tetzlaff, Altmann, & The PRISMA Group, 
2009).  The Maryland Scale of Scientific Rigor (Sherman et al., 1998) was applied to 
assess each study’s internal validity.  According to this scale, studies are ranked from 
1 (weakest) to 5 (strongest), with the main considerations pertaining to control of 
extraneous variables, minimisation of error variance, and sufficient power for 
meaningful statistical differences. Randomised clinical trials (RCT) and well 
controlled experimental studies provide the strongest level of scientific rigor 
(Sherman et al., 1998). Although experimental studies can inform the impact of acute 
doses, they provide limited information on chronic use, and the findings are based on 
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highly contrived circumstances.  Therefore, less rigorous designs (i.e., cross-
sectional, prospective) were also included in this review in order to enhance the 
ecological and clinical validity of the findings.  However, at the lowest level of 
evidence (Merlin, Weston, & Tooher, 2009), case studies were excluded from 
consideration due to their poor generalizability (Evans, 2003).  
3.2.1 Eligibility criteria. 
Studies investigating the relationship between benzodiazepines and 
aggression in adult human populations were located. Inclusion criteria included 
English language and peer-reviewed journal articles. Studies examining self-
reported, observed, and behavioural analogues of other-directed aggression, defined 
as physical behaviour directed towards another person with the goal of harming or 
injuring that person who is motivated to avoid such behaviour, were included. 
Exclusion criteria included animal studies, unrelated neurobiological studies, case 
studies, and clinical trials which did not explicitly measure aggression. Articles were 
excluded if they only investigated hostility, anger, self-directed aggression (e.g., self-
harming behaviours), the intent to act aggressively, or verbal or psychological 
aggression. Articles were also excluded if they investigated non-benzodiazepine 
sedatives, hypnotics, or anxiolytics. Synthesis articles (i.e., reviews, meta-analyses) 
were excluded following examination of their reference lists for original articles 
meeting the above criteria. 
3.2.2 Information sources. 
The search was applied to Medline Complete, PsycARTICLES, PsycINFO, 
Academic Search Complete, and the Psychology and Behavioural Sciences 
Collection electronic databases. Search terms used were: benzo*, BZD, sedative, 
hypnotic, anxiolytic, anti-anxiety medication, anti-anxiety drug, tranquilisers, 
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tranquilizers, diazepam, lorazepam, temazepam, alprazolam, flunitrazepam, 
oxazepam, clonazepam, nitrazepam, aggress*, and violen*. The limiter ‘English 
language’ was used for PsycINFO, Academic Search Complete, and Medline 
Complete. The limiter ‘peer reviewed’ or ‘scholarly (peer reviewed) journals’ was 
used for all databases except Medline as this was not available. The limiter of 
‘human’ or ‘human population’ was used for PsycARTICLES, PsycINFO, and 
Medline. The final search was run on 7 December, 2012. 
3.2.3 Study selection. 
Two authors (BA and PS) independently screened the titles and abstracts of 
all publications obtained by the search strategy (2492), and assessed the full text of 
selected articles (64) for inclusion. In questionable cases, the authors discussed the 
inclusion and exclusion requirements and came to a consensus. 
3.2.4 Data extraction. 
Information was extracted from each study on: (1) participant characteristics 
(including gender, age, clinical diagnosis, behavioural history if reported); (2) study 
design and method (including benzodiazepine type, dose, frequency; versus placebo; 
corroboration of self-reported information; single- or double-blinded techniques); 
and (3) type of outcome measure (including behavioural rating scale, behavioural 
analogues, self-report). 
3.3 Results 
3.3.1 Study selection. 
The initial database search revealed a total of 2492 articles. Of these, 2428 
studies were discarded as duplicates or because they did not meet the criteria (see 
Fig. 1). The full text of the remaining 64 citations was examined in more detail. An 
additional 15 articles were identified by examining the reference lists of these 
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citations and through previous literature searches. Thirty articles did not meet the 
inclusion criteria as described, including 19 non-systematic reviews, and a review 
investigating the behavioural side effects of benzodiazepines in individuals with an 
intellectual disability (Kalachnik, Hanzel, Sevenich, & Harder, 2002). Upon detailed 
study, two studies were excluded (Cherek, Steinberg, & Kelly, 1987; Cowdry & 
Gardner, 1988) because they reported the same data as a further two (Cherek, 
Steinberg, Kelly, Robinson, & Spiga, 1990; Gardner & Cowdry, 1985, respectively); 
the latter two contained more methodological and statistical detail. One experimental 
study (Brown, 1978) was excluded as it failed to report methodological or statistical 
outcome detail. Hence, 46 studies met the inclusion criteria.  
3.3.2 Study characteristics. 
 The 46 studies varied considerably in terms of study design, type of samples, 
the range of benzodiazepines examined and doses considered. Due to the 
heterogeneity of study design and benzodiazepine type and dose, it was not possible 
to conduct a meta-analysis on the reviewed data. Design: The association between 
benzodiazepine consumption and subsequent aggressive behaviour had been 
explicitly investigated in two prospective studies, 25 cross-sectional studies, six 
clinical studies, and 13 experimental studies. Sample: The studies investigated 
clinical (n = 15), forensic (n = 12), and healthy community (n = 19) samples. Drug 
Type: Benzodiazepines investigated across the studies included diazepam, 
alprazolam, flunitrazepam, triazolam, temazepam, clonazepam, oxazepam, 
lorazepam, and clorazepate. Diazepam and alprazolam received the most attention (9 
and 6 studies, respectively), and 43.5% (n = 20) studies explored non-specific 
benzodiazepine use.  Dose: The included studies investigated both therapeutic and 
higher doses; approximate DZM equivalent doses for the clinical and experimental  
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Figure 1. PRISMA Flow Diagram depicting the flow of information through the 
stages of the systematic review. 
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studies ranged between 3.3-100mg and 2-20mg, respectively. The experimental 
studies examined acute benzodiazepine administration, whilst the clinical studies 
explored chronic administration ranging from four days to three months. Cross-
sectional and prospective studies did not specify dose. Table 1 and 2 detail the 
characteristics of the included studies. 
3.3.3 Risk of bias within studies. 
There were multiple risks of bias in each article reviewed, ranging from 
limited generalizability to potential confounding by drug interactions, as detailed in 
the tables. Application of the Maryland Scale of Scientific Rigor (Sherman et al., 
1998) demonstrated that overall, 56.5% (n = 26) of the included studies are of a 
Level 1 standard, and only 6.5% (n = 3) are of a Level 5 standard, indicating that the 
quality of the evidence base surrounding the benzodiazepine-aggression relationship 
is poor. 
3.4 Synthesis of Results  
Does benzodiazepine consumption increase aggressive behaviour in adult 
humans? 
The reviewed literature demonstrated a moderate relationship (with some 
inconsistency) between benzodiazepine consumption and subsequent aggression. 
Diazepam demonstrated the greatest association with increased aggression (n = 6 
studies), and has been examined in more high level (Levels 4 and 5; n = 3) studies 
than any other benzodiazepine.  
3.4.1 Experimental studies. 
The 13 experimental studies utilised either the Taylor Aggression Paradigm 
(TAP; n = 10) or the point subtraction aggression paradigm (PSAP; n = 3), with the 
majority utilising placebo-controlled (n = 11) and double-blind (n = 9) methods. The  
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Table 1 
Characteristics of included studies assessing non-specific benzodiazepine-related aggressive behaviour, ordered by year of publication.  
Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
Haller & 
Deluty, 
1990 
 
Cross-
sectional 
100 
cases 
(80 
clients; 
49% 
F) 
- Severely 
assaultive 
psychiatric 
patients  
File 
examination 
Specificity – 
“anxiolytics” 
No temporal causality  
 
Anxiolytic prescription 
positively related to assault 
severity 
1 
Dawson, 
1997 
Cross-
sectional 
18352 18 or older Current drinkers Self-report 
questionnair
e 
Specificity – “sedatives”, 
“tranquilisers”  
Reliance on self-report 
Exclusion of licit use of 
substances 
0.4% used sed/tranq only 
Sed/tranq use not predictive of 
past-year alcohol or drug-
related fighting 
1 
Ryden et 
al., 1999 
Cross-
sectional 
116 
(73%F
) 
85.4 (7.9) Cognitively 
impaired, 
consistently 
File 
examination 
 
Sampling bias 
No control group (i.e., 
non-agg sample) 
41.4% received anxiolytics 
(most common L & A) 
Receiving anxiolytics more 
1 
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Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
aggressive, 
nursing home 
residents 
Behavioural 
observation 
No temporal causality agg & more likely to be 
restrained but n.s. 
Anxiolytic &/or psychotropic  
sig predicted physical agg 
Shah et 
al., 2000 
Prospective  
(6 months) 
412 
(64% 
F) 
82.3 (9.5) Melbourne 
nursing home 
residents 
SOAS 
RAGE 
Measurement variability 
(sensitivity) 
Lack of temporal 
causality 
SOAS: Agg patients prescribed 
greater no. of BZD 
RAGE: most likely to be agg 
not prescribed BZD 
3 
Friedman 
et al., 
2003 
Cross-
sectional 
612 
(50%F
) 
26.23 
(1.52) 
African-
American, low 
socio-economic 
status, young 
adults 
Database 
analysis 
Specificity – 
“seds/tranqs” 
Cultural and SES 
generality/confounds 
Degree of sed/tranq use 
predicted number of assault & 
weapon possessions offences, 
& total violence score for high 
delinquent sub-group 
No association for low-
delinquent group 
1 
Voyer et Cross- 2633 65 or older Patients of long- Structured Limited generality BZD not associated with 1 
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Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
al., 2005 sectional (75.4%
F) 
term care 
facilities 
(Quebec) 
interview 
Systematic 
medical file 
review  
Contextual factors not 
assessed/controlled 
Questionable data quality 
– busy, time-limited staff 
physical aggression (only 
verbal) 
Giancola 
& Parrott, 
2005 
Experiment 
(PC) 
Mixed 
design 
330 
(50%F
)  
23.04 
(2.85) 
Healthy social 
drinkers 
TAP 
Self-report 
questionnair
e 
Specificity – “sedatives” 
Reliance on self-report  
Not double-blind 
Sedative use not related to 
agg/extreme agg 
Alc did not influence relation 
between sedative use & agg 
3 
Haggård-
Grann et 
al., 2006 
Cross-
sectional 
133 M 35.3 (12.0) Convicted 
violent offenders 
& offenders 
undergoing 
forensic 
psychiatric 
evaluation 
Structured 
interviews 
Case-
crossover 
design  
Recall bias 
No corroboration via 
blood/urine tests 
BZD alone at regular doses = 
lower violence risk 
BZD & alcohol = increased 
risk but not greater than 
alcohol alone 
1 
Whitty & Cross- 295 - Incident reports Retrospectiv Limited generality Of clients involved in physical 1 
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Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
O’Connor
, 2006 
sectional cases 
(157 
clients) 
for out-patient 
methadone 
stabilisation & 
detox program 
e file 
examination 
Small sample - only 20 
clients provided urine 
sample 24hrs prior to 
incident 
No control group 
agg, 80% of those tested were 
positive for BZD 
Feingold 
et al., 
2008 
Cross-
sectional 
 
150 M 28 
(0.5) 
At least 1 long-
term relationship 
(1 year) 
Database 
analysis 
 
Limited generality 
Low statistical power 
Specificity – “sedatives” 
Sedative problems not 
predictive of IPV 1 
Stalans & 
Ritchie, 
2008 
Cross-
sectional 
19338 
cases 
(54.7F
) 
18-50 Living with 
intimate partners 
No treatment for 
substance use in 
past year 
Database 
analysis 
Specificity – 
“sedatives/pain relievers”  
Reliance on self-report 
Limited measure of IPV 
perpetration (1 item) 
Use of sedatives independently 
and sig increased likelihood of 
perpetrating IPV after 
controlling demographic/social 
factors 
1 
Moore et 
al., 2010 
Cross-
sectional 
1937 
cases 
- Violence report Database 
analysis 
Reliance on adverse 
incidence database – 
confounding factors, 
TZ, D, A, C disproportionately 
associated with violence (4/31 
drugs) 
1 
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Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
unreported events  
No temporal causality 
Nabors, 
2010 
Cross-
sectional 
1635 
(61%F
) 
19 Undergraduates  Self-report 
questionnair
e 
Specificity – 
“depressants”  
Limited generality 
No temporal causality 
Use of depressants 57% more 
likely to perpetrate IPV  
Depressant use strongest 
predictor of F IPV perpetration 
1 
Rouve et 
al., 2011 
Cross-
sectional 
56 
cases 
(48M) 
 
46 Physical 
aggressiveness 
against others 
Database 
analysis  
 
Case/non-
case method 
Reliance on adverse 
incidence database – 
confounding factors, 
unreported events 
BZD most frequent nervous 
system drugs documented 
Physical agg sig assoc with A 
& bromazepam  
1 
Hakansso
n et al., 
2011 
Cross-
sectional 
5659 29.7-34.8 Swedish CJS 
clients 
Database 
analysis 
 
Specificity – 
“tranquilizers” 
Limited generality  
No temporal causality  
Lack of sample 
26% reported tranq use 
Tranqs one of the predictors of 
difficulty controlling violent 
behaviour 
1 
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Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
homogeneity 
Recall bias – interviews 
between 6mth-2years 
after intake into CJS 
Shin et 
al., 2012 
Prospective 
(5-12 
month) 
376 
(49.5%
F) 
41.15 
(13.33) 
Help-seeking US 
veterans with 
PTSD 
Self-report 
questionnair
e 
 
Small subsample with 
BZD prescription (23%) 
No temporal causality 
Reliance on self-report 
BZD prescription did not 
significantly explain variance 
between baseline & follow-up 
agg 
BZD associated with increased 
agg among those high in 
baseline agg  
2 
Lundholm 
et al., 
2012 
Cross-
sectional 
194 
(22F) 
F: 
30.68 
(9.64) 
M: 30.51 
(10.88) 
Remand 
prisoners 
suspected of 
violent crime 
Structured 
interviews 
 
Case-
crossover 
Recall bias 
No corroboration with 
blood/urine records 
 
High BZD dose associated 
with violence 
Regular BZD dose associated 
with reduced risk of violence 
BZD expectations: feel better, 
1 
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Source Design 
Participant Data 
Aggression 
Measure 
Limitations Outcomes 
Q.I
. No. 
Mean age 
(SD) 
Details 
design reduced anxiety 
Afifi et 
al., 2012 
Cross-
sectional 
25778 
(54%F
) 
20 and 
above 
12 month 
romantic 
relationship 
Database 
analysis 
Low prevalence & 
specificity (‘sedatives’, 
‘tranquilisers’) 
Underpowered model  
No temporal causality   
Covariates – only select 
mental dx 
Sed/tranq use increased odds 
of IPV perpetration than non-
users – however n.s. in fully 
adjusted model 
F with sed/tranq use less likely 
to perpetrate IPV than M 
counterparts 
1 
Mattson 
et al., 
2012 
Cross-
sectional 
181 F: 39.9 
(9.3) 
M: 42.7 
(8.9) 
Married/ 
cohabiting 
heterosexual 
couples 
M: substance 
abuse treatment  
M: alcohol 
dependence 
Individual 
interview; 
self- and 
other- 
reported 
aggression 
(highest 
value used) 
Gender bias in model  
Specificity of “sedatives” 
No temporal causality 
Use of highest agg value 
– overestimate agg? 
No direct association between 
sedative use & physical agg 
F: sed use indirectly increased 
minor physical agg 
F: sed use indirectly predicted 
decreased severe physical agg 
Effects of F sed use eliminated 
when agg levels combined  
1 
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Notes. Q.I. = quality indicator; A = alprazolam; D = diazepam; C = clonazepam; TZ = triazolam; L = lorazepam; P = participants; DB = double-blind; 
PC = placebo-controlled; SOAS = Staff Observation Aggression Scale; RAGE = Rating Scale for Aggressive Behavior in the Elderly; agg = aggression; 
F = female, M = male; IPV = intimate partner violence; CJS = criminal justice system; n.s. = non-significant; B/subjects = between-subjects design; 
W/subjects = within subjects design. 
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Table 2  
Characteristics of included studies assessing benzodiazepine-related aggressive behaviour, ordered by benzodiazepine type and year of publication. 
Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
Diazepam      
Feldman, 
1962 
Clinical 
B/subjects 
87 
(31F) 
37(-) Patients 
with 
hypoactive 
syndrome  
Diazepam 
– dose 
unclear 
Tx approx. 
3 months 
Evaluator 
assessment 
Potential drug interactions 
Limited information re 
control, dose, responses, 
inter-rater reliability 
No comparison group, 
blinding methods 
Progressive development 
of “hatefulness” which 
led to violence  
1 
Wilkinso
n, 1985 
Experimen
t (DB, PC)  
W/subjects 
60 M  18-24 Undergrad
uates  
Diazepam 
– 10mg 
TAP 
 
Limited generality 
Ecological validity 
D increased agg over 
placebo (p < .01) 
D-related agg enhanced 
in low-anxious Ps (p < 
.05) 
4 
Gantner 
& Taylor, 
Experimen
t (PC, 
36 
(50%
19 or 
over 
Undergrad
uates  
Diazepam 
– 10mg 
TAP 
 
Not double-blind – 
expectancy bias? 
D increased agg 
behaviour (p <.01) 
3 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
1988 random 
allocation) 
B/subjects 
F) 60-min between D & task 
Cherek et 
al.,1990 
Experimen
t (DB, PC) 
W/subjects 
9 M - Healthy 
volunteers 
Diazepam 
– 2, 5, 
10mg/ 
70kg 
PSAP 
 
Successive drug doses 
separated by 96hrs 
Small sample 
Self-selection (response bias) 
Ecological validity 
D decreased agg (p 
<.025) 
2P increased agg 
responding (5mg, 
10mg/70kg) 
- high hostility 
3 
Ben-
Porath & 
Taylor, 
2002 
Experimen
t (DB, PC, 
random 
allocation) 
B/subjects 
60 M 18-24 Undergrad
uates  
Diazepam 
– 10mg 
TAP 
 
Limited generality 
Reliance on self-reported 
hostility 
Ecological validity 
 
D increased agg 
compared to placebo (p = 
.05) 
- influence of hostility 
(n.s) 
5 
Wallace 
& Taylor, 
Experimen
t (DB, PC) 
30 M 18 or 
over 
Undergrad
uates  
Diazepam 
– 10mg 
TAP 
 
Limited generality 
Self-selection (response bias) 
D significantly increased 
agg compared to placebo  
3 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
2009 W/subjects  (p <.05) 
Forsyth et 
al., 2011 
Cross-
sectional 
202 
M 
16-20 Young 
serious 
offenders 
Diazepam  Qualitative 
interviews  
Self-report 
questionnaire 
Reliance on self-report 
Limited generality 
D drug most often 
blamed for crime 
D more likely to facilitate 
violence when with 
alcohol 
1 
Flunitrazepam  
Dåderma
n & 
Lidberg, 
1999 
Cross-
sectional 
19 M 14-20 
M = 
17 
(1.2) 
Juvenile 
offenders 
(serious 
offences), 
Fl abusers 
Fl Structured 
interviews  
File 
examination 
Questionable temporal 
causality 
Reliance on self-report  
Confounding variables? 
Limited generality  
Targeted sample without 
comparison group 
All Fl-abusers committed 
violent offences 
High boredom 
susceptibility, verbal agg 
associated with high Fl 
use 
No sig diff re. type or no. 
of crime for abusers/non-
abusers 
1 
28 M 14-20 
M = 
17 
(1.3) 
Juvenile 
offenders, 
non-Fl 
abusers 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
Dåderma
n & 
Edman, 
2001 
Cross-
sectional 
60 M 27 
(5.7) 
Non-
psychotic 
forensic 
psychiatric 
patients 
Fl Structured & 
open-ended 
interviews 
File 
examination 
Limited generality 
Reliance on self-report 
Low statistical power 
No personality difference 
between Fl non/abusers  
Fl abusers more likely to 
commit robbery, weapon, 
theft crimes 
No sig difference re 
violent crime 
1 
Dåderma
n et al., 
2002 
Cross-
sectional 
 
5 M 23-26 Swedish 
offenders 
who had 
used Fl 
Fl File 
examination 
Confounded – concurrent 
drug use 
No controls (i.e., non-anxious 
Fl users) 
Limited generality 
Small, targeted sample 
Violence promoted in 
individuals with 
psychiatric vulnerability 
(i.e., anxiety) 
1 
Bramness 
et al., 
2006 
Cross-
sectional 
415 
cases 
(16%
30 
(9.3) 
DUI under 
Fl only 
Fl  Database 
analysis  
Social/environment/personal 
factors not available 
Reliance on adverse 
Fl not significantly 
different between violent 
& non-violent cases 
1 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
F) incidence database – 
confounding factors, 
unreported events 
7 
cases 
(M) 
 
21.9 
(2.6) 
Violent 
crime 
where Fl 
only drug 
Dåderma
n et al., 
2012 
Cross-
sectional 
114 
M 
22.5 
(6.6) 
Non-
psychotic 
offenders 
& juvenile 
delinquents 
Fl Interviews 
File 
examination 
Small sample pure Fl users – 
limited power to assess 
unique characteristics 
No temporal causality 
34% used Fl 
Fl use associated with 
Facet 4 psychopathy 
(poor behavioural 
control, early behavioural 
problems, criminal 
versatility) 
1 
Clonazepam  
Karson et 
al., 1982 
Clinical  
(DB, PC) 
W/subjects 
13 
(3F) 
21-45 Inpatients 
-chronic 
schizophre
C 1mg/o.d. 
(gradually 
increased, 
Staff 
behavioural 
ratings 
2wk stabilisation period prior 
to C – sufficient? 
Drug interactions? 
4 patients had agg 
behaviour during study 
(only 1 other-agg during 
2 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
A-B-A nia tapered)  
28 days tx 
Limited generality C tx, at 4mg) 
Rosenfel
d et al., 
1987 
Cross-
sectional 
38 
(18F) 
13-41 Intractable 
seizure 
disorder 
Clonazepa
m  
File 
examination 
Drug interaction? 
Variations in testing – prior to 
or during C tx 
Limited generality 
1P displayed “marked 
agg” 
Sig diff in VIQ-PIQ 
discrepancy compared to 
non-side effect patients 
(not specific to 
behavioural side effect) 
No personality 
differences 
1 
Alprazolam  
Gardner 
& 
Cowdry, 
1985 
Clinical 
(DB, PC) 
W/subjects 
16 F  24-42 Outpatients 
Borderline 
personality 
disorder 
Alprazolam 
– FDS (1-
6mg; M = 
4.7mg o.d.) 
Self-report 
Behavioural 
observation 
Histories of dyscontrol 
1wk washout – carry over 
effects? 
Limited generality 
A increased severe 
dyscontrol over placebo 
1P displayed other-
directed agg 
2 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
6 weeks tx 
Noyes et 
al., 1988 
RCT 
(DB, PC, 
random 
allocation) 
B/subjects 
525 
(67%
F) 
M: 
36.8 
(11.1) 
F:37.1 
(10.2) 
Panic 
disorder, 
agoraphobi
a & panic 
attacks 
Alprazolam 
– FDS 
(1-10mg) 
8 weeks tx 
Behavioural 
observation 
Self-report 
1wk medication washout – 
sufficient? 
Limited generality 
Aggressive/violent 
behaviour reported by 1P 
(4mg o.d.) 
Dose reduction – no 
recurrence of behaviour 
3 
Bond & 
Silveira, 
1993 
Experimen
t (DB, PC, 
random 
allocation) 
B/subjects 
48 
(50%
F) 
- Moderate 
social 
drinkers 
Alprazolam 
– 1mg 
(with & 
without 
alcohol) 
 
Modified 
TAP 
Ecological validity A did not increase agg 
compared to placebo  
Alcohol & A = increased 
agg more than the sum of 
the single effects (p <.01) 
4 
O’Sulliva
n et al., 
1994 
RCT (DB, 
PC, 
random 
allocation) 
154 
(81%
F)  
35 Inpatients  
Panic 
disorder 
with 
Alprazolam 
– FDS  
(1-10mg) 
8 wks tx (8 
Structured 
interview  
 
Assessor & 
Limited generality 
 
A increased agg in 2Ps 
No increase in hostility 
 
3 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
B/subjects agoraphobi
a 
wks 
tapered tx-
free f/up) 
self-ratings 
Bond et 
al., 1995 
Experimen
t (PC, 
random 
allocation) 
B/subjects 
23 
(17F) 
A: 
40.8 
Placeb
o: 38.5 
Patients 
Panic 
disorder 
with 
agoraphobi
a 
Alprazolam  
(post 8wks 
treatment; 
O’Sullivan 
et al) 
Modified 
TAP 
Self-report 
Limited generality 
Ecological validity 
Not double-blind 
A increased agg 
following provocation 
(p<.01) 
Decrease in hostility 
4 
Triazolam  
Cherek et 
al., 1991 
Experimen
t (DB, PC) 
W/subjects 
5M 25-36 Healthy 
volunteers 
Triazolam 
– 0.125, 
0.25, 
0.5mg/70k
g 
PSAP Self-selection (response bias) 
Limited generality 
Ecological validity 
Unreported data for 1P 
T decreased agg in 2Ps 
T at 2 lower doses 
increased agg in 1P 
T dose-dependently 
increased agg in 1P 
3 
Berman Experimen 46 M 18-30 Undergrad Triazolam TAP Limited generality T increased agg 5 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
& Taylor, 
1995 
t (DB, PC) 
B/subjects 
uates 
Non-
smoking 
– 0.25mg   Self-selection (response bias) 
No examination of T dose-
response curve  
Ecological validity 
responding (p < .01) & 
increased no. of Level 10 
shocks (p <.01) 
compared to placebo 
Threat did not influence 
T-related agg responding  
Oxazepam  
Burgio et 
al., 1992 
Clinical 
(SB) 
B/subjects 
21 
(7F)  
77.8(-) Gero-
psychiatry 
inpatients  
Dementia, 
severe 
behavioural 
disturbance 
Oxazepam 
– FDS (10-
30mg o.d.) 
4-26 days 
tx 
 
Behavioural 
microanalysi
s 
Single-blind method – 
observer bias?  
No non-treatment comparison 
group 
Treatment effects collapsed 
over O & Haloperidol groups 
No significant change 
between baseline agg & 
agg during treatment  
Physical agg least 
frequent of targets 
 
3 
Temazepam   
Hammers Cross- 100 16-30 Single Temazepa Semi- Limited generality T unique contributor to 1 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
ley & 
Pearl, 
1997 
sectional (44%
F) 
Homeless m structured 
interviews  
No control for polydrug use 
Reliance on self-report 
No temporal causality 
violence 
Lorazepam  
Pietras et 
al., 2005 
Experimen
t 
(PC) 
W/subjects 
8 M 20-
37(30.
4) 
Parolees  Lorazepam 
– 1, 2, 4mg 
PSAP 
 
Self-report 
questionnaire 
Self-selection (response bias) 
Blinding method unclear 
30mins between dose & task 
– sufficient? 
Not double blind 
L decreased agg for 7Ps 
(p<.01) 
1P displayed increased 
agg (by 400%) compared 
to placebo 
No association between 
psychometric & 
behavioural agg 
4 
Combined Benzodiazepines  
Bond & 
Lader, 
1988 
Experimen
t (DB, PC, 
random 
45 
(20F) 
19-46 Healthy 
volunteers 
Oxazepam 
– 15, 30mg 
Lorazepam 
Modified 
TAP 
Self-selection (response bias) 
Ecological validity 
L & O increased agg 
compared to placebo  
(p < .05) 
3 
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Source Design 
Participant Data 
BZD 
Aggression 
Measure 
Limitations Outcomes Q.I. 
N 
Age  
M(SD) 
Details 
allocation) 
B/subjects 
– 1.0, 
2.0mg 
L greater increase in agg 
than O (p < .05) 
High L dose showed 
greatest increase in agg 
Weisman 
et al., 
1998 
Experimen
t (DB, PC) 
B/subjects 
44 M 18-24 Undergrad
uates  
Diazepam 
– 10mg 
O – 50mg 
CL – 15mg 
TAP 
 
Limited generality  
Self-selection (response bias) 
 
O & CL no effectg 
D increased agg at low 
provocation compared to 
placebo (p< .05) 
5 
Rothschil
d et al., 
2000 
Cross-
sectional 
323 18-82 Psychiatric 
hospital 
inpatients 
Alprazolam 
C 
No BZD 
Blind chart 
review  
Non-randomised 
Limited generality 
No sig difference 
between A, C, or no BZD 
groups on assaults 
1 
Notes. Q.I. = quality indicator; RCT = randomised control trial; BZD = benzodiazepine; A = alprazolam; D = diazepam; Fl = flunitrazepam; T = 
temazepam; C = clonazepam; O = oxazepam; TZ = triazolam; CL = clorazepate; L = lorazepam; P = participants; DB = double-blind; PC = placebo-
controlled; PSAP = Point Subtraction Aggression Paradigm; TAP = Taylor Aggression Paradigm; SOAS = Staff Observation Aggression Scale; RAGE 
= Rating Scale for Aggressive Behavior in the Elderly; FDS = flexible dose schedule; agg = aggression; F = female, M = male; CJS = criminal justice 
system; AOD = alcohol and drug; n.s. = non-significant; B/subjects = between subjects design; W/subjects = within-subjects design; f/up = follow up. 
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TAP involves participants administering and receiving electrical shocks under a 
competitive reaction time task, where the participant’s shock setting for a (fictional) 
opponent gives a proxy measure of behavioural aggression. Reaction to provocation 
is also measured, by providing participants with an indication of the shock set per 
trial by their opponent. Modifications involve using noise instead of shocks (e.g., 
Bond and Lader, 1988). The PSAP provides participants with a choice between 
escape responding, non-aggressive monetary-reinforced responding, and a proxy 
measure of aggression involving the subtraction of money from a (fictional) 
opponent, following provocation. It is noted that although laboratory proxy measures 
of aggression have demonstrated some external (Anderson & Bushman, 1997), and 
construct validity (e.g., Cherek, Lane, Dougherty, Moeller, & White, 2000; Giancola 
& Parrott, 2008; Golomb, Perez, Jaworski, Mednick, & Dimsdale, 2007), debate 
continues as to the empirical value and external validity of laboratory aggression 
paradigms (e.g., Ferguson & Rueda, 2009; Ferguson, Smith, Miller-Stratton, Fritz, & 
Heinrich, 2008). Eleven studies investigated undergraduate students or community 
members (18-46 years old), and one study each explored a clinical (28-40 years; 
Bond, Curran, Bruce, O’Sullivan, & Shine, 1995) and forensic (20-37 years; Pietras 
et al., 2005) sample.   
Variable effects were reported both within and across benzodiazepine types. 
Diazepam was found to invariably increase responding indicative of behavioural 
aggression in five studies and produce mixed responses in one study; two studies 
demonstrated increased responding indicative of aggression following alprazolam 
consumption; lorazepam, oxazepam, and triazolam each demonstrated varied results 
between two studies; and one study demonstrated clorazepate to have no effect on 
responding. Study methodology may have influenced these findings, as responding 
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indicative of aggression generally increased in TAP studies and decreased in PSAP 
studies post-benzodiazepine consumption. Studies which utilised the original or 
modified TAP demonstrated enhanced aggressive responding following consumption 
of triazolam (Berman & Taylor, 1995), lorazepam, oxazepam (15mg, 30mg; Bond & 
Lader,1988), alprazolam (Bond et al., 1995), combined alcohol and alprazolam 
(Bond & Silveira, 1993), and diazepam (Ben-Porath & Taylor, 2002; Gantner & 
Taylor, 1988; Wallace & Taylor, 2009; Weisman, Berman & Taylor, 1998; 
Wilkinson, 1985), but not clorazepate or oxazepam (50mg; Weisman et al., 1998), 
and self-reported ‘sedative’ use in healthy adults did not influence alcohol-related 
aggressive responding (Giancola & Parrott, 2005). The variation concerning 
oxazepam may reflect a dose effect or an insufficient absorption period by Weisman 
and colleagues (1998) (90 minutes versus 4 hours), as oxazepam has been found to 
have a later onset of action (Bond & Lader, 1988).  Interestingly, Wilkinson (1985) 
reported that aggressive responding was enhanced in low-trait anxious participants 
compared to high-trait anxious participants. Comparatively, the PSAP studies 
demonstrated decreased responding indicative of aggression in the majority of 
participants following lorazepam (n = 8; Pietras et al., 2005), triazolam (n = 5; 
Cherek, Spiga, Roache, & Cowan, 1991), and diazepam consumption (n = 9; Cherek 
et al., 1990). Interestingly, response patterns in the latter study indicated increased 
aggressive responding in high hostile participants (n = 2). Personality characteristics 
were measured in a further four studies (Bond et al., 1995; Bond & Lader, 1988; 
Bond & Silveira, 1993; Pietras et al., 2005), however none discussed whether 
individual differences were related to patterns of responding. 
The most common approximate DZM equivalent doses administered acutely 
were 5mg and 10mg (DZM range = 2-20mg), and each produced variable results. 
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Findings of two out of five studies using 5mg (Berman & Taylor, 1995; Bond & 
Lader, 1988) and five out of ten studies using 10mg (Ben-Porath & Taylor, 2002; 
Bond & Lader, 1988; Gantner & Taylor, 1988; Wallace & Taylor, 2009; Wilkinson, 
1985) suggested increased aggression. Higher doses either failed to influence 
aggressive responding (DZM = 16.7mg; Weisman et al., 1998) or resulted in 
decreased responding indicative of aggression (DZM = 20mg; Pietras et al., 2005), 
and only one participant displayed increased aggressive responding following the 
low equivalent dose of 2.5mg (Cherek et al., 1991).  Only one study considered 
chronic administration, where participants engaged in the laboratory task following 
eight weeks of alprazolam treatment (DZM = 10-100mg) or placebo (Bond et al., 
1995). Although the findings indicated alprazolam use increased behaviour 
indicative of aggression compared to placebo the flexible dosing schedule precludes 
consideration of dose effects.  
Overall, the experimental studies suggest that acute administration of certain 
benzodiazepines (i.e., diazepam, alprazolam) can result in an aggressive response in 
adults. However, the use of analogue representations of aggression greatly limits the 
ecological validity of the findings. Moreover, the studies cannot inform our 
understanding of chronic benzodiazepine use, and the reliance on healthy community 
samples reduces their ability to inform clinically pertinent prescribing practices. 
3.4.2 Clinical studies. 
The review identified six clinical studies of varying methodological rigor. In 
each instance, aggression following benzodiazepine use was a secondary 
consideration. The clinical populations varied widely, including individuals with 
panic disorder and agoraphobia (Noyes et al., 1988; O’Sullivan et al., 1994), chronic 
schizophrenia (Karson, Weinberger, Bigelow, & Wyatt, 1982), borderline personality 
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disorder (BPD; Gardner & Cowdry, 1985), hypoactive syndromes (Feldman, 1962), 
and psychogeriatric patients (Burgio et al., 1992). Across the combined samples, 
aggressive behaviour was reported following benzodiazepine consumption in less 
than one percent (0.6%) of participants.   
Only two of the clinical studies reviewed were RCTs (Noyes et al., 1988; 
O’Sullivan et al., 1994).  Both explored acceptance and side effects of alprazolam 
treatment over eight weeks in individuals with panic disorder and agoraphobia (n = 
525, Noyes et al., 1988; n = 154, O’Sullivan et al., 1994). Inspection of the data 
indicates that one (0.19%; Noyes et al., 1988) and two (1.3%; O’Sullivan et al., 
1994) patients demonstrated elevated physical aggression during treatment, in one 
case following a DZM equivalent dose of 40mg (Noyes et al., 1988). Further 
interpretation of the role of alprazolam in these events is hampered by inadequate 
detail regarding dosing schedules and the length of alprazolam treatment prior to the 
aggressive incidents.  
Two studies utilised double-blind and placebo-controlled methods in a 
within-subjects design to explore the effect of clonazepam on individuals with 
chronic schizophrenia (n = 13; Karson et al., 1982) and alprazolam on behavioural 
dyscontrol in females with BPD (n = 16; Gardner & Cowdry, 1985). Each of the 
studies reported aggressive responding in a single patient, following either an 
equivalent dose of 80mg (Karson et al., 1982) or twenty days of treatment (Gardner 
& Cowdry, 1985). Less rigorous designs and poor reporting characterised the final 
two studies. An unclear number of individuals with hypoactive syndromes 
demonstrated aggressive responding following an unreported dose of diazepam 
(Feldman, 1962), and collapsed treatment effects across oxazepam and haloperidol 
suggested no changes in aggressive behaviour during treatment (4-26 days) in a 
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sample of psychogeriatric patients (n = 21; Burgio et al., 1992). It is interesting, and 
potentially clinically pertinent, that the latter study utilised a substantially lower dose 
schedule (DZM = 3.3-10mg) than the above studies (DZM = 10-100mg) and 
reported no changes in aggression. However, any oxazepam-specific results are 
obscured by the authors’ decision to collapse the treatment effects. 
The above findings suggest that instances of aggressive responding to 
benzodiazepines are rare in the clinical populations investigated. However, poor 
reporting makes consideration of control methods and dose schedules difficult.  
Moreover, although the results appear to suggest that higher doses may be more 
risky, it is difficult to draw conclusions regarding chronic administration of 
benzodiazepines, due to the large variation in treatment periods (i.e., four days to 
three months; Burgio et al., 1992; Feldman, 1962, respectively), and the potential of 
other drug interactions, with medication wash-out periods ranging from one (Burgio 
et al., 1992; Gardner & Cowdry, 1985; Noyes et al., 1988) to two weeks (Karson et 
al., 1982; O’Sullivan et al., 1994). 
3.4.3 Prospective studies. 
Only two prospective studies were identified, and both suggest an association 
between benzodiazepine consumption and aggressive behaviour. However, due to the 
associative nature of the studies, neither provide evidence of causality.  
The association between benzodiazepine prescription and aggression lacked 
robustness in both papers, as the associative strength varied according to the 
operationalization of aggression. In a six month study of nursing home residents, the 
finding of an association between increased benzodiazepine prescription and 
heightened levels of aggression depended on the observation rating scale used to 
classify participants as aggressive (Shah, Chiu, Ames, Harrigan, & McKenzie, 2000). 
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As residents were assessed using both scales, this variation suggests some issues with 
scale validity. The second prospective study followed a random sample of help-
seeking U.S. veterans with PTSD, of whom 23% were prescribed benzodiazepines, 
over 5-12 months (Shin, Rosen, Greenbaum, & Jain, 2012). The findings 
demonstrated that although benzodiazepine prescription did not explain overall 
variance between baseline and follow-up aggression scores, benzodiazepine 
prescription was related to increased aggressive behaviour in individuals who were 
aggressive at baseline. However, as the authors operationalized aggression as the 
sum of four items adapted from the Conflict Tactics Scale, where only one item 
referred to other-directed physical aggression, it is unclear which aspect/s of 
aggressive behaviour increased between baseline and follow-up. Combined, these 
studies indicate how variable measurement of aggression can affect findings, and in 
turn, our understanding of the relationship between benzodiazepine use and 
subsequent aggression. Tentatively, however, individuals with higher baseline 
aggression levels may be more likely to experience benzodiazepine-related 
aggression. 
Overall, both studies indicate some level of association between 
benzodiazepine prescription and aggressive behaviour. However, as neither study can 
suggest temporal order, the associations may reflect increased benzodiazepine 
prescriptions to manage aggressive behaviour. Moreover, both studies investigated 
highly specific samples, limiting generalizability, and neither study explored 
variations in benzodiazepine type or dose, and therefore fail to inform clinical 
practice. 
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3.4.4 Cross-sectional studies. 
The cross-sectional studies explored a range of sample types, including 
clinical (i.e., psychiatric, addiction, hospital; n = 7), healthy or community (n = 7), 
and forensic (i.e., criminal justice involvement or incidents, forensic psychiatric; n = 
11). Per sample type, a large proportion of studies suggested an association between 
benzodiazepine use and aggression (63.6-71.4%).  
Overall, fourteen (56%) cross-sectional studies demonstrate positive 
associations between benzodiazepine consumption and aggressive behaviour (Afifi, 
Henriksen, Asmundson, & Sareen, 2012; Dåderman, Fredriksson, Kristiansson, 
Nilsson, & Lidberg, 2002; Dåderman, Edman, Meurling, Levander, & Kristiansson, 
2012; Forsyth, Khan, & Mckinlay, 2011; Hakansson, Schlyter, & Berglund, 2011; 
Haller & Deluty, 1990; Hammersley & Pearl, 1997; Lundholm, Haggård, Möller, 
Hallqvist, & Thiblin, 2013; Moore Glenmullen, & Furberg, 2010; Nabors, 2010; 
Rouve et al., 2011; Ryden et al., 1999; Stalans & Ritchie, 2008; Whitty & O’Connor, 
2006), and three studies provide mixed findings according to gender and level of 
aggression (Mattson, O’Farrell, Lofgreen, Cunningham, & Murphy, 2012), 
delinquent status (Friedman, Terras, & Glassman, 2003), and unclear differences in 
cognitive assessment scores (Rosenfeld, 1987). The final eight studies suggest that 
benzodiazepine use is not associated with physical aggression or violence (Bramness, 
Skurtveit, & Mørland, 2006; Dåderman & Edman, 2001; Dåderman & Lidberg, 
1999; Dawson, 1997; Feingold, Kerr, & Capaldi, 2008; Haggård-Grann, Hallqvist, 
Långström, & Möller, 2006; Rothschild, Shindul-Rothschild, Viguera, Murray, & 
Brewster, 2000; Voyer et al., 2005). The latter point may relate to similar 
temperament and sensation seeking scores between benzodiazepine users and non-
users (Dåderman & Edman, 2001), however other cross-sectional findings suggest 
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that certain personality traits assessed through empirically supported personality 
inventories (i.e., boredom susceptibility, verbal aggression, Dåderman & Lidberg, 
1999; antisocial psychopathy characteristics, Dåderman et al., 2012) and file-based 
indicators of psychiatric vulnerability (e.g., anxiety, impulsivity; Dåderman et al., 
2002) may influence an aggressive response to flunitrazepam.  
Operationalization and measurement of benzodiazepines and aggression 
varied considerably across studies. Examination of specific benzodiazepines 
suggested that aggressive behaviour was associated with temazepam (Hammersley & 
Pearl, 1997) and diazepam (Forsyth et al., 2011), but not alprazolam (Rothschild et 
al., 2000), with mixed results for flunitrazepam (Bramness et al., 2006; Dåderman et 
al., 2002; Dåderman et al., 2012; Dåderman & Edman, 2001; Dåderman & Lidberg, 
1999) and clonazepam (Rosenfeld et al., 1987; Rothschild et al., 2000). However, 
nine studies utilised poorly defined terms such as sedatives or tranquilizers (e.g., 
Afifi et al., 2012; Dawson, 1997; Feingold et al., 2008; Friedman et al., 2003), or 
grouped benzodiazepines with other substances (e.g., opiates, GHB; Mattson et al., 
2012; Nabors, 2010; Stalans & Ritchie, 2008), reducing the specificity of results, and 
attenuating the associative or predictive strength of the findings (e.g., Dawson, 
1997). Furthermore, many studies failed to statistically control for concurrent 
substance use (e.g., Dåderman et al., 2002; Dåderman & Lidberg, 1999; Hammersley 
& Pearl, 1997). Similarly, although some studies clearly defined aggression (i.e., 
violent crime including manslaughter, assault; Dåderman et al., 2002; Dåderman et 
al., 2012; Dåderman & Edman, 2001; Dåderman & Lidberg, 1999; Haggård-Grann et 
al., 2006; Lundholm et al., 2013; Moore et al., 2010), only two studies utilised the 
same questionnaire (Conflict Tactics Scale-Revised; Afifi et al., 2012; Mattson et al., 
2012), and five studies inferred aggression from endorsement of one (Hakansson et 
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al., 2011; Hammersley & Pearl, 1997; Nabors, 2010; Stalans & Ritchie, 2008) or two 
(Dawson, 1997) items, reducing the interpretability of findings. Such variable 
operationalization limits the ability to compare findings and form accurate 
conclusions about the benzodiazepine-aggression association. 
Nonetheless, a tentative conclusion may be drawn regarding the role of dose 
with reference to the findings of two similar forensic studies. Both case-crossover 
designs, the studies operationalized violence as violent interpersonal crime (i.e., 
manslaughter, assault, murder), and employed structured interviews with convicted 
male violent offenders undergoing forensic psychiatric evaluation (n = 133; 
Haggård-Grann et al., 2006), and remand prisoners suspected of violent crime (n = 
194; Lundholm et al., 2013). The studies demonstrated that benzodiazepines 
consumed alone (i.e., without alcohol) and in regular doses were associated with a 
reduced risk of violence (Håggard-Grann et al., 2006; Lundholm et al., 2013), but an 
increased risk of violence was associated with unusually high intake of 
benzodiazepines (Lundholm et al., 2013). However, these findings must be 
considered in light of the following limitations. That is, they rely on ambiguous 
definitions of ‘regular’ or ‘unusually high’ doses, and on uncorroborated 
retrospective self-report from forensic samples.  
3.5 Discussion  
The literature review demonstrated a relative paucity of published papers 
explicitly examining the benzodiazepine-aggression relationship given its clinical 
importance. Of those papers which met inclusion criteria, the majority of findings 
pertain to experimental studies of acute low doses of benzodiazepines, or cross-
sectional examination of self-report data. According to the reviewed papers, 
benzodiazepine use is moderately associated with subsequent aggressive behaviour. 
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Nine (69.2%) of the experimental studies reported a significant increase in behaviour 
indicative of aggression. However, there are clear limitations in generalising from 
simulated responses in contrived experimental settings to interpersonal aggression. 
Indeed, the clinical studies reported aggressive responding in less than one percent of 
participants (0.6%) during benzodiazepine treatment. However, as aggressive 
responding was not a focus of these studies, many lacked detail which limited the 
ability to draw conclusions to inform clinical prescribing practices. Although an 
association between benzodiazepine use and aggressive behaviour was indicated in 
the majority of the cross-sectional studies (n = 17) and both prospective studies, the 
varied operationalization of aggression and benzodiazepines impedes consideration 
of the proportion of individuals reporting benzodiazepine-related aggression. 
Moreover, as the correlational nature of these studies precludes analysis of temporal 
causality, their findings may reflect increased benzodiazepine use in order to manage 
aggressive tendencies.  The discrepancies within the literature regarding the 
benzodiazepine-aggression relationship likely relate to differing methodologies, 
samples, and benzodiazepines tested.  
3.5.1 Sample. 
The most methodologically rigorous studies (Levels 4 and 5) were conducted 
primarily on non-clinical samples (71%) such as undergraduates or social drinkers, 
with only two high level studies exploring a clinical or forensic sample. The lack of 
high-quality evidence pertaining to these latter populations greatly hinders our ability 
to understand the clinical and legal implications arising from the benzodiazepine-
aggression relationship. 
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3.5.2 Benzodiazepine type. 
Diazepam was the most commonly examined benzodiazepine, and was associated 
with increased responding indicative of behavioural aggression in five out of six 
methodologically strong experimental studies.  Unfortunately, some benzodiazepines 
are examined in fewer than two studies, limiting our understanding of whether all 
benzodiazepines promote a risk of aggressive responding. 
3.5.3 Benzodiazepine dose. 
The inconsistent nature of the clinical and experimental dose-related findings 
suggests that a dose effect does not adequately explain benzodiazepine-related 
aggression. Aggression, or behavioural responses indicative of aggression, can result 
after both acute (single dose) and chronic (continuous treatment) administration of 
benzodiazepines. Examination of approximate DZM equivalent doses suggested that 
therapeutic doses (i.e., 5-10mg) may be more likely to be associated with aggressive 
responding when administered acutely, whereas higher doses (i.e., 40mg, 80mg) may 
be more risky following chronic administration.  
3.5.4 Personality. 
Four cross-sectional studies explicitly examined personality, however the use 
of targeted sampling (i.e., flunitrazepam using violent offenders; Dåderman et al., 
2002; Dåderman & Lidberg, 1999) and the lack of non-violent control groups 
(Dåderman et al., 2012; Dåderman & Edman, 2001) precludes definitive conclusions 
that personality influences flunitrazepam-related violence. Controlled laboratory 
testing also demonstrated that diazepam-enhanced aggressive responding was 
associated with low levels of trait anxiety (Wilkinson, 1985) and high levels of 
hostility (Cherek et al., 1990). These findings suggest that trait levels of anxiety and 
hostility may indicate a vulnerability to the experience of benzodiazepine-related 
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aggression, however further research is needed to corroborate and clarify the role of 
interpersonal vulnerabilities in this response. 
3.5.5 Limitations. 
Due to the inclusion criteria, only the studies which explicitly examined the 
relationship between benzodiazepine consumption and subsequent aggressive 
behaviour were reviewed, and therefore clinical drug trials where aggressive 
behaviour was observed, but not explicitly measured or discussed in the design were 
not identified.  Furthermore, the review was limited to English studies and published 
data, which can limit the generalizability of the data (Cole and Kando, 1993).  
Operationalization of aggression in the cross-sectional studies was considerably 
inconsistent, and studies often failed to control for concurrent substance use, use 
control or comparison groups, or clearly report methodological or statistical 
techniques. Overall, the quality of the included studies was poor, indicating a need 
for higher quality studies exploring the benzodiazepine-aggression relationship. Of 
concern, none of the clinical studies considered benzodiazepine-related aggression a 
primary focus. Furthermore, investigation of forensic participants and individual 
differences was rare, reducing our ability to draw conclusions regarding the forensic 
implications of this review. Moreover, the majority of the experimental studies 
examined male-only samples (Ben-Porath & Taylor, 2002; Berman & Taylor, 1995; 
Cherek et al., 1990; Cherek et al., 1991; Pietras et al., 2005; Wallace & Taylor, 2009; 
Weisman et al., 1998; Wilkinson, 1985), limiting generalizability to females, who 
have been demonstrated to use benzodiazepines for non-medical reasons at a high 
rate (DCPC, 2007; Loxley, 2007; McGregor, Gately & Fleming, 2011).  
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3.6 Conclusions  
The benzodiazepine-aggression response is an urgent clinical issue with 
serious clinical and forensic implications. Although aggression has been noted to 
follow benzodiazepine use in a number of experimental and non-causational studies, 
inconsistency within the literature means that the circumstances under which 
aggressive behaviour is likely to follow benzodiazepine consumption remain poorly 
understood. The evidence base requires high quality and systematic investigation of 
the various benzodiazepines and doses.  Jones and colleagues (2011) outline 
recommendations to reduce benzodiazepine-related harms when prescribing; 
however there is limited evidence to further inform practice policy or legal defences. 
Such examination  is especially pertinent with increasing evidence that amnesia is a 
common consequence of benzodiazepine use (e.g., Chavant, Favrelière, Lafay-
Chebassier, Plazanet, & Pérault-Pochat. 2011; Dåderman et al., 2003; Tannenbaum, 
Paquette, Hilmer, Holroyd-Leduc, & Carnahan, 2012), which, when coupled with 
their afore-mentioned disinhibitory properties, may lead to unprecedented use of 
benzodiazepine-related legal defences (i.e., impaired responsibility, consideration of 
mitigating circumstances) in cases involving interpersonal violence.  Advances in the 
literature are pertinent at a time when Australia has recently re-scheduled alprazolam 
to a controlled drug and considers similarly up-scheduling other benzodiazepines to 
Schedule 8.  
3.7 Chapter Summary  
A systematic literature review was conducted to explore the benzodiazepine-
aggression relationship. Results of this review indicated that the related literature 
base is flawed and has poor explanatory power. Alprazolam and diazepam are the 
most commonly researched benzodiazepines, presumably due to their preferential 
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use within community, clinical and forensic populations, and as such have been most 
closely associated with subsequent episodes of aggressive behaviour. One area which 
has been understudied is the role of intrapersonal factors in benzodiazepine-related 
aggression, despite arguments that such factors are highly important in understanding 
this response (Lion et al., 1975; Hoaken & Stewart, 2003). The following two 
original studies were designed in order to further our understanding of the role of 
intrapersonal factors such as personality, motivational traits, and mental health 
functioning in this response. 
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Chapter Four: Motivational drive and alprazolam misuse: A recipe for 
aggression? 
Please note, the following chapter presents an expanded version of an original 
manuscript submitted for review to Psychiatry Research (May, 2015), due to 
copyright reasons. Details of the submitted article have been appended for your 
consideration (Appendix C). 
4.1 Introduction 
Benzodiazepines are commonly used to manage anxiety or agitated behaviour 
(Ashton, 2002). However, for an estimated 1-20% of users, benzodiazepine use is 
followed by an aggressive response (Lader, 2011). The somewhat paradoxical nature 
of this response, coupled with the high medical, financial and personal costs 
associated with aggressive behaviour, suggests that changes to prescribing policies 
and regulatory strategies may be required to reduce the likelihood of benzodiazepine-
related aggression from occurring.  However, surprisingly little attention has been 
paid to understanding the psychological processes associated with benzodiazepine-
related aggression. Controlled laboratory studies have demonstrated that alprazolam 
and diazepam often result in an increased aggressive response in some participants 
(e.g., Ben-Porath & Taylor, 2002; Bond et al., 1995; Bond & Silveira, 1993; Wallace 
& Taylor, 2009), and animal studies have alluded to the possible influence of 
concurrent alcohol use (de Almeida, Saft, Rosa, & Miczek, 2010) and pre-existing 
aggressive tendencies (Ferrari, Parmigiani, Rodgers, & Palanza, 1997; Weerts, 
Miller, Hood, & Miczek, 2010) in benzodiazepine-related aggression. Yet, few 
human studies have examined potential contributory factors (i.e., dose, other 
substance use, psychological or intrapersonal factors, situation; see Albrecht et al., 
2014, for systematic review). Of note, irrespective of a long-standing proposal that 
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intrapersonal factors are important in understanding this response (Hoaken & 
Stewart, 2003; Lion et al., 1975), only a handful of studies have investigated the role 
of various personality characteristics in benzodiazepine-related aggression (i.e., trait 
anxiety, hostility; Ben-Porath & Taylor, 2002; Cherek et al., 1990; Dåderman et al., 
2002; Wilkinson, 1985). The absence of a clear theoretical framework with which to 
explore benzodiazepine-related aggression impacts our ability to develop 
meaningful, and testable, hypotheses and intervention strategies. We argue that 
current models of approach and avoidance motivational tendencies may be able to 
inform our understanding of benzodiazepine-related aggression.  
Motivational systems are theorised to underlie a number of human 
behaviours, including violent and aggressive behaviour. Gray’s (1982) 
Reinforcement Sensitivity Theory and its’ recent revision (rRST; Gray & 
McNaughton, 2003) purports to explain behavioural output and emotional expression 
based on three separate but interacting motivational systems. The behavioural 
approach system (BAS) promotes movement towards incentives and rewards, often 
involving goal-directed behaviour and impulsive action. The fight-flight-freeze 
system (FFFS) promotes fearful avoidance of a threat, and over-activation clinically 
presents as phobia or panic (Corr & Perkins, 2006). The behavioural inhibition 
system (BIS) promotes risk assessment and conflict resolution (Corr, 2008), and is 
stimulated by simultaneous and similar activation of the other two systems 
(Pickering & Corr, 2008). As demonstrated by prior research, the independent and 
interactive effects of these motivational systems have informed our understanding of 
aggressive behaviour. It is therefore expected that the application of this theory to 
benzodiazepine-related aggression will provide meaningful insight into the response, 
on which intervention strategies can be based.   
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Aggression appears to involve a strong approach motivational component 
(i.e., BAS mediated action such as antagonism; Smits & Kuppens, 2005). That is, 
aggression may result due to a strong motivation towards desired goals or rewards. 
Indeed, studies with university students have reported that high levels of BAS are 
associated with anger and aggressive behaviour (Harmon-Jones, 2003; Harmon-
Jones & Peterson, 2008). However, theoretical understanding of approach motivation 
(BAS) suggests that it involves multiple aspects, including behavioural restraint, 
planning and goal-directed behaviour (Segarra, Poy, López, & Moltó, 2014), and the 
use of a broad, unidimensional measure of BAS in the above studies fails to account 
for such complexity. Instead, greater specificity is afforded through the use of a 
multidimensional measure of approach motivation. The BIS/BAS scales (Carver & 
White, 1994) were designed to account for the dynamic and multifaceted nature of 
the BAS. The division of BAS into three subscales (fun seeking, drive, and reward 
responsiveness) has allowed for discrete exploration of how these motivational 
tendencies differentially relate to behavioural outcomes, including the expression of 
anger and aggression.  
Empirical evidence suggests that Drive is the most important facet in our 
understanding of aggressive behaviour. Drive (BAS-Dr) involves persistent goal 
pursuit and functional impulsivity; whilst fun seeking involves dysfunctional 
impulsivity, with minimal thought to consequences; and reward responsiveness 
involves positive energy and affect in response to reward cues (Tull, Gratz, Latzman, 
Kimbre, & Lejuez, 2010).  BAS-Dr has been positively associated with the 
experience of anger (Cooper, Gomez, & Buck, 2008; Harmon-Jones, 2003; Smits & 
Kuppens, 2005), anger arousal, displaced aggression, the tendency to not suppress 
angry feelings or prevent the expression of anger (Cooper et al., 2008), self-reported 
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physical aggression (Harmon-Jones, 2003), relational aggression (Miller, Zeichner, 
& Wilson, 2012), and laboratory proxies of aggressive behaviour (Seibert, Miller, 
Pryor, Reidy, & Zeichner, 2010).  In addition, Beaver, Lawrence, Passamonti, and 
Calder (2008) identified that with increasing BAS-Dr, neural structures and 
dopaminergic pathways are activated in a similar pattern to that observed in relation 
to both reward processing and aggression, providing some explanation as to why 
BAS-Dr is so important in understanding aggression. Further conceptual 
understanding of the link between BAS-Dr and aggressive behaviour is afforded 
through the concept of frustrative non-reward, which is experienced when the 
expected reward is higher than the actual reward (Corr, 2002). Indeed, although 
predominantly associated with the experience of positive affect (i.e., through goal 
attainment), BAS-Dr has also been associated with the experience of negative affect, 
especially sadness, frustration and anger, experienced in the context of blocked or 
challenged reward attainment (Carver, 2004). Such scenarios may influence an 
aggressive response. Following such theorising, aggression may be especially likely 
if the individual also experiences sensitivity to cues of punishment or threat (i.e., 
avoidance motivational tendencies). Essentially, aggressive behaviour may involve a 
facilitative interplay between appetitive and aversive motivational systems, where 
aggression is more likely when an individual with high BAS-Dr also experiences 
strong avoidance tendencies.  
Such an interaction may be especially important in the understanding of 
benzodiazepine-related aggression. Evidence suggests that benzodiazepines 
selectively interfere with the conflict resolution system (BIS) by making approach 
behaviour more likely (Pickering & Corr, 2008). Such movement away from risk 
averse behaviour, coupled with a strong BAS-Dr, may increase the likelihood an 
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individual engages in aggressive behaviour following benzodiazepine use. In 
addition, BIS has been associated with reactive aggression (Miller et al., 2012), 
potentially reflecting the frustration response, and at extremely high levels of BIS 
activation, the related emotional disturbance may increase aggression risk (Hatfield 
& Dula, 2014). As yet no studies have attempted to explore the role of these 
motivational tendencies, or their interactions, in substance-related aggression, 
particularly benzodiazepine-related aggression. Such investigation of the rRST 
motivational systems and their interactive effects should provide further insight into 
this relationship.    
4.2 The Current Study 
The current study aims to test the premise that motivational factors are 
important in understanding benzodiazepine-related aggression, through the 
application of the rRST to this response. Due to their prevalence, the current study 
explicitly focuses on diazepam and alprazolam in relation to both general aggressive 
behaviour (i.e., anger, hostility, verbal aggression) and specifically physical 
aggression. In order to ascertain a holistic picture of the participants, data regarding 
their substance use, mental health, and criminal history, and recent psychological 
functioning are also gathered. It is predicted that: 
1. Motivational factors will significantly predict engagement in benzodiazepine-
related aggressive behaviour over and above benzodiazepine type or use (e.g., 
Hoaken & Stewart, 2003; Lion et al., 1975). 
2. BAS-Dr, or the tendency to persistently pursue appetitive goals, will significantly 
predict general aggression and physical aggression.  
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3. BAS-Dr will moderate the relationship between BIS and aggressive outcomes.  
Specifically, it is predicted that the relationship between BIS and aggressive 
behaviour will be stronger for individuals with high levels of BAS-Dr. 
The current study is the first to explore the role of BAS-Dr in substance-
related aggression, particularly benzodiazepine-related aggression. It is hoped that 
this study will provide a deeper, theoretically driven, conceptualisation of this 
response than that currently afforded by the literature base. 
4.3 Method 
4.3.1 Design and procedure.  
Participants were recruited via a purposeful sampling method, which utilised 
an online electronic questionnaire and paper based questionnaires located at health 
services. Online participants were recruited through electronic, newspaper, and paper 
flyer advertising, and health clinic participants were recruited via flyers posted at two 
health clinics, or through discussion with their treating clinician. Each recruitment 
method included a brief summary of the research, the plain language statement 
(PLS), and questionnaire. The PLS detailed the expected use of the data, and 
participants’ freedom to end the questionnaire at any point, but the inability of 
researchers to remove their data once submitted due to the anonymity of the 
responses. Consent was implied by completion of the questionnaire. After 
completing the questionnaire, participants were invited to enter a draw for one of six 
shopping vouchers and to provide feedback on forms which were kept separate from 
their responses. At the completion of data collection, all draw entries were collated 
and the winning participants were notified and sent the vouchers. 
Inclusion criteria were age of 18 years or older and use of benzodiazepines in 
the past 12 months. There were no additional exclusion criteria. The study was 
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approved by the Deakin University Human Ethics Advisory Group (HEAG-H 
123_2012) and the Eastern Health Human Research Ethics Committee (E42-1213).  
4.3.2 Materials.   
Screening item. An item assessed whether participants had used 
benzodiazepines in the previous 12 months. Those who responded ‘no’ were not 
eligible for participation. 
Demographics. A brief self-report questionnaire assessed participant age, 
gender, country of origin, student status and education, employment and occupation, 
whether they were currently taking prescribed medication, treatment history for drug, 
alcohol, and mental health issues, and whether they had been charged or convicted 
with an alcohol or drug offence or with physical crimes against another person. 
Participants were instructed to select the most appropriate answer or provide brief 
written responses. 
Substance and benzodiazepine use. A modified version of the Alcohol, 
Smoking and Substance Involvement Screening Test (ASSIST), an eight-item 
questionnaire designed to detect psychoactive substance use and related problems 
(WHO ASSIST Working Group [WHO], 2002), was used to assess lifetime 
substance involvement and benzodiazepine-related dependency and harms. The 
ASSIST usually covers frequency of use and associated problems for 10 substances 
(tobacco, alcohol, cannabis, cocaine, amphetamines type stimulants, inhalants, 
sedatives, hallucinogens, opioids, and ‘other drugs’), though the majority of the items 
were altered to refer only to the benzodiazepine the respondent selected as their 
preferred type for non-medically prescribed use (see below). Specific substance 
involvement scores (SSI) were therefore calculated in relation to the preferred 
benzodiazepine. Moderate-high to high test-retest coefficients have been established 
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over one to three days (WHO, 2002), and both internal consistency (α = 0.77-.94) 
and convergent and concurrent validity has been established (Humeniuk et al., 2008).  
A 15-item self-report questionnaire was constructed to examine prescribed 
and non-medically prescribed benzodiazepine use. The literature utilises various 
definitions to distinguish benzodiazepine use for medical reasons from abuse, and 
confusing terms (e.g., medical versus non-medical) may result in inaccurate 
responding (e.g., self-medication, even at a high rate, may be interpreted as medical 
use). Therefore, the definition utilised in research needs to clearly differentiate 
between what constitutes appropriate consumption of benzodiazepines and abuse, or 
over-consumption. In the current study, medically prescribed use is when an 
individual takes benzodiazepines in the amount and frequency prescribed by their 
doctor. Non-medically prescribed use (NMP) is when benzodiazepines are not 
prescribed by their doctor or are taken more frequently or at higher doses than their 
doctor has prescribed. NMP benzodiazepine use can include to feel better, get high, 
have fun, or to substitute a usual drug of choice. By separating medically-prescribed 
and NMP use, we were able to isolate data regarding the misuse of benzodiazepines, 
and specifically explore aggressive responses following such use. We focussed on 
NMP use in order to further our understanding of the sequelae of benzodiazepine use 
which may not be readily observed or monitored by prescribers or other health 
professionals (e.g., due to the frequent diversion of benzodiazepines onto the black 
market; Best et al., 2013), and therefore only these participants completed the 
aggression measure. Additional items regarding benzodiazepine and substance use 
patterns were developed through consultation with academics and clinicians within 
the alcohol and other drugs field, specifically regarding item wording, relevance and 
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exhaustiveness. Respondents were instructed to select the most appropriate answer/s 
or provide brief written responses.  
BIS/BAS. The Behavioural Inhibition System and Behavioural Activation 
System Scales (BIS/BAS; Carver & White, 1994) is a 24-item self-report 
questionnaire designed to assess Gray’s (1982) reward and punishment sensitivities. 
A five factor model was used to reflect the revised theory; the three BAS factors, 
BIS, and FFFS (Heym, Ferguson, & Lawrence, 2008). Items are rated on a 4-point 
Likert scale (1 = strongly agree, 4 = strongly disagree) with four filler items (i.e., not 
included in the analysis). Moderate test-retest coefficients have been demonstrated 
over an eight week period (Carver & White, 1994), and each subscale has 
demonstrated moderate to high internal reliability (α = .54-82), although BIS-FFFS 
demonstrates low to high coefficients between various populations (α = 0.17-0.73; 
Dissabandara et al., 2012; Heym et al., 2008). Convergent and discriminant validity 
has also been established (Carver & White, 1994; Heym et al., 2008).  In the current 
study, moderate to high internal consistency was demonstrated per subscale (α = .67 
- .82), and the revised five-factor model was confirmed (see Appendix B).  
Mood state. The Depression, Anxiety, and Stress Scales (DASS-21; 
Lovibond & Lovibond, 1995) is a 21-item self-report questionnaire assessing state 
levels of depression, anxiety, and stress, with seven items per factor. Participants rate 
the degree to which each statement applied to them over the past week on a 4-point 
Likert scale (0 = did not apply to me at all, 3 = applied to me very much). Scale 
scores range from 0 to 21, and Australian norms are available (Crawford, Cayley, 
Lovibond, Wilson, & Hartley, 2011). High internal consistency has been 
demonstrated for each subscale and the total score (α = 0.79-.94; Crawford et al., 
2011; Henry & Crawford, 2005; Osman, Wong, Bagge, Freedenthal, Gutierrez, & 
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Lozano, 2012; Sinclair, Siefert, Slavin-Mulford, Stein, Renna, & Blais, 2012). 
Reliability coefficients were also high for each subscale in the current study (α = 
.853-.928). Convergent (Henry & Crawford, 2005; Osman et al., 2012) and 
concurrent validity has been established (Antony, Bieling, Cox, Enns, & Swinson, 
1995).  
Aggression. The Aggression Questionnaire (AQ; Buss & Perry, 1992) is a 
29-item self-report questionnaire which measures various components of aggression; 
physical aggression (9 items), verbal aggression (5 items), anger (7 items), and 
hostility (8 items). Items are rated on a 5-point Likert scale (1 = extremely 
uncharacteristic of me, 5 = extremely characteristic of me). A total aggression score 
can be calculated by summing all subscale scores. The AQ has demonstrated 
moderately high to high internal consistency (α = .70-.92; Buss & Perry, 1992; 
Harris, 1997; O’Connor, Archer, & Wu, 2001), and temporal stability over nine 
weeks (Buss & Perry, 1992) and seven months (Harris, 1997). Moreover, convergent 
(Harris, 1997; McMurran, 2009; O’Connor et al., 2001) and concurrent validity have 
been established (García-León, Reyes, Vila, Pérez, Robles, & Ramos, 2002). The 
instructions were altered to prompt participants to respond to the questionnaire in 
relation to the last time they had used NMP benzodiazepines as defined above, on an 
occasion when they were not consuming other drugs or alcohol. Internal consistency 
for the current study was high for the total score (α = .946) and across all factors (α = 
.838-.880).  
4.3.3 Statistical analyses. 
The data were cleaned and analysed using SPSS PASW Statistics 18. Where 
possible, parametric analyses were conducted, and means, standard deviations, and 
95% confidence intervals (CI) are reported. Non-parametric chi-square tests of 
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independence are used where assumptions are violated and with categorical 
variables. Hierarchical multiple regressions were used to investigate the primary 
research questions. The dependent variables pertaining to aggressive behaviour 
reflect the AQ total score (i.e., a measure of general aggression) or the physical 
aggression factor score (i.e., a measure of physical aggression specifically). A total 
of 297 participants were recruited, though eight cases were removed due to the 
absence of benzodiazepine use detail, and 85 cases reported never using 
benzodiazepines for NMP reasons and therefore did not complete the AQ. The final 
sample size was therefore 204 participants. Preliminary screening of the data 
indicated a number of random item responses across the standardised questionnaires 
were missing (0.34%), and each item’s sample median was imputed to fill this 
missing data. In order to retain the originality of the data, due to its uniqueness in the 
literature base, violations of normality were either dealt with by pulling in extreme 
outliers, or by recoding into categorical variables. The variables used to compose the 
interaction term (BAS-Dr, BIS-Anx) were centered prior to forming the interaction 
term, in order to reduce multicollinearity, and categorical variables included in the 
regression analyses were standardized using dummy-coding.  
4.3.3.1 Model specification and invariance testing. Model specification was 
purely conceptual, and based on understandings of the aggression and rRST 
literature. Therefore, age, gender, previous drug and alcohol use, and prior violent 
convictions were statistically controlled. However, due to the use of two recruitment 
methods, it was necessary to determine whether the data could be pooled without 
deleterious effects on the main analyses. It was determined through bivariate 
analyses that the internet and health centre recruitment subsamples differed on a 
number of demographic variables, including age (t(286) = -8.041, p = .000, 95% CI: 
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-13.19 to -8.01, Cohen’s d = -1.21), education (χ2(2) = 39.131, p = .000, Cramer’s V 
= .37), employment status (χ2(1) = 26.885, p = .000, Phi = .32), previous violent 
(χ2(1) = 17.789, p = .000, Phi = -.27) and AOD convictions (χ2(1) = 26.048, p = .000, 
Phi = -.31), and prior engagement in alcohol (χ2(1) = 112.281, p = .000, Phi = -.65) 
or drug treatment (χ2(1) = 50.662, p = .000, Phi = -44), but not gender (χ2(1) = .000, 
p = .989, Phi = .01) or mental health treatment history (χ2(1) = 2.635, p = .105, Phi = 
-.11). Therefore, invariance analyses using the Chow test (Demaris, 2004) were 
conducted, at the p < .05 standard. Based on the outcome of these tests, the 
prediction of both general aggression (∆χ2 (15) = 9310.373, p < .05) and physical 
aggression (∆χ2 (15) = 1368.56, p < .05) varied according to whether the data was 
pooled or separated into recruitment samples. However, due to the size of the health 
centre subsample relevant for the aggression analyses (i.e., NMP use of 
benzodiazepines with AQ scores; n = 30), it is likely that the lack of power in the 
health centre subsample may have artificially led to a significant difference from the 
pooled sample model. The planned model on such a small subsample would likely 
inflate the chance of Type 2 error, due to the lack of statistical power available. It 
was therefore decided to pool the data and include a sample recruitment variable in 
the analyses.  
4.4 Results 
4.4.1 Participant characteristics.  
The final sample consisted of 204 adult community members (62.7% male) 
who regularly use benzodiazepines, recruited via the internet (n = 174; 63.2% male) 
and health services (n = 30; 60.0% male), aged between 18 and 51 years old (M = 
27.12, SD = 8.21). Participant demographic characteristics are displayed in Table 1.  
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The sample reported moderate to high scores across the BIS/BAS scales, and 
moderate levels of psychological distress (see Table 2). The sample reported high 
rates of poly-substance use, with the two most commonly used substances in the 
month prior to reporting (other than tobacco) being alcohol and cannabis (see Table 
1). Less than a third of the sample admitted previously injecting an illicit substance 
(n = 61; 29.9%), though almost half of these participants had done so in the last three 
months (n = 27; 44.26%). In the three months prior to survey completion, half 
(54.4%) of the sample reported drinking alcohol on at least a weekly basis, whilst 
82.4% reported using illicit drugs on at least a weekly basis. Of these, the majority 
reported using one or two types of illicit drugs per week (77.4%), with 17.9% using 
three types, and only 4.8% (n = 8) using 4 or more types of illicit drugs per week.  
 
Table 1 
Participant demographic characteristics. 
Characteristic  N % 
Gender 
Male 128 62.7 
Female 76 37.3 
Country of Origin 
Australia 74 36.3 
New Zealand 5 2.5 
Asia 6 2.9 
Europe/UK 21 10.3 
USA/Canada 96 47.1 
Other 2 1.0 
Student Yes 89 43.6 
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No 112 54.9 
Education 
Before year 12 31 15.2 
Year 12 79 38.7 
University/TAFE 94 46.1 
Employed 
No 100 49.0 
Yes 100 49.0 
  Ever Current 
Treatment 
Drug 86 (42.2) 42 (20.6) 
Alcohol 31 (15.2) 23 (11.3) 
Mental Health 140 (68.6) 83 (40.7) 
  Ever charged Ever convict 
Criminal History 
AOD 66 (32.4) 39 (19.1) 
Violence 16 (7.8) 10 (4.9) 
  Lifetime Month prior 
Substance Use 
Tobacco 183 (89.7) 124 (60.8) 
Alcohol 194 (95.1) 156 (76.5) 
Cannabis 189 (92.6) 121 (59.3) 
Cocaine 122 (59.8) 27 (13.2) 
Amphetamines 168 (82.4) 76 (37.3) 
Inhalants 67 (32.8) 15 (7.4) 
Hallucinogens 143 (70.1) 41 (20.1) 
Opioids 148 (72.5) 85 (41.7) 
Note. Unless where specified, sample percentages are enclosed in brackets.  
Note. AOD = Alcohol and other drugs; convict = convicted. 
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Benzodiazepine profile. On average, participants began using NMP benzodiazepines 
at 20.46 years old (SD = 6.17). NMP benzodiazepines were most frequently acquired 
through friends (53.4%) or the black market (34.3%), and only 13.7% reported to 
have engaged in doctor shopping. Most participants (72.5%) reported using 
benzodiazepines with other substances; especially alcohol (17.6%), cannabis 
(11.3%), or both (8.3%).  As expected, diazepam and alprazolam were most likely to 
be used for NMP reasons (52.9% and 54.3% respectively; see Table 3), and were 
explicitly preferred for NMP use by 23.5% and 39.7% of participants, respectively. 
ASSIST scores generally reflected a moderate risk of dependence (see Table  2). 
Although used relatively infrequently over the year prior to survey completion (Table 
3), participants consumed diazepam and alprazolam at high average doses (see Table 
4). Alprazolam was used at the highest average doses, and at a level considerably 
higher than recognised prescribing guidelines1 (i.e., up to 33mgs; ‘Alprazolam’, 
2013). Diazepam and alprazolam were mostly used to reduce anxiety and tension 
(29.8%, 30.0% respectively) or to get high (14.5%, 24.6% respectively), as well as to 
reduce withdrawal from other substances (11.3%) for diazepam and to assist sleep 
(8.5%) for alprazolam.  
4.4.2 Main analyses.  
Bivariate correlations between the variables of interest demonstrated that both 
general and physical aggression scores were significantly associated with higher risk 
of alprazolam and diazepam dependence, psychological distress (DASS), BAS-
Drive, and having a violent conviction (see Table 5). Physical aggression was also 
positively associated with having a substance-related conviction. Increased 
alprazolam doses were significantly associated, albeit at a low strength, with weaker  
                                                          
1 Prescribing guidelines suggest a daily range of 0.5-4.0mg per day (‘Alprazolam’, 2013). 
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Table 2  
Standardised questionnaire score ranges, means and standard deviations. 
Tool 
 Total 
 Range M (n) SD (%) 
ASSIST 
SSI diazepam (n = 45) 2-36 12.76 10.20 
    Low risk 0-3 (9) (20.0) 
    Moderate risk 4-26 (30) (66.7) 
    High risk 27+ (6) (13.3) 
SSI alprazolam (n = 
77) 
0-39 
15.74 11.22 
    Low risk 0-3 (8) (10.4) 
    Moderate risk 4-26 (52) (67.5) 
    High risk 27+ (17) (22.1) 
DASS-21 
Depression 0-21 10.12 6.44 
Anxiety 0-21 7.78 5.57 
Stress 0-21 10.01 5.38 
BIS/BAS 
BAS-Dr 5-16 10.66 2.47 
BAS-FS 6-16 12.11 2.37 
BAS-RR 11-20 15.99 2.11 
BIS-Anx 6-16 13.09 2.41 
BIS-Fear 4-12 9.21 2.08 
AQ 
Total 29-137 69.99 23.90 
Physical 9-43 19.06 7.91 
Note. ASSIST = Alcohol, Smoking and Substance Involvement Screening Test 
(WHO, 2002); AQ = Aggression Questionnaire (Buss & Perry, 1992); BIS/BAS = 
Behavioural Inhibition System and Behavioural Activation System Scales (Carver & 
White, 1994); BAS-Dr = Drive, BAS-RR = Reward Responsiveness; BAS-FS =Fun 
Seeking; BIS-Anx = Anxiety; DASS-21 = Depression, Anxiety, and Stress Scales 
(Lovibond & Lovibond, 1995); SSI = Specific Substance Involvement score. 
 
BIS-related anxiety and fear, a history of a substance-related conviction, and a 
tendency to use multiple other substances when consuming benzodiazepines. Higher 
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diazepam doses were associated with having violent and substance-related 
convictions. Increased risk of dependence to alprazolam and diazepam was 
associated with increased psychological distress, though alprazolam risk was not 
associated with DASS-anxiety. 
 
Table 3  
Lifetime NMP use per benzodiazepine, frequency of alprazolam and diazepam use in 
past year. 
Benzodiazepine 
Ever NMP  Frequency of use 
n (%)  Alprazolama Diazepama 
Alprazolam 157 (54.3) Never 33 (20.2) 36 (22.0) 
Temazepam 61 (21.2) Once/ twice 49 (30.1) 61 (37.2) 
Oxazepam  39 (13.5) Monthly 30 (18.4) 28 (17.1) 
Lorazepam  71 (24.6) Weekly 32 (19.6) 14 (8.5) 
Diazepam 153 (52.9) Daily 19 (11.7) 25 (15.2) 
Clonazepam  70 (24.2)    
Flunitrazepam  27 (9.3)    
a Percentages reflect those reporting ever using selected benzodiazepine for NMP 
reasons. 
4.4.2.1 Predicting benzodiazepine-related aggression. Two hierarchical 
multiple regressions were conducted, to explore whether BIS/BAS variables could 
predict benzodiazepine-related aggression over and above control and 
benzodiazepine variables. In both models, control variables were entered at Step 1, 
diazepam and alprazolam use at Step 2, BIS/BAS main effects at Step 3, and the 
interaction term at Step 4. Preliminary analyses were conducted to explore the 
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assumptions of normality, linearity, multicollinearity, and homscedasticity. Two 
multivariate outliers were identified via Mahalonobis’ distance, and case summaries 
indicated these cases placed substantial leverage on both aggression models (Field, 
2009). These cases were therefore removed from the following analyses. For general 
aggression, casewise diagnostics demonstrated that only 1.4% of cases had 
standardised residuals of + 2.0, and only 0.9% of + 2.5, with none + 3.0 (Field, 
2009). For physical aggression only one case (.05%) had a standardised residual of + 
2.5 (Field, 2009). Examination of this specific case indicated that it was not having 
undue influence on the model and it was retained in the analysis. 
 
Table 4  
Typical and maximum daily alprazolam and diazepam doses, with approximate 
diazepam equivalent doses (DZM). 
BZD 
Typical Maximum 
n Range M (SD) 
DZMa 
(mgs) 
n Range M (SD) 
DZM 
(mgs) 
Alpraz 119 0-15.0 3.88 (4.29) 38.8 118 0-33.0 8.12 (8.71) 81.2 
Diaze 111 0-61.0 
16.96 
(15.71) 
16.96 110 1-161.0 
39.81 
(41.97) 
39.81 
Note. BZD = benzodiazepine; Alpraz = alprazolam; Diaze = diazepam; DZM = 
approximate diazepam equivalent dose; mgs = milligrams.  
a Approximate DZM computed using a 1:10 ratio for alprazolam, as suggested by 
dosing conversion table outlined by Farinde (2014). 
 
. 
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Table 5 
Bivariate correlations between factors of interest. 
 A B C D E F G H I J K L M N O P Q R S T U 
A -                     
B .21^                     
C .25^ .01                    
D .13 -.04 .91^                   
E .02 -.07 .35^ .40^                  
F -.04 -.07 .29* .37^ .83^                 
G .08 .01 .08 .10 .08 .05                
H .04 .09 -.12 -.13 .16 .09 .58^               
I .11 .11 -.03 -.05 .15 .09 .66^ .80^              
J .06 .05 .08 .11 .12 .11 .03 .24^ .23^             
K .00 -.06 .08 .18 .04 .11 .08 .07 .03 .48^            
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 A B C D E F G H I J K L M N O P Q R S T U 
L .00 .07 .05 .07 .03 -.02 -.16* .00 .03 .40^ .38^           
M .04 .13 -.25^ -.28^ -.06 -.14 .24^ .29^ .36^ -.17^ -.19* .11          
N -.01 .08 -.21* -.25^ .05 -.12 .30^ .30^ .36^ -.24^ -.32^ -.00 .54^         
O .04 -.03 .09 .08 .14 .17 .33^ .33^ .46^ .21^ -.01 .05 .08 .08        
P .04 -.06 .10 .10 .14 .16 .22^ .22^ .34^ .22^ .03 .05 -.04 -.07 .87^       
Q .10 -.03 .07 .14 .16 .40^ .04 .12 .15* .28^ .18^ .08 -.05 -.23^ .17* .21^      
R .25^ -.06 .24^ .28^ .19 .30^ .05 .11 .04 .13 .14* .04 -.11 -.15* .05 .14* .35^     
S -.04 -.07 .25^ .25^ .15 .03 .10 .15* .14* .22^ .25^ .14* -.02 -.05 .13 .12 .14* .05    
T .24* -.17 .38^ .41^ .50^ .50^ .27* .17 .31^ .16 .04 -.01 .02 -.12 .33^ .28* .21 .30^ .24*   
U .33* .28 -.18 -.22 .39* .46^ .30* .43^ .54^ .28 -.05 .05 .25 .07 .53^ .48^ .26 .13 .11 a  
V -.07 -.02 .18 .13 .02 -.06 .15 .05 .10 .12 .21^ .02 -.15 -.10 .14 .14 .03 .13 .22^ .23 -.14 
Note. A = age; B = gender; C = alprazolam typical dose; D = alprazolam maximum dose; E = diazepam typical dose; F = diazepam maximum dose; G = 
DASS Depression; H = DASS Anxiety; I = DASS Stress; J = BAS-Drive; K = FAS-Fun Seeking; L = BAS-Reward Responsiveness; M = BIS-Anxiety; 
N = BIS-Fear; O = general aggression; P = physical aggression; Q = violent conviction; R = substance-related conviction; S = use of other substances 
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when taking non-medically prescribed benzodiazepines; T = ASSIST score for those who prefer alprazolam; U = ASSIST score for those who prefer 
diazepam; V = number of substances regularly (at least weekly) used.   
a correlation unable to be computed as discrete subsamples based on preferential benzodiazepine used for non-medically prescribed reasons. 
* p < .01 
^ p < .001 
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General aggression. Inclusion of the control variables at Step 1 explained 
5.5% of the variance in general aggression (Fchange (6, 195) = 1.903, p = .082). Entry 
of the benzodiazepine variables at Step 2 significantly improved the model, 
explaining an additional 3.7% of the variance; Fchange (2, 193) = 3.910, p = .022. 
Entry of the BIS/BAS main effects at Step 3 again significantly improved the model, 
explaining an additional 6.7% of the variance; Fchange (5, 188) = 3.009, p = .012. The 
inclusion of the interaction term at Step 4 did not significantly improve the model 
(∆R2 = .008); Fchange (1, 187) = 1.769, p = .185. However, the final model, with all 
the variables in the equation, was significant and accounted for 16.7% of the total 
variance in general aggression; F(14, 187) = 2.682, p = .001. Alprazolam and 
diazepam use, and BAS-Dr significantly attributed unique variance to general 
aggression, whilst recruitment group and BAS-FS approached significance (see 
Table 6).  Inspection of the data indicates that BAS-Dr and alprazolam use made the 
strongest unique contributions to general aggression. Combined, BAS-Dr (5.29%) 
and alprazolam use (4.04%) contributed just under 10.0% towards the explanation of 
variance in general aggression, as calculated from the part correlation coefficients 
(Pallant, 2007). 
It is notable that prior to the inclusion of the recruitment variable in the first 
step, the pooled data model indicated a significant effect of the interaction term (p = 
.044), accounting for 1.8% unique variance. Upon entering the recruitment variable 
the influence of the interaction term fell just outside significance (p = .075), before 
moving further from significance in the final model (i.e., following final case 
removal). This suggests that an extremely weak, but potentially clinically meaningful 
moderation of BAS-Dr on the BIS-Anx and general aggression relationship may 
exist, and may benefit from further research. 
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Table 6 
Hierarchical multiple regression predicting benzodiazepine-related general 
aggression. 
 B S.E Beta t p 
95% C.I. for B Part 
cor 
coef 
Lower Upper 
Constant 91.56 20.09  4.558 .000 51.93 131.19  
Recruitment 8.96 4.10 .15 1.793 .075 -.90 18.82 .120 
Age -.06 .20 -.03 -.316 .752 -.45 .33 -.021 
Gender -1.13 3.42 -.02 -.331 .741 -7.88 5.62 -.022 
Viol Conv 10.09 7.82 .10 1.290 .199 -5.34 25.52 .086 
Reg Dr -2.42 4.71 -.04 -.513 .609 -11.70 6.87 -.034 
Reg Alc 2.12 3.89 .05 .545 .586 -5.55 9.80 .036 
Alprazolam 11.70 3.88 .25 3.012 .003 4.04 19.36 .201 
Diazepam -8.83 3.73 -.19 -2.366 .019 -16.19 -1.47 -.158 
BAS-FS -.166 .87 -.17 -1.905 .058 -3.38 .06 -.127 
BAS-RR -.76 .90 -.07 -.849 .397 -2.53 1.01 -.057 
BAS-Dr^ 2.86 .83 .30 3.451 .001 1.23 4.50 .230 
BIS-Anx^ .10 .83 .01 .124 .901 -1.54 1.74 .008 
BIS-Fear 1.03 .98 .09 1.056 .293 -.90 2.97 .070 
AnxXDr ^ .35 .26 .09 1.330 .185 -.17 .86 .089 
Note. Part cor coef = part correlation coefficient; Viol Conv = violent conviction; 
Reg Drg = regular drug use (previous 3 months); Reg Alc = regular alcohol use 
(previous 3 months); BAS-Dr = drive subscale, BAS-RR = reward responsiveness 
subscale; BAS-FS = fun seeking subscale; BIS-Anx = anxiety subscale; BIS-Fear = 
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fear subscale; AnxXDr = interaction term.  
^ centered variables. 
 
Due to the significant findings pertaining to diazepam and alprazolam, it was 
explored whether general aggression differed according to benzodiazepine dose. Two 
follow-up independent samples t-tests (two-tailed) indicated that levels of general 
aggression did not differ between those using alprazolam within the prescribing 
range or above (t(116) = -1.054, p = .294, 95% C.I. = -13.52 to 4.13, Cohen’s d = -
.20), or between those using diazepam within the prescribing range or above; t(108) 
= -.849, p = .398, 95% C.I. = -14.25 to 5.71, Cohen’s d = -.18.  
Physical aggression. Inclusion of the control variables at Step 1 explained 
6.4% of the variance in physical aggression; Fchange(6, 195) = 2.209, p = .044. Entry 
of the benzodiazepine variables at Step 2 did not significantly improve the model 
(∆R2 = .015); Fchange (2, 193) = 1.542, p = .217. Entry of the BIS/BAS variables at 
Step 3 did however significantly improve the model (∆R2 = .057); Fchange (5, 188) = 
2.459, p = .035. The inclusion of the interaction term at Step 4 did not significantly 
improve the model (∆R2 = .000); Fchange (1, 187) = .000, p = .991. However, the 
model remained significant at each step, and the final model, with all the variables in 
the equation, accounted for 13.5% of the total variance in physical aggression; F(14, 
187) = 2.084, p = .014. Again, alprazolam and BAS-Dr significantly attributed 
unique variance to physical aggression, although recruitment group and BAS-FS 
approached significance (see Table 7). As calculated from the part correlation 
coefficients (Pallant, 2007), BAS-Dr (4.6%) and alprazolam use (1.8%) contributed a 
combined 6.4% towards the explanation of variance in physical aggression.  
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Table 7 
Hierarchical multiple regression predicting benzodiazepine-related physical 
aggression. 
 B S.E Beta t p 
95% C.I. of B Part 
cor 
coef 
Lower Upper 
Constant 29.51 6.79  4.349 .000 16.12 42.89  
Recruitment 3.15 1.69 .16 1.867 .063 -.18 6.48 .127 
Age -.02 .07 -.03 -.319 .750 -.15 .11 -.022 
Gender -.46 1.16 -.03 -.397 .692 -2.74 1.82 -.027 
Viol Conv 3.79 2.64 .11 1.434 .153 -1.42 9.00 .098 
Reg Drg -.06 1.59 -.00 -.037 .971 -3.20 3.08 -.003 
Reg Alc .86 1.31 .06 .654 .514 -1.73 3.45 .044 
Alprazolam 2.63 1.31 .17 2.004 .046 .04 5.22 .136 
Diazepam -1.95 1.26 -.12 -1.546 .124 -4.44 .54 -.105 
BAS-FS -.58 .29 -.18 -1.96 .052 -1.16 .01 -.133 
BAS-RR -.19 .30 -.05 -.613 .541 -.78 .41 -.042 
BAS-Dr^ .88 .28 .28 3.154 .002 .33 1.44 .215 
BIS-Anx^ -.12 .28 -.03 -.419 .676 -.67 .44 -.028 
BIS-Fear -.16 .33 -.04 -.47 .639 -.81 .50 -.032 
AnxXDr ^ .00 .09 .00 .011 .991 -.17 .17 .001 
Note. Part cor coef = part correlation coefficient; Viol Conv = violent conviction; 
Reg Drg = regular drug use (previous 3 months); Reg Alc = regular alcohol use 
(previous 3 months); BAS-Dr = drive subscale, BAS-RR = reward responsiveness 
subscale; BAS-FS = fun seeking subscale; BIS-Anx = anxiety subscale; BIS-Fear = 
fear subscale; AnxXDr = interaction term. 
^ centered variables. 
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A follow-up independent samples t-test (two-tailed) indicated that levels of 
physical aggression did not differ between those using alprazolam within the 
prescribing range or above (t(116) = -1.658, p = .100, 95% C.I. = -5.36 to .48, 
Cohen’s d = -.31).  
4.5 Discussion 
Benzodiazepine-related aggression is poorly understood. In an effort to 
understand this response in greater depth, the current study aimed to explore the role 
of motivational tendencies in benzodiazepine-related aggression. It was proposed 
that such characteristics would predict aggressive responding over and above 
benzodiazepine type, and that BAS-Dr specifically would be important in 
understanding this response. It was also predicted that BAS-Dr would moderate an 
association between risk averse motivational tendencies and benzodiazepine-related 
aggression. The data generally supported these predictions, however the moderation 
effect was not observed.  
4.5.1 Role of BAS-Dr in benzodiazepine-related aggression. 
The tendency to pursue appetitive goals in a persistent manner (BAS-Dr) has 
been consistently associated with aggression and related tendencies (i.e., anger; 
Cooper et al., 2008; Miller et al., 2012; Seibert et al., 2010). The current study 
extends this literature, by hypothesising that BAS-Dr is important in benzodiazepine-
related aggression. In support of this hypothesis, BAS-Dr was the strongest unique 
predictor of both general aggression and physical aggression, over and above the 
influence of benzodiazepine type (diazepam and alprazolam). Such outcomes align 
with research indicating the importance of BAS-Dr in the prediction of aggressive 
behaviour compared to other intrapersonal factors (Seibert et al., 2010), and 
importantly, support the contention that our understanding of benzodiazepine-related 
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aggression may be enhanced via recourse to intrapersonal differences (Hoaken & 
Stewart, 2003; Lion et al., 1975).  
Individuals with strong BAS-Dr have been described as antagonistic, 
competitive, and willing to work hard to achieve goals, even if at the expense of 
others (Segarra et al., 2014). Such individuals hold high expectations of rewards 
following goal attainment (Harmon-Jones, 2003) and their experienced affect is 
strongly reflective of their perceived progress towards their goal (Carver, 2004). For 
example, in the context of challenged or blocked goal attainment, individuals with 
high BAS-Dr may experience frustration or anger (Carver, 2004), such as frustrative 
non-reward (Corr, 2002). Aggressive behaviour then becomes increasingly likely, as 
during frustration, such individuals display reduced impulse control (Beaver et al., 
2008) and attention to risk or punishment cues (Avila, 2001). Their ability to respond 
appropriately to stressors or frustrations may become further disinhibited in the 
context of benzodiazepine use (Paton, 2002). Indeed, the current data indicate that 
individuals with stronger BAS-Dr tendencies experienced greater anxiety and stress, 
which may reflect difficulty attaining desired outcomes (Carver, 2004), and tended to 
consume benzodiazepines in the context of other substances, which may further 
impact their coping or self-regulation ability. However, the absence of appropriate 
causal testing limits the conclusions able to be drawn from such associations, though 
the findings do clearly support the role of persistent action towards desired goals in 
benzodiazepine-related aggressive behaviour. As such, prescribers may benefit from 
exploring patients’ ability to engage in effective impulse control and frustration 
tolerance strategies prior to prescribing benzodiazepines. Such information may be 
gleaned from knowledge of the patient’s psychosocial background, or by specifically 
enquiring into their coping strategies, tendency to act without consideration of 
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consequences, engagement in risky behaviour, and ability to respond to frustration in 
a pro-social manner (i.e., delayed consult time, smaller prescription than requested). 
Interestingly, the expected moderation effect between a strong appetitive and 
strong aversive motivational system on benzodiazepine-related aggressive behaviour 
failed to significantly influence either aggression model. Given that our sample 
displayed only moderate levels of aggression, such an effect may be more likely in a 
more violent sample, against clearly defined violent incidents. Furthermore, 
aggression risk may be associated with extremely high levels of BIS activation 
(Hatfield & Dula, 2014), whilst our sample displayed only moderately-high BIS 
activation. The moderating effect may therefore only be relevant to investigations of 
benzodiazepine-related aggression in individuals with more complex motivational 
presentations than those observed in the current sample.   
4.5.2 Role of benzodiazepine type in benzodiazepine-related aggression. 
The current findings suggest that alprazolam poses a greater risk than 
diazepam for subsequent aggressive behaviour. As described elsewhere (Horyniak, 
Reddel, Quinn, & Dietze, 2012; Rintoul, Dobbin, Neilsen, Degenhardt, & Drummer, 
2013), alprazolam is one of the most problematic benzodiazepines, and has recently 
been rescheduled to a controlled substance within Australia, in order to mitigate the 
risks associated with it. Given its short acting effects, association with poly-
substance use in the current sample, and the common goal to become intoxicated 
(25.6%), alprazolam-related aggression may reflect the context of use, rather than the 
physiological effects of alprazolam. Indeed, aggressive behaviour did not differ 
according to alprazolam dose. When considered with our finding that intrapersonal 
factors accounted for greater amounts of variance than alprazolam use alone, the 
current data appear to support Lion and colleagues’ (1975) supposition that it is the 
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interaction between benzodiazepine use, the situation and intrapersonal factors that 
influences subsequent aggressive behaviour. However, further research using 
urinalysis and an in-depth analysis of substance use patterns is required.  
Interestingly, general aggression was significantly negatively predicted by 
diazepam use. Within the current sample, diazepam is used more for alleviation of 
negative emotional and physical states (i.e., anxiety, tension, or effects of 
withdrawal; 41.1%), rather than to get high (14.5%), whereas alprazolam use is more 
evenly attributed to both reasons.  This differentiation further highlights the role that 
approach motivations (rather than avoidance motivational tendencies) may have in 
the experience of benzodiazepine-related aggression. Furthermore, unlike 
alprazolam, diazepam appears to be infrequently used within the context of poly-
substance use, and therefore may be generally used in scenarios less conducive to 
aggressive interactions. In addition, only when diazepam-preferring participants were 
examined in isolation, of whom predominantly displayed a moderate or high risk of 
dependence (i.e., difficulty managing diazepam use, experience of problematic 
diazepam-related outcomes), did we find a positive association with aggressive 
outcomes. Comparatively, the regression analyses were conducted with all 
participants who had reported historically using diazepam for NMP reasons (i.e., not 
necessarily frequent, ongoing, dependent use). Therefore, it could be concluded that 
diazepam poses a risk for benzodiazepine-related aggression only in those who 
display increasingly problematic patterns of diazepam use, rather than to the majority 
who use diazepam on a less regular basis. This has important implications for the 
continued prescription of diazepam, highlighting the importance of prescribers 
carefully monitoring patient adherence to low dose, short term use, and the potential 
benefits of prioritising non-medicinal approaches in assisting patients (Dobbin, 2014; 
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Lader, 2014). Comparatively, alprazolam appears to be a risk for aggression at both 
dependent (problematic) levels and for those with less frequent use, and may be best 
prescribed only after exhausting other treatment options.  
4.5.3 Limitations and strengths.  
A number of limitations must be acknowledged. Due to the cross-sectional 
nature of the study, causality cannot be implied, and data collection relied on 
uncorroborated, retrospective self-report which may be vulnerable to attributional 
biases and memory decay. In addition, the study did not involve a manipulation 
check to ensure that the modification to the aggression questionnaire was successful, 
meaning that conclusions should be considered with an element of caution, 
especially given the lack of measurement of aggressive tendencies in the absence of 
benzodiazepine use. The questionnaire was considered already burdensome (on 
average more than 45 minutes to complete) that to also include such a measure 
(possibly the AQ without the modified instructions) would result in increased 
participant dropout. The temporal duration between benzodiazepine consumption and 
the aggressive response was also not assessed, and therefore the possibility that the 
response occurred during benzodiazepine withdrawal (Votava, Kršiak, Podhorná, & 
Miczek, 2001) cannot be discounted.  Benzodiazepine use was also assessed through 
a non-standardised and non-piloted questionnaire. Participant feedback indicated that 
the questionnaire was lengthy and failed to include an exhaustive list of street names 
for various licit and illicit substances. Furthermore, the predictive models were 
unable to be explored based on recruitment type, due to the insufficient sample size 
of the health centre subsample. In addition, the findings are limited in generality, and 
cannot be reliably applied to individuals who commit more severe violence. 
Moreover, it cannot be discounted that other substances used in combination with 
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benzodiazepines may have impacted the findings (Sweeney & Payne, 2012). Finally, 
the current study did not permit direct examination of frustrative non-reward as this 
can only be examined when reward pathways are activated.  
Despite these caveats, the current study has a number of important and unique 
strengths. First, specific benzodiazepines are explored, allowing greater specificity 
than the majority of cross-sectional studies available. Greater specificity is also 
permitted through the separate examination of general aggressive tendencies and 
physical aggression specifically. Third, the sample is relatively large, with an almost 
even gender split; the latter feature absent in a number of well-designed, though 
male-only, examinations of benzodiazepine-related aggression (see Albrecht et al., 
2014 for a review). The most important contribution of the current study, however, is 
that it is the first study to have a theoretically informed examination of 
benzodiazepine-related aggression, thus offering a clear model against which such 
behaviour can be more greatly understood, and interventions can be designed. The 
application of the rRST at the facet level provides additional specificity in order to 
inform such implications (Jones, Miller, & Lynam, 2011; Miller et al., 2012; Segarra 
et al., 2014).  
4.6 Implications and Conclusions 
Lion and colleagues (1975) suggested that it is the interaction between 
benzodiazepine use, intrapersonal factors, and context which can explain 
benzodiazepine-related aggression. Our data alludes to the influence of goal-driven 
tendencies and certain benzodiazepine use, though the situational context remains 
unclear. Future investigations could therefore benefit from an exploration of the 
context surrounding the aggressive act (i.e., presence of frustration or goal 
challenge), as well as consideration of beliefs and attitudes regarding the 
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acceptability of aggressive behaviour (i.e., aggressive scripts; Anderson & Bushman, 
2002).  
In lieu of these aspects receiving further attention, the current findings do 
demonstrate the importance of intrapersonal factors in understanding 
benzodiazepine-related aggression (Hoaken & Stewart, 2003; Lion et al., 1975). 
Notably, benzodiazepine users may be more likely to engage in aggressive behaviour 
if they exhibit persistent tendencies to pursue desired goals. In addition, general 
diazepam use (i.e., not in the context of dependency) appears to reduce the risk of 
general aggressive behaviour (i.e., anger, hostility, verbal aggression), whilst 
alprazolam increases the risk of aggression, regardless of dose. Although further 
work is necessary to confirm the mechanisms underlying the association between 
motivational drive and benzodiazepine-related aggression, the findings highlight the 
benefit of attending to frustration tolerance and aggression scripts in individuals with 
high BAS-Dr, and support the rescheduling of alprazolam to a controlled substance. 
4.7 Chapter Summary 
The application of a theory-drive research approach has highlighted the 
importance of intrapersonal factors in understanding benzodiazepine-related 
aggression. Notably, persistent approach of desired goals was associated with 
increased aggressive behaviour. In addition, alprazolam was highlighted as more 
risky than diazepam in regards to self-reported physical aggression, aligning with 
recent national and international concerns about the benzodiazepine. Community 
based studies are important in the examination of this response, as they provide 
insight into the population likely to access community-based health centres and drug 
and alcohol clinics. However, the low base rate of aggressive behaviour in such 
samples suggests that a clearer understanding of this response may be afforded by 
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investigation of a violent criminal justice sample. As will be discussed in the 
following chapter, such samples have received minimal attention in related literature, 
despite the potential that such examination has to inform the use of prescribed 
benzodiazepines in justice health contexts, and the development of appropriate 
violent offender rehabilitation strategies.  
Due to local restrictions on new research protocols with justice populations, the 
following study involved analysis of a previously-acquired database, developed in 
the absence of strong theoretical reasoning. It is hoped that the uniqueness of the 
database (i.e., benzodiazepine-using offenders) provides valuable insight into this 
response, and informs the development of future, more theoretically rigorous, 
research protocols exploring benzodiazepine-related aggression in violent samples. 
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Chapter Five: Violent crime: A complex interplay of benzodiazepine use, 
psychological distress, and problematic impulsive behaviours. 
Please note, this chapter presents an expanded version of an original 
manuscript submitted for review to Journal of Substance Abuse (September, 2015), 
due to copyright reasons. Details of the submitted article have been appended for 
your consideration (Appendix D).  
5.1 Introduction 
Why any individual commits a violent act is a question that generally 
frightens and confronts us. Years of research and investigation have shown that 
violence involves a complex interplay of social, environmental, biological and 
situational elements (Anderson & Bokor, 2012; Steinert & Whittington, 2013). 
However, in spite of examinations of the construct from a broad array of disciplines, 
including neurobiology, mental health, sociology, criminology, and addiction (for 
reviews, see Anderson & Bokor, 2012; Chereji, Pintea, & David, 2012; Friedman, 
1998; Schenk & Fremouw, 2012), a number of questions still remain. One of these 
questions involves identifying the role of various substances in the commission of 
violent behaviour. Despite knowing that pharmacological properties of substances 
can have a profound influence on neurobiology, mental state, and behaviour, we 
know relatively little about how this differs between substances to effect violent 
behaviour (i.e., both stimulants and depressants have been associated with violence; 
e.g., Lennings, Copeland, & Howard, 2003; McKetin et al., 2014). While the role of 
alcohol in violent behavior has been studied at length, benzodiazepine use on the 
other hand has been surprisingly under-researched. Given the increasing misuse of 
benzodiazepines (ACC, 2014), particularly amongst those with mental health issues 
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and forensic backgrounds (Ng & Macgregor, 2012; Stafford & Burns, 2013; 
Sweeney & Payne, 2012), further research is warranted. 
A recent systematic review (Albrecht et al., 2014) suggests that 
benzodiazepines may play a role in aggressive behavior and violent crimes (e.g., 
French, 1989; Ben-Porath & Taylor, 2002; Lundholm, Haggård, Möller, Hallqvist, & 
Thiblin, 2013; Moore, Glenmullen, & Furberg, 2010). For example, an estimated 1-
20% of benzodiazepine users report experiencing some form of increased anger or 
aggression following use (Lader, 2011). While this may seem counter-intuitive given 
the sedating effects of benzodiazepines, neurobiological theories suggest that such 
paradoxical effects may arise due to disinhibition following benzodiazepine use 
(Bond, 1998; Longo & Johnson, 2000). This unlikely effect has been repeatedly 
demonstrated in experimental laboratory studies, where increased responding 
indicative of aggression has followed consumption of acute doses of benzodiazepines 
(e.g., alprazolam, diazepam) compared to placebo (e.g., Wilkinson, 1985; Bond, 
Curran, Bruce, O’Sullivan, & Shine, 1995). However, the use of analogue 
representations of aggression in highly controlled circumstances greatly limits the 
ecological validity of such findings.  
5.1.1 Benzodiazepines and violent crime. 
Criminal justice samples have been found to misuse benzodiazepines more 
than the general community (e.g., AIHW, 2011; Ng & Macgregor, 2012). Yet, 
empirical literature examining the association between benzodiazepine use and 
subsequent violent crime is rare (see Albrecht et al., 2014, for a review). Although 
benzodiazepines, either alone or in combination with other substances, have been 
empirically associated with criminal behaviour, including acquisitive and property 
crime (Bradford & Payne, 2012; Darke & Ross, 1994; Darke, Ross, Mills, Teesson, 
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Williamson, & Havard, 2010; Payne & Gaffney, 2012; Smith, Miller, O’Keefe, & 
Fry, 2007), comparatively little attention has been paid to their association with 
violent offences.  To date, no research has explored the relationship between 
benzodiazepine use and actual violent crime in an adult community criminal justice 
sample.  This is despite recent research demonstrating young community based 
offenders (aged 16-20 years) attribute their violent crimes most commonly to 
diazepam (often in conjunction with alcohol; Forsyth, Kahn, & McKinlay, 2011). 
Furthermore, studies of remanded and incarcerated violent offenders report positive 
associations between violent crime and higher doses of (unspecified) 
benzodiazepines (and combined alcohol use; Haggård-Grann, Hallqvist, Långström, 
& Möller, 2006; Lundholm et al., 2013).  The focus of this study is to examine in 
detail how community-based offenders engaged in violent crime differ from those 
engaged in non-violent crimes across a range of mental health and substance abuse 
behaviours with a particular focus on their use of benzodiazepines. Findings will 
have particular relevance to law enforcement and addiction treatment services in the 
community, at a time when recent rescheduling of alprazolam to a controlled 
substance (Schedule 8) in Australia may impact the already increasing diversion of 
benzodiazepines onto the black market (ACC, 2014). 
Importantly, the available literature provides little insight into the specific 
dose schedules or types of benzodiazepines which present increased risk of violence. 
That is, the nature of the benzodiazepine-violence relationship appears to vary 
according to administration and dosing schedules of specific benzodiazepines. For 
example, methodologically diverse investigations have provided evidence both for 
and against the role of alprazolam in violent behaviour (e.g., Bond et al., 1995; Bond 
& Silveira, 1993; O’Sullivan et al., 1994). In addition, existing cross-sectional 
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studies often group benzodiazepines together (ignoring concepts such as the half-life 
or function of specific benzodiazepines), fail to consider dose, and at times do not 
include non-violent controls (e.g., Dåderman, Fredriksson, Kristiansson, Nilsson, & 
Lidberg, 2002). Such methodological limitations have hampered our understanding 
of the relationship between benzodiazepine use and subsequent violent crime.  
Improving our understanding of these relationships may have important medical and 
legal implications for prescribing practices, especially when benzodiazepines are 
commonly used to manage agitation (Ashton, 2002), often in public spaces such as 
hospital emergency rooms.  
5.1.2 The current study. 
In order to address some of these gaps, the present study aims to examine the 
relationship between benzodiazepine use and engagement in violent crime within a 
benzodiazepine-using, community-based criminal justice sample. Previously 
gathered data are re-analysed with this specific research question in mind. The 
current study uses a non-violent offender comparison group, and uniquely explores 
whether benzodiazepine type or dose level is more closely associated with violent 
than non-violent crimes. Alprazolam and diazepam are specifically examined due to 
their frequent misuse in forensic populations (McGregor, Gately, & Fleming, 2011; 
Sweeney & Payne, 2012), and benzodiazepine use during the month and day 
preceding a recent crime is explored. It is predicted that individuals engaged in 
violent crime will report greater benzodiazepine use, and higher doses, than non-
violent offenders. In order to attend to the complexity of violent behaviour (DeWall, 
Anderson, & Bushman, 2011), core factors understood to play a role in violent crime 
are also assessed. Based on prior literature, it is expected that individuals engaged in 
violence will exhibit a heightened level of impulsivity (Derefinko, DeWall, Metze, 
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Walsh, & Lynam, 2011; Smith & Waterman, 2006), increased psychological distress 
or disorder (e.g., Swogger, Walsh, Houston, Cashman-Brown, & Connor, 2010; 
Umberson, Williams, & Anderson, 2002), poly-substance use (Friedman, 1998), and 
prior criminality (Rice, Harris, & Lang, 2013). 
5.2 Method 
5.2.1 Participants. 
Participants were recruited through purposive sampling techniques via drug 
treatment programs and initiatives within the criminal justice system in Melbourne, 
Australia, including the Court Integrated Services and other drug treatment services, 
through liaison with service managers and forensic counsellors. Eligibility criteria 
were (i) 18 years and over, (ii) committed a crime within six months of the interview, 
and (iii) used benzodiazepines (prescribed or non-prescribed) at least once per month 
in the last six months. The current study uses the term ‘index offence’ to refer to the 
participants’ most recent crime, to which eligibility criteria (ii) relates. Participants 
were divided into violent and non-violent groups based on this offence. 
5.2.2 Design and Procedure.   
The study involved a specifically developed semi-structured interview 
protocol. Participants provided demographic information, mental health and 
substance use history, and the context of their index charge (i.e., employment and 
residential information). Interviews lasted 45-60 minutes and were conducted either 
face-to-face or over the telephone, and were audio recorded and transcribed 
verbatim. Analysis of the de-identified data was approved by the relevant ethics 
committees. 
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5.2.3 Measures. 
Psychological distress. The Kessler Psychological Distress Scale (K-10; 
Kessler et al., 2002) is a 10-item questionnaire designed to measure self-reported 
psychological distress over the most recent 4-week period, or in this case the month 
before the crime. A score of 30 or more has been demonstrated to be the most 
accurate indicator for a severe mental disorder (Andrews & Slade, 2001). The K-10 
has demonstrated predictive validity in a national Australian sample (Furukawa, 
Kessler, Slade, & Andrews, 2003). 
Impulsivity. The UPPS Impulsive Behaviour Scale (UPPS; Whiteside & 
Lynam, 2001) is a 45-item questionnaire measuring impulsivity across four sub-
scales2, with higher scores indicating greater levels of impulsivity. The subscales are 
Urgency (12 items; e.g., “when I am upset I often act without thinking”), (lack of) 
Premeditation (11 items; e.g., “I like to stop and think things over before I do them”), 
(lack of) Perseverance (10 items; e.g., “I concentrate easily”), and Sensation Seeking 
(12 items; e.g., “I’ll try anything once”). The four factor model has demonstrated 
construct and differential validity (Miller, Flory, Lynam, & Leukefeld, 2003; 
Whiteside, Lynam, Miller, & Reynolds, 2005), and concurrent validity within a 
sample of alcohol-consuming college students (Magid & Colder, 2007). The 
subscales have shown good internal consistency (α = 0.82-0.91; Whiteside & Lynam, 
2001). 
Substance use and dependence. The Severity of Dependence Scale (SDS; 
Gossop & Darke, 1995) is a five-item questionnaire providing a score indicating the 
degree of dependence to a certain substance. Data was collected regarding 
dependence to benzodiazepines, in the month prior to the index offence. The items 
                                                          
2 The original study utilised a 5-point Likert scale (0 = not at all, 2 = sometimes, 4 = very much). It is 
recognised that this departs from the standardised application of the UPPS, which uses a 4-point 
Likert scale (1 = strongly agree, 4 = strongly disagree). 
  127 
 
are scored on a 4-point scale (0-3) with a total score obtained by the sum of all item 
ratings. A score of 7 or higher indicates benzodiazepine dependence (de las Cuevas, 
Sanz, de la Fuente, Padilla, & Berenguer, 2000).   
A 28-day timeline follow back method (Sobell & Sobell, 1992; Sobell, 
Brown, Leo, & Sobell, 1996) was used to measure benzodiazepine, alcohol, 
pharmaceutical opiate and illicit drug use in the month prior to the index crime. 
Participants were asked about drug type and amount used, route of administration, 
days of no use/withdrawal, days of increased use, and days of different drug 
combinations or administration methods. 
Criminality. The Criminality Index from the Opiate Treatment Index (OTI; 
Darke, Hall, Wodak, Heather, & Ward, 1992) was used as a measure of criminal 
behaviour in the month prior to the index offence. The Criminality Index explores 
the frequency of recent property crime, drug dealing, fraud, and violent crime using a 
5-point Likert scale (0 = no crime, 2 = once a week, 4 = daily). Scores are summed to 
form a total score (0-16), with higher scores indicating greater criminal involvement. 
The Criminality Index has demonstrated test-retest reliability over a one week period 
(0.96), and construct validity with official criminal records and the Addiction 
Severity Index (ASI) crime days measure, but limited internal reliability (α = 0.38; 
Darke et al., 1992), potentially due to the nature of the items all referring to specific 
and disparate crime types. The violent crime item has demonstrated agreement 
between a person’s self-report and collateral report (94% agreement, kappa: -0.03) 
and conviction records (89.2% agreement; kappa = .0713; Darke et al., 1992).   The 
tool has been successfully applied in a study exploring benzodiazepine use (Darke & 
Ross, 1994). 
                                                          
3 Low kappa figures with a high agreement may reflect the low base rate of the behaviour under the 
agreement analysis (Viera & Garrett, 2005) 
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5.2.4 Statistical analyses. 
The data were analysed in SPSS PASW Statistics 18. Preliminary screening 
informed the deletion of six cases due to no data, and indicated that there was a 
proportion of incomplete data for the dose variables (nrange = 44-60; 53.70-73.17%). 
Due to the unique nature of the data, statistical imputation was not conducted, though 
pairwise case exclusion was applied to analyses. This may have attenuated the 
statistical power available, and influenced the choice of statistical analyses that were 
conducted. Where normality was violated, variables were recoded, including number 
of mental of health diagnoses (zero; one; two or more diagnoses), OTI Violence 
(violent vs non-violent), and benzodiazepine dose (within or above the standard 
dosing range4 outlined in the MIMS; “Alprazolam”, 2013; “Diazepam”, 2013). 
Inspection of bivariate correlations indicated an absence of multicollinearity. The 
final sample size was 82.  
Due to concerns of the veracity of the impulsivity data provided (i.e., pre-
computed scale scores), a research assistant not involved in the current research 
study extracted the item-level impulsivity data from the raw data, into a de-identified 
electronic spreadsheet. Impulsivity data for 76 cases were provided. Inspection of 
this item-level data by the first author indicated that the scale scores provided in the 
de-identified database were incorrect. In order to align the final scores with those 
possible within the standardized version of the UPPS (i.e., zero scores are not 
possible), 7.25% (n = 248) of the data points required re-scoring from zero to one.  
Inspection of missing data indicated that less than 1% (n = 35) of the data points 
were missing, and these were imputed with the sample median per item. Items were 
reverse-scored, taking into consideration the already reversed scale direction (i.e., 4 = 
                                                          
4 Alprazolam: 0.5-4.0mg per day; Diazepam: 5-40mg per day. 
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very much, whilst standardized UPPS uses 4 = strongly disagree)5, and scale totals 
were calculated using SPSS Compute Variable.  Only impulsivity data of 74 cases 
were transferred into the main database, due to the prior deletion of two cases above. 
All scale scores were normally distributed, with no univariate outliers, and the 
assumption of multicollinearity was upheld.   
Sample characteristics were explored using descriptive and frequency 
analyses. Where possible, group differences were explored using independent 
samples t-tests (two-tailed), and means, standard deviations, and 95% confidence 
intervals (CI) are reported. For categorical variables, or when assumptions are 
violated, non-parametric tests were conducted. 
5.3 Results 
5.3.1 Participant characteristics.  
The final sample consisted of 82 individuals, aged between 21-56 years old 
(M = 34.6, SD = 7.1; see Table 1 for sample demographics).  
5.3.2 Crime profile. 
Eleven (13.4%) participants were charged with a violent index offence, which 
included assault, armed robbery, aggravated burglary, serious threats, and sexual 
assault.  In the month prior to the index offence, 64 (78.0%) participants reported 
engaging in criminal activity of some kind, most commonly property crime (69.5%), 
followed by drug dealing (36.6%), violent crime (22.0%), and fraud (20.7%). Total 
frequency of crime (OTI total) was positively associated with urgency and a total 
impulsivity score, as well as increased use of substances and benzodiazepines in the 
12-24 hours prior to the index offence. 
 
                                                          
5 It is noted that the scale used may have conceptual implications both when impacting the 
participant’s answer, and for over-all interpretability (i.e., estimation of frequency versus degree the 
participant agreed with each statement). 
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Table 1 
Demographic characteristics of the sample population 
Characteristic n % Characteristic n % 
Gender   Country of birth   
Male 65 79.3 Australia 73 89.0 
Female  17 20.7 Other  9 11.0 
ATSI status   Highest education   
Aboriginal 10 12.2 Yr 9 or below 35 42.7 
Torres Strait Islander 2 2.4 Yr 10-11 32 39.0 
Neither 70 85.4 Yr 12 9 11.0 
   Diploma/Tafe 6 7.3 
Main source of 
incomea 
  Housing statusa   
FT/PT employment 4 4.8 Homeless 14 17.1 
Temporary benefit 33 40.2 Rented house or flat 25 30.5 
Pension 35 42.7 
Privately owned 
house/flat 
4 4.9 
Criminal activity 9 11.0 Boarding house/hostel 15 18.3 
Other 1 1.2 
AOD treatment 
residence 
2 2.4 
   Other  22 26.8 
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Table 2 
Participant substance use and mental health histories, and recent distress ratings. 
Previous AOD 
treatment 
  Lifetime substance use   
Opiate substitution  68 82.9 Cannabis 82 100.0 
AOD counselling 67 81.7 Amphetamines 82 100.0 
Inpatient detoxification 54 65.9 Tobacco 81 98.8 
Self-help programs 38 46.3 Alcohol 81 98.8 
Residential 
rehabilitation 
35 42.7 Heroin 79 96.3 
Supported accomm 27 32.9 Ecstasy 69 84.1 
Outreach worker 
support 
17 20.7 Hallucinogens 57 69.5 
Unspecified/other 17 20.7 Cocaine 57 69.5 
Self-reported diagnosis   Psychological distress   
Depression 51 62.2 Likely well 6 7.3 
Anxiety 37 45.1 Mild mental disorder 11 13.4 
Bipolar disorder 20 24.4 Mod mental disorder 17 20.7 
Drug-induced 
psychosis 
18 22.0 Severe mental disorder 43 52.4 
Panic disorder 18 22.0    
Schizophrenia 13 15.9    
Personality disorder 9 11.0    
Note. ATSI = identify as Aboriginal or Torres Strait Islander; FT/PT = full time or 
part time; AOD = alcohol and other drugs; accomm = accommodation’ mod = 
moderate. 
astatus refers to the month prior to index offence. 
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5.3.3 Benzodiazepine use profile.  
The most commonly used benzodiazepine over the lifetime (including 
prescribed and non-prescribed) was diazepam (98.8%), followed by temazepam 
(95.1%), alprazolam (93.9%), oxazepam (92.7%), and clonazepam (62.2%). More 
than one third (39.0%) had used six types of benzodiazepines (including ‘other’), 
whilst more than half (59.8%) regularly used four or more types. Nearly half (46.3%) 
exhibited benzodiazepine dependence, and participants specifically referenced 
difficulty with diazepam (39.0%) or alprazolam (37.8%) when responding to the 
SDS. As shown in Table 3, benzodiazepine dependence was significantly, positively 
associated with urgency, sensation seeking, psychological distress, and the number of 
other substances used on a regular basis. Non-medical acquisition methods (i.e., 
without a prescription) were extremely common (91.5%), though 70.7% of the 
sample reported using both non-medical and medical sources during their lifetime.   
In the 12-24 hours immediately prior to the index offence, 84.1% of the 
sample reported using a benzodiazepine, with high rates of diazepam (61.0%) and 
alprazolam (57.3%) use. More than a third (36.6%) reported using two types of 
benzodiazepines prior to the index crime. Examination of approximate diazepam 
equivalent doses (DZM) indicates that alprazolam was consumed at the highest doses 
both in the day and month prior to the offence, at levels more than twice, and triple, 
national prescribing recommendations, respectively (“Alprazolam”, 2013; see Table 
4).  
5.3.4 Substance use profile. 
As shown in Table 2, all participants reported lifetime use of cannabis and 
amphetamines, while other drug use was also high. The entire sample had used five 
or more drugs in their life (M = 17.9, SD = 3.5), and reported a large number of 
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Table 3 
Means (M), standard deviations (SD) and bivariate correlations between factors of interest 
 M (SD) Age OTI Total 
SDS 
BZD K-10 
UPPS 
PRE 
UPPS 
URG 
UPPS 
SS 
UPPS 
PER 
UPPS 
Total Sub Reg 
BZD 
Reg 
Sub 12-
24 
OTI 
Total 3.8 (3.3) -.16            
SDS 
BZD 6.6 (4.3) .01 .02           
K-10 31.5 (9.5) .06 .20 .51**          
UPPS 
PRE 30.5 (7.0) .21 .20 -.20 -.04         
UPPS 
URG 33.5 (8.0) .09 .31** .32** .53** .30**        
UPPS 
SS 31.2 (8.8) -.11 .12 .37** .17 -.13 .12       
UPPS 
PER 26.1 (5.4) -.10 .19 -.20 .06 .51** .26* -33**      
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 M (SD) Age OTI Total 
SDS 
BZD K-10 
UPPS 
PRE 
UPPS 
URG 
UPPS 
SS 
UPPS 
PER 
UPPS 
Total Sub Reg 
BZD 
Reg 
Sub 12-
24 
UPPS 
Total 
121.3 
(16.8) .04 .36** .19 .34** .66** .74** .42** .48**     
Sub 
Reg 12.8 (3.9) .07 .17 .24* .15 -.13 .23 .05 -.09 .05    
BZD 
Reg 3.8 (1.4) .03 .09 .27* .13 -.02 .07 .05 .06 .07 .79**   
Sub 12-
24 4.21 (1.29) .01 .25* .12 .177 -.07 .11 -.13 -.08 -.08 .35** .33**  
BZD 
12-24 1.22 (.69) -.02 .26* .20 .174 -.20 .10 -.14 -.15 -.17 .20 .21 .54** 
Note. OTI Total ದ frequency of crime in last month; SDS BZD ದ total Severity of Dependence score for benzodiazepines; K-10 ದ Kessler distress 
scales total score; UPPS PRE ದ (lack of) premeditation; UPPS URG ದ urgency; UPPS SS ದ sensation seeking; UPPS PER ದ (lack of) 
perseverance; UPPS Total ದ total impulsivity score; MH DX ದ number of mental health diagnoses; Sub Reg ದ number of substances regularly 
used; BZD Reg ದ number of benzodiazepines regularly used; Sub 12-24 ದ number of substance used 12-24 hours prior to index crime; BZD 12-
24 ದ number of benzodiazepines used 12-24 hours prior to index crime. 
* p < .05 
** p < .01 
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substances regularly used (M = 12.8, SD = 3.9). In addition, the majority of the 
sample (96.3%) had previously sought treatment for alcohol and/or drug (AOD) 
difficulties, predominantly in the form of opiate substitution programs (82.9%). In 
the 12-24 hours immediately prior to the index offence, 98.8% of the sample reported 
using a substance in addition to benzodiazepines.  
5.3.5 Mental health profile.  
Scores on the K-10 indicated that the sample was highly distressed, with more than 
half of the sample (52.4%) scoring 30 or above (see Table 2). The majority of the 
sample reported being diagnosed with a mental illness in their life (82.9%), with 
64.6% reporting more than one mental health diagnosis (M = 2.2, SD = 1.7). The 
most commonly reported diagnoses were depression (62.2%) and anxiety (45.1%), 
followed by bipolar disorder (24.4%), drug induced psychosis (22.0%), panic 
disorder (22.0%), schizophrenia (15.9%), and personality disorder (11.0%). 
5.3.6 Group differences. 
Benzodiazepine use. As shown in Table 5, the degree of benzodiazepine 
dependence significantly differed between those who committed violent and non-
violent index offences. Individuals who committed a violent offence reported a 
greater degree of benzodiazepine dependence than those who committed a non-
violent index offence (t(76) = -2.120, p = .037, 95% C.I.: -5.84 to -.18, Cohen’s d = 
0.73). The use of non-prescribed (i.e., illicit) benzodiazepines did not differ between 
violent and non-violent offenders (p = .186; OR = 0.27, 95% CI: .04-1.71). 
Alprazolam use. Non-parametric Fisher’s exact tests (two-tailed) found that 
individuals who committed a violent index offence were significantly more likely to 
use alprazolam at doses above the SDR (90.0%) in the month prior to the index 
offence, than individuals who committed a non-violent offence (54.0%; p = .040; OR 
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= 7.67, 95% CI: .90-65.13). Indeed, violent offenders reported average alprazolam 
doses substantially higher than the SDR (M = 26.60, SD = 31.13), compared to the 
high, though less extreme, average doses reported by non-violent offenders (M = 
9.54, SD = 14.92). However, although a similar trend was observed, alprazolam dose 
used in the 12-24 hours prior to the index offence did not significantly differ between 
violent (M = 14.57, SD = 16.56) and non-violent groups (M = 9.95, SD = 16.54); p = 
.416; OR = 2.76, 95% CI: .48-15.95. Neither group was significantly more likely to 
have used alprazolam in the month (p = .441, OR = 3.21, 95% CI = .38-26.91) or day 
(p = .754, OR = 1.31, 95% CI: .35-4.90) prior to the index offence. 
 
Table 4  
Benzodiazepine use the month and day prior to the index offence 
 Month prior to offence 
 12-24 hours prior to 
offence 
 
N who 
reported 
use  
Est. 
frequen
cy 
(days) 
Est. 
dose 
per 
use 
(mgs) 
Approx
. DZMa 
(mgs) 
 N 
who 
report
ed 
use  
Est. 
dose 
prior to 
crime 
(mgs) 
Approx
.  DZM 
(mgs) 
Benzodiazepin
e  
N 
(%) 
M (SD) M 
(SD) 
M  N (%) M (SD) M 
Diazepam 
68 
(82.9) 
19.5 
(10.7) 
35.2 
(50.3) 
35.2 
 50 
(61.0) 
41.4 
(53.2) 
41.4 
Alprazolam 
63 
(76.8) 
14.2 
(11.0) 
12.4 
(19.3) 
124.0 
 47 
(57.3) 
10.6 
(16.4) 
106.0 
Note. Approx DZM = approximate diazepam equivalent dose; Est = estimated; mgs 
= milligrams.  
a Approximate DZM computed using a 1:10 ratio for alprazolam, as suggested by 
dosing conversion table outlined by Farinde (2014). 
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Table 5  
Independent t-tests pertaining to substance use and commission of a violent index 
offence 
 
Violent 
Index 
M (SD) 
Non-
violent 
Index 
M (SD) 
df 
t 
statistic 
p 
(two-
tailed) 
Mean 
difference 
95% C.I. 
d 
Lower Upper 
SDS 
BZD 
9.20 
(3.52) 
6.19 
(4.27) 
76 -2.120 .037 -3.01 -5.84 -.18 .73 
No. BZD 
Reg 
Used 
4.45 
(1.69) 
3.73 
(1.29) 
80 -1.657 .101 -.72 -1.59 .14 .54 
No. BZD 
12-24 
1.27 
(.79) 
1.21 
(.68) 
79 -.260 .796 -.06 -.51 .39 .08 
No. Sub 
Reg 
Used 
13.64 
(5.39) 
12.72 
(3.70) 
80 -.717 .476 -.92 -3.47 1.63 .24 
No. Sub 
12-24 
3.73 
(1.56) 
4.29 
(1.24) 
79 1.340 .184 .56 -.27 1.39 .44 
Note. C.I. = Confidence Interval; SDS = Severity of Dependence Scale total score 
(benzodiazepines); BZD = benzodiazepine; No. Sub = number of substances; 12-24 
= 12-24 hour period prior to the index offence. 
 
Diazepam use. Non-parametric Fisher’s exact tests (two-tailed) failed to find 
significant group differences relating to diazepam average dose in the month prior to 
the offence (p = .616; OR = 1.75, 95% CI: .30-10.27) or in the 12-24 hours preceding 
the offence (p = .369; OR = 2.33, 95% CI: .44-12.45). Neither group was 
significantly more likely to have used diazepam in the month (p = 1.000, OR = .84, 
95% CI = .16-4.42) or day (p = 1.000, OR = 1.06, 95% CI = .28-3.97) prior to the 
index offence. 
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Mental health. Although those who committed a violent index offence (M = 
37.25, SD = 9.97) reported higher distress scores than those who committed a non-
violent index offence (M = 30.81, SD = 9.31), this difference failed to reach 
statistical significance; t (75) = -1.839, p = .070 (two-tailed), 95% CI: -13.41 to .53, 
Cohen’s d = 0.70. Fisher’s exact tests (two-tailed) found that individuals who 
committed a violent offence were significantly more likely to be diagnosed with 
depression (90.9% vs 57.7%; p = .045; OR = 7.32, 95% CI: .89-60.29) and 
personality disorder (36.4% vs 7.0%; p = .016; OR = 7.54, 95% CI: 1.64-34.77) than 
those who committed a non-violent index offence. There were no significant group 
differences based on anxiety (p = .210; OR = 2.39, 95% CI: .64-8.91), panic disorder 
(p = .246; OR = 2.33, 95% CI: .60-9.07), or bipolar (p = .449; OR = 2.29, 95% CI: 
.51-7.57), although the analyses regarding schizophrenia (p = .068; OR = 3.94, 95% 
CI: .96-16.18) and short-term psychosis (p = .058; OR = 3.72, 95% CI: .98-14.07) 
approached significance.  
Criminality. Frequency of reported crime involvement (OTI total) in the 
month prior to the index offence did not significantly differ between those who 
committed violent and non-violent index offences; t (79) = -.043, p = .966, 95% CI = 
-2.19 to 2.10, Cohen’s d = .01. However, Fisher’s exact test (two-tailed) found that 
individuals who committed a violent index offence were more likely to have engaged 
in violence in the month prior (54.5%) than those who committed a non-violent 
index offence (17.1%; p = .012; OR = 5.8, 95% CI: 1.52-22.15). 
Impulsivity. Individuals who committed a violent index offence (M = 37.38, 
SD = 7.54) displayed significantly higher sensation seeking tendencies than non-
violent offenders (M = 30.42, SD = 8.72); t (72) = -2.157, p = .034, 95% C.I.: -13.38 
to -.53, Cohen’s d = .82. No further group differences were observed (see Table 6). 
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Table 6  
Independent t-tests pertaining to impulsivity and commission of a violent index 
offence 
 
Violent 
Index 
M (SD) 
Non-
violent 
Index 
M (SD) 
df 
t 
statistic 
p 
(two-
tailed) 
Mean 
difference 
95% C.I. 
d 
Lower Upper 
(lack of) 
Premed 
27.00 
(8.02) 
30.97 
(6.86) 
72 1.519 .133 3.97 -1.24 9.18 .58 
Sensation 
Seeking 
37.38 
(7.54) 
30.42 
(8.72) 
72 -2.157 .034 -6.95 -13.38 -.53 .82 
Urgency 
34.63 
(8.85) 
33.32 
(7.93) 
72 -.435 .665 -1.31 -7.29 4.68 .17 
(lack of) 
Persev 
25.00 
(5.63) 
26.24 
(5.41) 
72 .611 .543 1.24 -2.81 5.30 .23 
Note. C.I. = Confidence Interval; Premed = premeditation; Persev = perseverance. 
 
5.4 Discussion  
The relationship between benzodiazepine use and violent crime was explored 
in a benzodiazepine using, community criminal justice sample. Consideration was 
also given to factors understood to play a role in the commission of violent crime, 
notably mental health, impulsivity, substance use, and prior criminal behaviour. Of 
note, our sample was highly distressed, at levels substantially greater than that 
reported by persons entering Australian custodial settings (AIHW, 2013), a national 
sample of injecting drug users (Stafford & Burns, 2013), and the general Australian 
population (AIHW, 2014). Taken with the sample’s high rate of poly-substance use 
and strong tendency towards impulsive action, such complex presentations are 
however common in community criminal justice and AOD services; indeed, nearly 
all of the participants reported having sought AOD treatment in the past.  
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In line with the violence literature, our findings demonstrate that violence is 
multiply-determined, influenced by both unchanging and dynamic factors (DeWall, 
Anderson, & Bushman, 2011). Individuals who committed a violent index offence 
were significantly more likely to report benzodiazepine dependence, use alprazolam 
doses above the recognized standard prescribing range, display strong sensation 
seeking tendencies, report engaging in violent behaviour in the month prior to the 
index offence, and report diagnoses of depression and personality disorder, than 
those who committed a non-violent index offence. The use of non-prescribed (i.e., 
illicit) benzodiazepines or other substances did not differ between violent and non-
violent offenders. Importantly, it appears that a general tendency towards high dose 
benzodiazepine use is insufficient to indicate violence risk; it is the constellation of 
risk indicators which is important (Lion, Azcarate, & Koepke, 1975). 
Individuals who committed a violent index offence exhibited significantly 
higher levels of benzodiazepine dependence than those who committed a non-violent 
offence. This indicates that violent offenders were more likely to report difficulty 
controlling their use, and greater concern about their use of benzodiazepines. Such 
difficulties may have reduced their ability to effectively negotiate other situational 
stressors, increasing their likelihood of responding to stressors in an emotional, rash 
manner (e.g., violence). Enhanced disinhibition following benzodiazepine use 
(Paton, 2002) may underlie this response. However, this response may also be 
influenced by a series of indirect mechanisms, as suggested by significant 
correlations found with benzodiazepine dependence in our study, but which were 
unable to be investigated due to insufficient statistical power. For example, impulsive 
action in the context of negative emotions (urgency) may influence the relationship 
between benzodiazepine dependence and violence, by increasing the likelihood that 
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an individual who is experiencing distress and using high levels of benzodiazepines 
may act spontaneously and violently without considering the consequences (see 
Figure 2). Urgency was found to associate with general offending, though in the 
context of problematic benzodiazepine use may heighten the risk of violent 
behaviour. Such a model aligns with research associating urgency with negative 
substance use outcomes (Coskunpinar, Dir, Cyders, 2013), and as influential in the 
relationship between emotional lability and violence (Dvorak, Pearson, & Kuvaas, 
2013). Testing of such models would improve our understanding of this response, 
and offer individually tailored treatment options.   
We also found that sensation seeking tendencies were associated with 
increased benzodiazepine dependence and engagement in violent offending; however 
given the cross-sectional nature of the data causality cannot be inferred. 
Nevertheless, sensation seeking has been associated with violent behaviour in 
samples of undergraduate students (Derefinko et al., 2011; Dvorak et al., 2013; 
Miller, Zeichner, & Wilson, 2012) and violent prisoners (Shoham, Askenazy, Rahay, 
Chard, & Addl, 1989), and is often an observed characteristic in substance-using  
 
Figure 2. Proposed relationships between psychological distress, impulsive coping, 
benzodiazepine dependence and violence. 
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samples (e.g., Horvath, Millch, Lynam, Leukefeld, & Clayton, 2004; Knafo, Jaffee, 
Quinn, & Harden, 2013). Such tendencies may predispose individuals to situations 
which place them at a greater risk of violence, particularly when using drugs that can 
further disinhibit behaviour. Further research would benefit from exploring the 
combined influence of sensation seeking and benzodiazepine use on violent crime in 
a more violent sample.  
Further research is needed to clarify the key factors underlying the 
benzodiazepine-violent crime relationship. Nonetheless, there is a growing body of 
evidence suggesting that high doses of alprazolam in particular may play a 
significant role in violent criminal behavior. Alprazolam is arguably the most 
concerning benzodiazepine due to its short-acting nature and potential for harm 
(Nicholas, Lee, & Roche, 2011; Rintoul, Dobbin, Nielsen, Degenhardt, & Drummer, 
2013), and is frequently abused in clinical and forensic populations (Horyniak, 
Reddel, Quinn, & Dietze, 2012; Sweeney & Payne, 2012). Notably, widespread 
evidence of alprazolam’s harm potential has led to its recent rescheduling to a 
controlled substance (Schedule 8) in Australia. Specifically pertaining to violence, 
alprazolam has been associated with instances of increased aggression in clinical 
studies (Gardner & Cowdry, 1985; Noyes et al., 1998; O’Sullivan et al., 1994), 
typically involving high dose regimes. Our data extend these findings, as general use 
of higher doses of alprazolam by non-clinical, criminal-justice involved individuals 
also appear to be associated with a greater likelihood of engaging in violent 
behaviour. Our findings also appear to tentatively support the idea that acute high 
doses of alprazolam may pose a proximal risk of violence. The identified trend 
suggests that, in contrast to laboratory findings (Bond & Silveria, 1993), higher acute 
doses of alprazolam may pose a greater risk of violence than regularly prescribed 
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doses. Indeed, although their case-crossover study did not specify benzodiazepine 
type, Lundholm and colleagues (2013) identified an association between acute, 
‘unusually high’ benzodiazepine doses and violent crime. It is emphasized, however, 
that this latter conclusion is based on a non-significant trend in the data, and merely 
identifies an area in need of further research. Moving forward, an additional 
consideration is the accessibility of the various benzodiazepines, as increased 
restrictions on alprazolam (in Australia) may create a domino effect where other 
benzodiazepines (or substances) are substituted to harmful levels. 
The diagnoses of personality disorder and depression may present further risk 
indicators for benzodiazepine-related aggression.  Personality disorders, especially 
antisocial (ASPD) and borderline (BPD) types, have been consistently associated 
with violent behaviour (Gillies & O’Brien, 2006; Latalova & Prasko, 2010; Yu, 
Geddes, & Fazel, 2012), and there is some evidence to suggest that comorbid 
substance abuse increases the risk of violence in people with such diagnoses 
(Fountoulakis, Leucht, & Kaprinis, 2008). The association between violence and 
personality disorders may be due to problematic enduring cognitive and affective 
characteristics, such as aggression-related and maladaptive cognitions and anger 
(Gilbert & Daffern, 2011), or a need for excitement (Howard, 2011), as well as the 
presence of diagnostic traits such as a callous disregard for others’ rights and lack of 
empathy (ASPD), and impulsive tendencies and emotional dysregulation (BPD; 
American Psychiatric Association, 2014).  The association between depression and 
aggressive behaviour may reflect common underlying factors (e.g., low serotonin, 
impaired attachment), violence resulting from depressive sequelae (e.g., reduced 
social support, increased alcohol use, angry rumination, impaired self-regulation or 
impulsivity; Dutton & Karakanta, 2013), or depression developing in response to 
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guilt, rumination and regret following an aggressive act (Graham, Bernards, Flynn, 
Tremblay, & Wells, 2012). The progression between depression and aggressive 
behaviour may also be non-linear, reflecting a complex dynamic progression over 
time, influenced by factors such as gender or violence type or severity (e.g., Angkaw, 
Ross, Pittman, Kelada, Valencerina, & Baker, 2013; Graham et al., 2012; Sadeh, 
Javdani, Finy, & Verona, 2011; Stith, Smith, Penn, Ward, & Tritt, 2004). Although 
our measure of lifetime diagnoses cannot suggest that active symptoms of depression 
were directly associated with violent offending, our data does suggest that a 
predisposition towards emotional disturbance, disrupted interpersonal functioning, 
and reduced executive functioning may be important in the assessment of violence 
risk, especially in substance-using samples.   
5.4.1 Limitations and strengths. 
The study has a number of limitations. Of note, the small sample size with 
some variables of interest having missing data (i.e., impulsivity characteristics, dose 
information), as well as the low base rate of violent offending, greatly precluded the 
types of analyses that were able to be performed, prompting reliance on non-
parametric analyses which have less stringent criteria. Such sampling issues may 
have also attenuated the statistical power available. In addition, due to the unique 
nature of the data, an a priori decision was made that non-normal variables would be 
recoded into categorical variables, and no correction was made to protect against 
Type 1 error. The measurement protocols used may have impacted our results, 
including the non-standardised UPPS response scale, a non-specific substance use 
variable which may have attenuated the effects of specific drugs (Sweeney & Payne, 
2012), and a criminal involvement scale with limited scope (i.e., beyond one month). 
Furthermore, data collection relied on retrospective self-report which is vulnerable to 
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memory decay and potential reporter bias, without any method to corroborate 
substance use (i.e., urinalysis), benzodiazepine dose, crime involvement (i.e., official 
data), or the accuracy and currency of reported mental health diagnoses. Indeed, a 
proportion of the sample neglected to provide crime information (i.e., non-specified 
‘other’ crime). In addition, the findings may have limited generality to individuals 
with less complex presentations, and greater insight may have been afforded through 
the use of a non-benzodiazepine using control group. It is noted that the observed 
relationship may reflect increased dependence to benzodiazepines arising from 
efforts to effectively manage pre-existing violent tendencies, or the occurrence of 
aggression and agitation during benzodiazepine withdrawal (Votava, Kršiak, 
Podhorná, & Miczek, 2001). It is further noted that benzodiazepine dependence was 
also significantly associated with poly-substance use, indicating that other substances 
may have influenced the identified relationship between benzodiazepine dependence 
and violent crime. The findings may have limited generality to individuals with less 
complex presentations. 
While acknowledging these limitations, the current study adds to the limited 
literature regarding the relationship between benzodiazepine use and violence in a 
criminal justice sample. First, our examination of a community-based criminal 
justice sample with regular benzodiazepine use and recent offending is unique within 
the literature. Previous research has predominantly focused on healthy community 
samples, clinical or substance using samples, or forensic samples in custodial settings 
(Albrecht et al., 2014), greatly reducing the ecological validity of their findings. 
Second, the research protocol offered numerous avenues of exploration, by way of 
the range of data that was collected. Notably, 84.1% of the sample reported using 
benzodiazepines in the day prior to committing an offence, and our data permitted 
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specific examination of the roles of diazepam and alprazolam in violent offending. 
With a less constrained sample size, the study had the potential to explore numerous 
points of interest. 
5.4.2 Implications and conclusions. 
Recent literature, including a letter written regarding the benzodiazepine 
acquisition practices of those included in the current database (Best, Wilson, Reed, 
Lloyd, Eade, & Lubman, 2013), has demonstrated that benzodiazepines are being 
frequently sought through illegal, or non-medically prescribed, means (Nielsen et al., 
2013). Of interest, although the majority of the current sample reported such a 
preference, every individual who engaged in violence in the month prior to the index 
offence reported preferring non-medically sourced benzodiazepines. This suggests 
that people at risk for violence may be less likely to be identified at the point of 
prescription, and intervention efforts should focus on management of the black-
market trade in benzodiazepines, with prevention efforts tailored towards (1) 
enhancing prescription selectivity, (2) reducing large prescriptions, and (3) strategies 
to reduce the ease of doctor and pharmacy shopping. Essentially, a two-tiered policy 
approach involving enhanced control over the prescription of benzodiazepines and 
greater regulation around the diversion of benzodiazepines onto the black market is 
required. The latter directive may involve further up-scheduling of all 
benzodiazepines to controlled substances. 
The findings highlight the importance of adhering to recognized prescribing 
protocols (e.g., Jones, Nielsen, Bruno, Frei, & Lubman, 2011), and addressing 
reasons for benzodiazepine use (i.e., to manage negative affect).  Our findings also 
promote the use of psychological approaches that target mental health and adaptive 
coping strategies (e.g., emotion identification and regulation techniques, 
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consequential thinking and impulse control strategies) in violent offenders. Such 
strategies can hopefully reduce the association between benzodiazepine consumption 
and being detained for violent offending (Australian Institute of Criminology, 2013). 
5.5 Chapter Summary 
Research exploring the benzodiazepine-violence relationship is rare in 
community samples with a recent criminal justice and benzodiazepine use history. 
Investigation of such a sample identified risk factors of benzodiazepine dependence, 
high alprazolam doses (i.e., above 4mg daily), sensation seeking, previous violence, 
depression, and personality disorder. The current findings detail a complex picture of 
psychiatric and impulsive functioning as influencing the relationship between 
benzodiazepine (notably alprazolam) use and subsequent involvement in violent 
crime. This picture highlights the need to take a holistic, multifaceted approach to the 
prevention and intervention of benzodiazepine-related aggressive behaviour. As will 
be discussed in greater detail in the following chapter, concurrent attention to 
limiting the widespread diversion of benzodiazepines, addressing reasons for 
benzodiazepines misuse, and promoting psychological approaches that target mental 
health and adaptive coping strategies among violent offenders is required in order to 
effect change and reduce the continued occurrence of benzodiazepine-related 
violence. 
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Chapter Six: Outcomes, Implications, and Future Directions 
Benzodiazepines are widely prescribed, used, and diverted through the black 
market. Yet, benzodiazepine use has been associated with an increased risk of harm, 
behavioural disinhibition, and aggressive behaviour. It is this latter response which is 
poorly understood, and has prompted further exploration within this thesis using both 
general community and criminal justice samples. As identified through a systematic 
review, the currently available literature is flawed and has limited explanatory power, 
though benzodiazepine-related aggressive responses appear to be linked most closely 
with alprazolam and diazepam use.  
In a study with a community sample, benzodiazepine-related aggression was 
more likely to be experienced by those who used alprazolam and exhibited persistent 
approach tendencies, or motivational drive.  It was posited that frustration 
(in)tolerance and difficulties regulating impulses when pursuing desired goals may 
influence aggressive responding. Examination of general and physical aggression 
allowed for the comparison of predictive models in this sample, and it was observed 
that for the general community, diazepam (used not to excess) may inhibit general 
aggressive tendencies such as anger, hostility or verbal aggression, but may not 
impact physically aggressive behaviour. Problematic use of diazepam (and 
alprazolam), however, was associated with increased general and physical 
aggression, highlighting the concerning sequelae that can result from problematic 
benzodiazepine use or dependence.  
In a study with an offender population, this response was associated with a 
complex picture of emotional, impulse control and interpersonal difficulties. Violent 
offenders were significantly more likely to present with benzodiazepine dependence, 
alprazolam use at higher doses, depression and personality diagnoses, sensation 
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seeking, and a history of violent behaviour than non-violent offenders. The findings 
highlighted the need to take a holistic, multifaceted approach to the prevention and 
intervention of benzodiazepine-related aggressive behaviour, and consider the 
reasons underlying benzodiazepine use whilst promoting adaptive coping strategies. 
Taken together, the systematic review and two studies showed alprazolam use 
to pose a greater risk of subsequent aggression than diazepam use, and demonstrated 
that intrapersonal factors can further our understanding of benzodiazepine-related 
aggression. Specifically, the two empirical studies highlighted the role of impulse 
control and maladaptive coping responses to negative affect in this response. 
Although the above findings do require replication and extension through further 
research, a number of pertinent clinical and forensic implications can be drawn from 
these outcomes. 
6.1 Clinical Implications 
6.1.1 Role of alprazolam.  
Alprazolam misuse has consistently been associated with problematic 
sequelae. The research conducted as part of this thesis supports national and 
international concern about alprazolam (Horyniak et al., 2012; Isbister et al., 2004; 
Rintoul et al., 2013), by highlighting its association with benzodiazepine-related 
aggression. However, the currently available findings cannot specify that it is the 
psychophysiological effects of alprazolam that result in aggressive behaviour. 
Instead, the link between alprazolam use and benzodiazepine-related aggression may 
be due to the context in which alprazolam is frequently used (i.e., poly-substance use, 
personality factors, high doses, unknown situational factors). Nevertheless, a positive 
association has been consistently observed between alprazolam and this response, 
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suggesting that those who consume alprazolam may be at an increased risk of 
experiencing benzodiazepine-related aggression.  
Alprazolam has recently been up-scheduled in Australia to a controlled 
substance (Schedule 8), in an effort to reduce alprazolam access, use, and related 
harms. However, as noted by Islam and colleagues (2014), it cannot be discounted 
that re-scheduling may result in increased black market trade in alprazolam, or a rise 
in misuse of a substitute benzodiazepine (or other substance). This will likely have 
implications for ambulance attendants, emergency departments and substance use 
treatment clinics, where clinicians should be aware of a possible rebound effect in 
benzodiazepine-related overdoses, health complications and/or mortality. Prescribers 
would also benefit by attending to the medicinal requests of patients who had 
previously received alprazolam prescriptions. In addition, acquisitive crime to fund 
black-market alprazolam use may increase, and border controls may see an increase 
in attempts to traffic alprazolam and/or a substitute benzodiazepine. Therefore, 
whilst it is important to continue monitoring the use of alprazolam, restricting its use, 
and engaging in further well-controlled examination of this response following 
alprazolam use, it is also imperative that policy approaches are broadened to the 
regulation and monitoring of all benzodiazepines, so as to reduce this substitution 
effect (Islam et al., 2014).  
6.1.2 Prescribing policy.  
Across both studies, benzodiazepine dependence was associated with 
aggressive (or violent) behaviour in a proportion of participants. As introduced in 
Chapter 5, the most appropriate course of action may involve a two-tiered policy 
system for the regulation of benzodiazepines. It is recommended that such a strategy 
would involve targeting the point of prescription whilst also targeting the point of 
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diversion. Such dual focus enhances the likelihood of accessing those who are 
unlikely to use health care services to obtain benzodiazepines.   
The first tier, targeting the point of prescription, is recommended to involve a 
number of strategies. These include increasing the selectivity of benzodiazepine 
prescriptions, which may involve a review of the indications appropriate for 
benzodiazepine treatment, reducing available prescription size and dosing strength 
(i.e., Ibañez et al., 2013), increased training regarding prescription protocols (and 
common side effects and risks associated with benzodiazepines), and greater 
consequences for off-label prescribing of benzodiazepines. Off-label prescribing to 
individuals already at increased risk of aggressive behaviour (i.e., violent offenders) 
or in contexts more conducive to interpersonal violence (i.e., prison) is especially 
concerning. The high dependence potential of benzodiazepines (i.e., physiological 
dependence; O’Brien, 2005) further warrants the development of national regulations 
regarding the upskilling or continuing professional development for benzodiazepine 
prescribers, and emphasises the importance of non-pharmacological (i.e., 
psychological) approaches to treatment (Dobbin, 2014; Lader, 2014). By targeting 
the point of prescription, it is expected that fewer inappropriate prescriptions (in dose 
or indication) will be made, resulting in reduced access to benzodiazepines for 
personal misuse, as well as a reduced market of prescribed benzodiazepines (Ibañez 
et al., 2013). Although some psychiatrists (n = 20) already consider both 
benzodiazepine factors (i.e., abuse and dependence potential) and person factors (i.e., 
suspicion of who takes the medication, history of abuse, feeling manipulated) when 
prescribing benzodiazepines (Marienfeld, Tek, Diaz, Schottenfeld, & Chawarski, 
2012), it is apparent that greater awareness (through enhanced regulation or training) 
is required. 
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The second tier, targeting the point of diversion, aims to further decrease the 
ease of which benzodiazepines are diverted onto the black market. Strategies could 
involve further up-scheduling of benzodiazepines, a nation-wide database to provide 
real-time information to pharmacies regarding the dispensing of benzodiazepines, 
and increased ramifications for those caught trafficking benzodiazepines or in 
possession of large quantities of benzodiazepines. Community health promotion 
strategies may be helpful in reaching individuals who are less likely to be accessed 
through health centres (i.e., lower income; Ibañez et al., 2013), and offer 
rehabilitation opportunities without negative consequences (i.e., misdemeanours for 
illicit drug use). It is noted that each of the above recommendations requires notable 
financial and personnel resources, and further research as recommended below may 
assist in garnering support for the provision of such resources.   
6.1.3 Poly-substance use.  
A complicating factor in the regulation of benzodiazepines, especially 
alprazolam, is the high rate of poly-substance use associated with benzodiazepine 
misuse. As demonstrated in Chapter 4, benzodiazepines are often used to enhance the 
effects of another drug, or to attenuate the negative effects of substance withdrawal. 
Therein, drug and alcohol interventions may involve concurrent treatment of 
benzodiazepine use and other substance use, and rely strongly on a comprehensive 
functional assessment as to why the individual (mis)uses benzodiazepines. 
 6.1.4 Chicken-egg intervention.  
Due to the absence of well-controlled longitudinal studies of this response, 
the progression between intrapersonal factors, benzodiazepine misuse, and the 
development of aggressive behaviour is currently unable to be determined. 
Therefore, intervention for an individual who has experienced benzodiazepine-
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related aggressive behaviour will likely depend on a comprehensive individual 
assessment. Such an assessment should inform the manner in which treatment is 
provided, and the prioritisation of the various components. For example, underlying 
anxiety may be prioritised as it leads to problematic benzodiazepine use, or 
aggressive or hostile attitudes may be targeted as this prompts benzodiazepine use 
and disinhibited violence, or benzodiazepine and other substance misuse may be 
targeted as the cycle of use increases distress and agitation, culminating in aggressive 
outbursts. Although the progression is still unclear in the general literature, core high 
risk intrapersonal factors requiring assessment have, however, been indicated by the 
current research (i.e., violent histories, sensation seeking, antisocial or borderline 
traits, psychiatric distress, and persistent pursuit of goals).  
Intrapersonal factors have long been argued to be important in the 
understanding of benzodiazepine-related aggression. The findings contained within 
this thesis support this premise, and highlight the importance of considering 
emotional identification and regulation, including identification of prosocial, 
solution-focused problem solving and coping strategies; impulse control, frustration 
tolerance, and consequential thinking training; and interpersonal conflict resolution 
training, when developing interventions following benzodiazepine-related 
aggression. Such factors can be considered regardless of whether the intervention is 
targeting underlying aggressive tendencies, problematic substance use, or psychiatric 
health, and may indicate responsivity issues which need to be addressed. It has been 
argued that effective substance use treatment needs to consider individual personality 
factors (Staiger, Kambouropoulos, & Dawe, 2007), and it is argued that this premise 
should extend to consideration of other intrapersonal factors (i.e., motivational 
tendencies) and to other forms of intervention (i.e., violent offender treatment). 
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Indeed, Davison and Janca’s (2012) review of the relationship between personality 
and criminal behaviour highlight that effective risk assessment, management, and 
treatment involves the integration of personality traits, substance misuse, and other 
intrapersonal factors such as attitudes, beliefs, anger and arousal.  
6.2 Theoretical Implications 
This thesis is the first to apply the rRST to substance-related aggressive 
behaviour, and the first to apply the theory to benzodiazepine use. Therefore, in the 
absence of similar studies, comparisons of the current data to the relevant literature 
relies on studies which explore general aggressive behaviour only. A number of 
important conclusions can be drawn from such comparisons. First, BAS-Dr is 
important in the understanding of aggressive behaviour. As discussed in Chapter 4, 
this may be due to frustrative non-reward, increasing neurological activation 
mimicking that of aggressive behaviour, the role of attitudes condoning the use of 
aggression in order to achieve desired goals, or a combination of these factors. 
However, by aligning with other violence research using the BIS/BAS scales, the 
role of BAS-Dr in aggression has been supported, indicating that even in the 
presence of intoxicating substances, underlying intrapersonal factors are important in 
the treatment of violent offenders. As such, interventions targeting this motivational 
tendency may involve frustration tolerance training, including impulse control, and 
solution-focused coping, as well as challenging any beliefs or attitudes condoning the 
use of aggression. Mindfulness or acceptance and commitment based strategies may 
also be involved, in order to assist the client to more effectively manage goal 
challenges.  
Reasoning regarding the role of frustrative non-reward (and aggression-based 
attitudes) is based on untested hypotheses, and therefore should be considered 
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cautiously. In the absence of follow-up research, the current findings can only 
highlight potentially relevant treatment targets for assessing and treating clinicians. It 
is notable, however, that such considerations do align with the frustration-aggression 
hypothesis (Dollard et al., 1939), and later expansions to the theory, that frustrations 
generate aggressive behaviour only to the degree to which they arouse negative 
affect (Berkowitz, 1989). According to Carver (2004), frustrative non-reward is 
dependent on the person’s perception of the imminence of goal attainment. 
Unfortunately, empirical investigation of the frustration-aggression hypothesis 
cannot currently provide further insight into benzodiazepine-related aggression, as 
the limited recent research (i.e., since 2000) explores bullying among Japanese 
school girls (Wai-ming Tam & Taki, 2007), aggression post sporting losses (Priks, 
2010), and a socio-economic argument of aggression (de Gaay Fortman, 2005); with 
no apparent application of the hypothesis to situations involving substance use.  
The role of affect regulation and coping capacity was in fact inferred by both 
empirical studies, despite their methodological differences. As noted above, the 
community sample study, through application of the rRST, posited that 
benzodiazepine-related aggression involves a problematic response to negative 
affective experiences (i.e., aggression in response to frustration or anger). Similarly, 
the findings from the criminal justice study prompted the argument that violent 
offending reflected impulsive action (urgency) in response to negative symptoms of 
distress. Although based on different measures and outcome variables, the similarity 
in results suggests that benzodiazepine-related aggression may involve problematic 
responding to negative affective experiences, highlighting the importance of 
emotional regulation and coping strategies, including problem-focused strategies, in 
both violent and substance use intervention. Difficulties regulating emotion have 
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frequently been linked with both problematic substance use (e.g., Berking & 
Wupperman, 2012) and violence (e.g., Roberton, Daffern, Bucks, 2015); however the 
current findings suggest that enhanced awareness and prioritisation of such treatment 
targets may reduce the risk of benzodiazepine-related aggression recurring. 
Although problematic responses to negative affect appears to be consistent 
across the two studies, it is notable that divergent findings were observed in relation 
to sensation seeking. Fun seeking (BAS-FS) negatively influenced the prediction of 
physical aggression in Chapter 4 (albeit non-significantly), whilst sensation seeking 
was positively associated with violent crime in Chapter 5. It is acknowledged that the 
studies used different measures of sensation seeking and aggression, and it can be 
argued that BAS-FS is not a pure measure of sensation seeking, instead also tapping 
into dysfunctional impulsivity (Leone & Russo, 2009; Segarra et al., 2014), thus 
likely explaining the divergence. However, it is interesting that the direction of the 
effect differs between the studies, especially as BAS-FS has been positively 
associated with physically aggressive behaviour (Harmon-Jones, 2003; Smits & 
Kuppens, 2005), and has predicted both direct and indirect aggression in a sample of 
pharmacy workers (Cooper et al., 2008). Sensation seeking tendencies have also 
been positively associated with aggression in both general community (Derefinko et 
al., 2011; Dvorak et al., 2013; Miller, Zeichner, & Wilson, 2012) and violent 
offender samples (Shoham, Askenasy, Rahav, Chard, & Addl, 1989). It is therefore 
tempting to infer that benzodiazepine-related aggression operates differently to 
general aggression, especially given that the findings relating to BAS-FS further 
support the role of persistent, planned approach behaviour in benzodiazepine-related 
aggression (in the community sample), and that rash impulsivity or sensation seeking 
tendencies are only relevant in antisocial or violent (i.e., criminal justice) samples. 
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However, given the methodological inconsistencies leading to this inference, further 
research comparing violent offender and general community samples on this 
response, using a standardised measure of sensation seeking, is required.  
6.3 Forensic Implications 
Disinhibition potentially due to benzodiazepine misuse has been previously 
suggested to result in criminal justice system involvement (Redman, 1994). Indeed, 
offenders have attributed their criminal, and violent, behaviour to the 
psychopharmacological effects of benzodiazepines (Forsyth et al., 2011; Payne & 
Gaffney, 2012), though limited corroboration has been provided for such 
physiological effects. However, it is likely that the current, and future, academic 
interest in benzodiazepine-related aggression will result in attempts to seek decreased 
culpability for violent offending.  It is emphasised that the aim of this research is not 
to excuse violence, or to provide an avenue under which a violent offender escapes 
punishment for a violent crime. Instead, the aim is to help inform whether the violent 
offender requires targeted treatment relating to his or her use of benzodiazepines, and 
whether there may be responsivity factors or intervention targets which may improve 
the offender’s rehabilitative prognosis (i.e., improve offender wellbeing, reduce risk 
of reoffending, improve community safety). Consideration of this research, indeed in 
the context of diminished responsibility due to intoxication, may enhance the 
awareness of the professionals receiving the violent offender pre- or post-sentence. 
Such awareness may, for example, inform decisions regarding further prescription of 
benzodiazepines, especially in the presence of related risk factors (i.e., psychological 
distress, impulsivity). 
Similar to the discussion above regarding clinical intervention planning, the 
outcomes of this research may aid discussion and planning about the offender’s 
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rehabilitation needs. This would hopefully include an assessment of whether 
continuing benzodiazepine treatment is the most appropriate option for the offender, 
and tailoring of intervention techniques to meet responsivity factors or treatment 
targets. This will culminate in recommendations regarding the priority of violent 
offender rehabilitation or substance use or mental health treatment. In addition, it is 
acknowledged that such consideration may inform the inclusion of specific 
conditions (i.e., excluding or enforcing certain intervention pathways) on high risk 
violent offenders’ parole orders, where parole is successfully attained. It would be 
highly recommended, based on findings of Chapter 5, that the prescription of 
benzodiazepines to violent offenders, or within highly violent contexts (i.e., 
incarceration), be limited and follow only comprehensive assessment and exhaustion 
of alternative treatment methods. 
6.4 Future Research 
Due to the current state of related literature, there are a number of 
methodological improvements which would assist our understanding of 
benzodiazepine-related aggression (e.g., Albrecht & Staiger, in press). Of note, well-
designed and controlled longitudinal research would prove valuable in determining 
true contributors to this response. In addition, regardless of study design (i.e., cross-
sectional, experimental), the use of appropriate control groups would enhance our 
ability to be confident in findings. For example, a four-group design using 
violent/non-violent and benzodiazepine using/non-using groups would be optimal 
(i.e., B+V+, B+V-, B-V-, B-V+). In addition, larger samples, with a focus on gender 
equality, would improve the generality of the literature base, and provide greater 
foundations on which to develop prescribing and regulatory policies. Larger samples 
will also provide additional statistical power in which more comprehensive and 
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rigorous statistical modelling can be used. Such modelling ability is imperative for 
the testing of the various mechanisms posited throughout this thesis (i.e., the role of 
frustrative non-reward, BIS/BAS interactions, or impulsive action in response to 
depressive symptoms). As noted in Chapter 1, misuse of benzodiazepines is an 
international concern, and researchers could endeavour to explore benzodiazepine-
related aggression cross-culturally.  
A core limitation of the current research and prior studies is the ability to 
effectively measure, and statistically control, other substance use. Future research 
could benefit by systematically exploring the role of substances such as heroin, 
marijuana, and alcohol (i.e., closely associated with benzodiazepine use) in 
benzodiazepine-related aggression. Physiological research could also provide insight 
into how the various substances in combination with benzodiazepines affect an 
individual’s responding. In addition, systematic examination of the different 
benzodiazepines and dosing schedules requires further attention. As noted in Chapter 
1, and replicated in the current research, alprazolam and diazepam have received the 
most empirical attention, likely due to their frequent use in both community, clinical 
and forensic populations. Further examination of the less-frequently used 
benzodiazepines is therefore required. Such examination would greatly benefit from 
the use of appropriate methods to corroborate self-report (i.e., urinalysis, systematic 
testing (using double blind methods) of various doses). Such techniques would 
increase the level of control of related studies, and improve our confidence in relying 
on research findings. 
Building on Lion and colleagues’ (1975) premise, an aspect which has been 
overlooked in the current literature is the role of context in understanding this 
response. Aggression is by definition an interpersonal behaviour (Baron & 
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Richardson, 1994), and is highly influenced by situational factors (Anderson & 
Bushman, 2002). However, no research has explored the context or situational 
factors associated with benzodiazepine-related aggression, or how situational factors 
may interact with intrapersonal responding and benzodiazepines (and other 
substance) use (Lion et al., 1975). Blending quantitative and qualitative approaches 
would likely provide greater understanding of these factors.  
Finally, there are a number of additional intrapersonal factors which have yet 
to be investigated in the benzodiazepine-aggression literature. Based on the current 
findings, and what is understood about violent behaviour in general (i.e., the general 
aggression model; Anderson & Bushman, 2002), individual goals, expectations, 
attitudes, and desires seem important. A number of questions could be asked, 
especially regarding perceptions of how substance use may vary the acceptability of 
aggressive behaviour, and tested through well-controlled experimental studies.  
As demonstrated throughout this thesis, the benzodiazepine-aggression 
literature base has a number of limitations, and the above areas for further research 
are suggested in order to reduce such flaws. It is hoped that further research adhering 
to the above points and following the above questions will improve the statistical and 
methodological rigour of the related literature base, and increase the specificity and 
explanatory power of related outcomes. This includes the replication and expansion 
of the findings included in this thesis. 
6.5 Conclusion 
Much remains to be understood about benzodiazepine-related aggressive 
behaviour. This thesis has highlighted the increased risk that alprazolam poses in the 
commission of violent or aggressive behaviour, though it is currently unclear 
whether this is due to the physiological effects of alprazolam, or the increased 
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disinhibition which may result from using alprazolam in combination with other 
substances. It is also important to consider whether individuals who engage in 
aggression merely have a tendency to select alprazolam over other benzodiazepine 
options, possibly for its fast-acting effects, or whether the aggressive response may 
occur during the withdrawal phase of alprazolam abuse. This thesis has also 
highlighted the importance of intrapersonal factors in understanding this response, 
and will hopefully inspire further research into the proposed interaction between 
benzodiazepine, intrapersonal, and situational factors (Lion et al., 1975). In order to 
reduce the incidence of this response, it is necessary to increase the regulation of 
benzodiazepine prescription and diversion onto the black market, and a two-tiered 
prescribing policy has been suggested. Violent offender and substance use treatment 
programs should explore notable intrapersonal factors in order to determine their 
relevance as responsivity factors and/or treatment targets. Although risks may differ 
between violent offenders and the general public, attention should be paid to 
impulsive tendencies in response to frustration or negative affect, persistent 
motivational tendencies, violent histories, problematic personality traits and 
disrupted interpersonal functioning, and regular, heavy consumption of alprazolam, 
especially in the context of poly-substance use. It is through attention to the above 
risks and recommendations that the incidence of benzodiazepine-related aggression 
may be reduced, reducing the financial and personal injury toll on the community, 
and improving community safety.  
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association between the subscales was observed (r = .519, p < .001), supporting 
the separation of the scales. 
 
  
 Appendix C 
 
 
Albrecht, B., Staiger, P. K., Hall, K., Kambouropoulos, N., & Best, D. 
Motivational drive and alprazolam misuse: A recipe for aggression? 
Submitted to: Psychiatry Research 
Submission date: 27 May 2015 
  
 AUTHORSHIP STATEMENT 
1.  Details of publication and executive author 
Title of Publication Publication details 
Motivational drive and alprazolam misuse: A recipe for 
aggression? 
Under review (submitted 
27.05.15) 
Psychiatry Research 
Name of executive author School/Institute/Division if 
based at Deakin; Organisation 
and address if non-Deakin 
Email or phone 
Bonnie Albrecht School of Psychology balbrech@deakin.edu.au 
2.  Inclusion of publication in a thesis 
Is it intended to include this publication in a higher 
degree by research (HDR) thesis? 
Yes / No 
 
 
If Yes, please complete Section 
3 
If No, go straight to Section 4. 
3.  HDR thesis author’s declaration 
Name of HDR thesis author if 
different from above. (If the 
same, write “as above”) 
School/Institute/Division if 
based at Deakin 
Thesis title 
As above 
 
School of Psychology Benzodiazepine-related 
aggression: Consideration of 
intrapersonal factors. 
If there are multiple authors, give a full description of HDR thesis author’s contribution to the 
publication (for example, how much did you contribute to the conception of the project, the 
design of methodology or experimental protocol, data collection, analysis, drafting the 
manuscript, revising it critically for important intellectual content, etc.) 
Conception of research question, statistical analysis plan, questionnaire development, preparing 
relevant ethics applications, cleaning and analysis of data, drafting of manuscript, editing of 
manuscript. 
 
I declare that the above is an accurate 
description of my contribution to this paper, 
and the contributions of other authors are as 
described below. 
Signature 
and date 
 
01.04.2015 
4.  Description of all author contributions 
Name and affiliation of 
author  
Contribution(s) (for example,  conception of the project, design 
of methodology or experimental protocol, data collection, 
analysis, drafting the manuscript, revising it critically for 
important intellectual content, etc.) 
Petra Staiger 
 
Supervision of DPsych candidate, overview of research question, 
consultation regarding questionnaire development, review 
ethics applications, editing of manuscript 
Kate Hall 
 
Associate supervision DPsych candidate, consultation regarding 
questionnaire development, clinical implications, editing of 
manuscript 
Nicolas Kambouropoulos 
 
Expertise regarding theoretical assumptions, editing of 
manuscript 
 David Best 
 
Consultation regarding questionnaire development, clinical 
implications, editing of manuscript 
 
5.  Author Declarations 
I agree to be named as one of the authors of this work, and confirm:  
vi. that I have met the authorship criteria set out in the Deakin University Research 
Conduct Policy, 
vii. that there are no other authors according to these criteria, 
viii. that the description in Section 4 of my contribution(s) to this publication is accurate,  
ix. that the data on which these findings are based are stored as set out in Section 7 
below. 
If this work is to form part of an HDR thesis as described in Sections 2 and 3, I further  
x. consent to the incorporation of the publication into the candidate’s HDR thesis 
submitted to Deakin University and, if the higher degree is awarded, the subsequent 
publication of the thesis by the university (subject to relevant Copyright provisions).   
 
Name of author Signature* Date 
Petra Staiger 
 
 
01.04.15 
Kate Hall 
 
 01.04.15 
Nicolas Kambouropoulos 
  
01.04.15 
David Best 
 
 
01.04.15 
6.  Other contributor declarations 
I agree to be named as a non-author contributor to this work. 
Name and affiliation of 
contributor 
Contribution Signature* and date 
 
 
  
 
 
  
* If an author or contributor is unavailable or otherwise unable to sign the statement of 
authorship, the Head of Academic Unit may sign on their behalf, noting the reason for their 
unavailability, provided there is no evidence to suggest that the person would object to being 
named as author 
7.  Data storage 
The original data for this project are stored in the following locations. (The locations must be 
within an appropriate institutional setting. If the executive author is a Deakin staff member and 
data are stored outside Deakin University, permission for this must be given by the Head of 
Academic Unit within which the executive author is based.) 
 Data format Storage Location Date lodged Name of custodian if 
other than the 
executive author 
Paper-based questionnaires School of 
Psychology, 
Deakin 
University 
(locked cabinet) 
2014  
De-identified electronic database, 
password protected 
Deakin 
University 
2014  
This form must be retained by the executive author, within the school or institute in which they 
are based. 
If the publication is to be included as part of an HDR thesis, a copy of this form must be 
included in the thesis with the publication. 
 
 Abstract 
Benzodiazepine-related aggression is understudied in the literature, in 
particular little is known about the motivational factors which may contribute to the 
development of this paradoxical response. The revised Reinforcement Sensitivity 
Theory (rRST) provides a theoretical framework from which to understand the 
relevant underlying motivational processes. The current study aimed to identify the 
role of approach and avoidance motivational tendencies in relation to 
benzodiazepine-related aggression. Data regarding benzodiazepine and other 
substance use, approach and avoidance motivation, and general and physical 
aggressive behaviour were collected via self-report questionnaires. Participants were 
a convenience sample (n = 204) who reported using benzodiazepines in the previous 
month. Participants were primarily male (62.7%), aged 18-51 years old. General and 
physical aggression were predicted by alprazolam use and Drive, a facet of approach 
motivation reflecting persistent goal-directed action. Overall, lower use of diazepam 
significantly predicted higher levels of general aggression. However, when 
diazepam-preferring participants were examined in isolation of the larger sample 
(23.5% of sample), problematic (dependent) diazepam use was associated with 
greater aggression scores, as was dependence risk for alprazolam-preferring 
participants (39.7% of sample). The findings highlight the importance of 
motivational factors and benzodiazepine use patterns in understanding 
benzodiazepine-related aggression, with implications for violent offender 
rehabilitation.  
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APPENDIX D: VIOLENT CRIME AND BENZODIAZEPINES  
Abstract 
 
Objective:  
To examine the relationship between benzodiazepine use and violent crime in a 
sample of offenders. 
 
Methods:  
Data regarding benzodiazepine and other substance use, mental health, personality 
characteristics, and crime involvement was collected through semi-structured 
interviews. Participants (n = 82, 79.3% male) were 21-56 years old, and, in the 
previous six months, had been charged with a criminal offence and used 
benzodiazepines at least monthly.  
 
Results:   
Individuals charged with violent offences were significantly more likely to use 
higher average doses of alprazolam, exhibit benzodiazepine dependence and report 
high levels of sensation seeking, have committed prior violence, and report the 
diagnoses of depression and personality disorder, than individuals charged with non-
violent offences.  
 
Conclusions:  
The findings suggest the existence of a complex dynamic between mental health and 
violent offending that may be influenced by benzodiazepine use (in particular 
alprazolam). Implications for prescribing and continued efforts to reduce 
benzodiazepine diversion are discussed. 
 
Key words: benzodiazepines, alprazolam, violence, impulsive behaviour, mental 
health 
